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Zusammenfassung 
Persistierende Infektionen mit einem humanen Papillomvirus (HPV) der Hochrisiko-Gruppe, meistens mit 
HPV16, bilden die notwendige Voraussetzung zur Entstehung von Gebärmutterhalskrebs (Zervixkarzinom). Bei 
der Tumorprogression kommt es häufig zur Integration der HPV-DNA in das Genom der Wirtszellen an 
unterschiedlichen Zielorten. Die Integration von HPV-DNA kann durch Insertionsmutagenese zur Veränderung 
flankierender zellulärer Gene führen und auch auf diese Weise zum Mehrstufenprozess der Karzinogenese 
beitragen. Das primäre Ziel dieser Arbeit war die Entwicklung einer neuen effizienten Strategie, die es 
ermöglicht, HPV16-DNA-Integrationsstellen in ausgewählten Proben von präkanzerösen und kanzerösen  
Zervixabstrichen auf Sequenzebene zu bestimmen. 
Bei Verwendung von Restriktionsstellen-PCR zur HPV16-DNA-Integrationsanalyse stellte sich die 
Zervixkarzinom-Zelllinie MRI-H186 als ein sehr interessanter Fall für HPV16-induzierte Insertionsmutagenese 
des c-myc Proto-Onkogens heraus. Deshalb wurden im Rahmen der Arbeit detaillierte Untersuchungen 
durchgeführt. Assoziiert mit der HPV16-DNA-Integration im c-myc-Locus wurde eine Überexpression von c-myc 
auf mRNA- und Proteinebene festgestellt. Verschiedene Varianten integrierter HPV16-DNA wurden auf 
Sequenzebene charakterisiert. Eine dieser Varianten zeigte eine starke Expression als myc-HPV16 
Hybridtranskript sowie als MycHPV16E2 Fusionsprotein. Beide myc-HPV16-Hybridmoleküle sind ein 
besonderes Charakteristikum von MRI-H186. Im MycHPV16E2-Fusionsprotein ist der aminoterminale Teil der 
MYC-Transaktivierungsdomäne mit der Linker- und DNA-Bindungsdomäne des HPV16 E2-Proteins fusioniert. 
Die Ergebnisse für MRI-H186 verstärken die Vermutung, dass Insertionsmutagenese, in diesem Fall die 
Aktivierung/Mutation von c-myc, bei der Zervixkarzinom-Entstehung eine Rolle spielen kann. 
Für die HPV16-DNA-Integrationsanalyse in klinischen Proben, von denen genomische DNA nur in Nanogramm-
Mengen und häufig degradiert zur Verfügung steht, wurde eine neue Strategie entwickelt und ausgetestet, die 
die gleichzeitige Sequenzierung vieler DNA-Proben ermöglicht. Die Strategie erhielt die Bezeichnung ASP16, 
da sie Gesamtgenom-Amplifikation (A), HPV16-DNA-Selektion (S) und Hochdurchsatz-Pyrosequenzierung (P) 
gefolgt von bioinformatischer Datenanalyse miteinander kombiniert. Zwei ASP16-Experimente wurden 
durchgeführt, mit denen die Ausführbarkeit der neuen Strategie bewiesen werden konnte. Die bekannte 3’ viral-
zelluläre Verbindungsstelle der integrierten HPV16-DNA in MRI-H186 konnte in beiden Experimenten 
nachgewiesen werden. HPV16-DNA-Integrationsstellen wurden in solchen klinischen Proben identifiziert, die 
einen hohen Anteil an integrierter HPV16 DNA enthielten. Krebsbezogene zelluläre Gene an den 
Integrationsstellen, besonders Gli1 und Grem2, sind interessante Kandidaten für eine HPV16-induzierte 
Insertionsmutagenese. Zukünftige Optimierungen der ASP16-Methode sollten hauptsächlich eine Erhöhung der 
durchschnittlichen Sequenzlängen zum Ziel haben, damit alle möglichen viralen DNA-Bruchpunkte in der 
HPV16 E1/E2-Region vollständig erfasst werden können. 
Die ASP16-Strategie bietet erstmalig die Möglichkeit, in klinischen Proben von Zervixabstrichen die HPV16-
DNA-Integrationsstellen in einem Multiplex-Ansatz systematisch zu bestimmen, unter besonderer 
Berücksichtigung der geringen Menge und Qualität der Proben-DNA. Dieses besondere Merkmal der ASP16-
Strategie wird eine Eingliederung der HPV16-DNA-Integrationsanalyse in Zervix-Screeningprogramme 
ermöglichen. Die Verwendung der ASP16-Methode wird dazu beitragen, progressive und hochgradig 
veränderte Zervix-Läsionen eindeutig zu identifizieren sowie weitere Einblicke in die molekularen Mechanismen 
der Zervixkarzinom-Entstehung zu erhalten.  
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Abstract 
Persistent infection with high-risk human papillomavirus (HPV) types, most frequently HPV16, 
is a necessary cause of cervical cancer. Correlated with tumor progression, the circular HPV 
DNA usually becomes integrated into the host cell genome with diverse target sites. HPV 
DNA integration may induce alterations of flanking cellular genes by insertional mutagenesis 
that contribute to the multistep process of carcinogenesis. The primary goal of this study was 
the design of a novel strategy to determine HPV16 DNA integration sites at the sequence 
level in selected pre-cancerous and cancerous lesions obtained from cervical scrapes.  
While testing restriction-site PCR for HPV16 DNA integration analysis, cell line MRI-H186 
was identified as an interesting case of HPV16-induced insertional mutagenesis of the c-myc 
proto-oncogene. Associated with HPV16 DNA integration into the c-myc locus, over-
expression of c-myc was found at both mRNA and protein levels. In addition, several HPV16 
integration variants were characterized at the sequence level. One of these variants is 
strongly expressed as myc-HPV16 hybrid transcript and MycHPV16E2 fusion protein both 
unique for MRI-H186. In MycHPV16E2, the amino-terminal part of the c-MYC trans-activation 
domain is fused to the linker and DNA-binding domain of HPV16 E2. These data strengthen 
the assumption that insertional mutagenesis, in this case c-myc activation/mutation, 
contributes to cervical carcinogenesis.  
For HPV16 DNA integration analysis in clinical samples from which genomic DNA is available 
only in nanogramme amounts and often degraded, a novel strategy enabling the 
simultaneous sequencing of multiple DNA samples was developed and examined in the 
present study. This strategy was named ASP16 because it combines whole genome 
amplification (A), HPV16 DNA selection (S) and high-throughput pyrosequencing (P) followed 
by bioinformatics data analysis. Two ASP16 experiments were performed, which have proven 
the feasibility of the novel strategy. The known 3’ viral-cellular junction sequence of integrated 
HPV16 DNA in MRI-H186 was identified in both experiments. HPV16 DNA integration sites 
were determined in clinical samples harbouring high percentages of integrated HPV16 DNA. 
Cancer-related cellular genes near or at the integration sites, namely Gli1 and Grem2, hold 
great potentials as candidates for HPV16-induced insertional mutagenesis. Future 
optimizations of the ASP16 method will focus primarily on increasing the average sequence 
length for a complete coverage of all possible viral DNA breakpoints in the HPV16 E1/E2 
region.  
Taken together, the ASP16 strategy offers for the first time the opportunity to systematically 
explore HPV16 DNA integration sites in a multiplex manner in clinical samples obtained from 
cervical scrapes, with particular respect to low quantity and poor quality of the template DNA. 
This unique feature is of great interest for the incorporation of HPV16 DNA integration 
analysis into routine cervical screening programs. Application of APS16 will contribute 
unequivocally to identify lesions of progressive or highly advanced disease and to obtain 
further insights into the underlying molecular mechanisms of cervical carcinogenesis. 
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1.   Introduction 
1.1  Human papillomaviruses and cervical cancer 
Cancer of cervix uteri is the second most frequent malignant disease diagnosed in 
women all over the world (Parkin et al., 2005). It has been estimated that in 2002 
there were about 493000 new cases of cervical cancer and 274000 deaths attributed 
to this sexually transmitted disease worldwide (Parkin et al., 2005). The human 
population comprises about 2329 million females currently at the age of 15 or older, 
who are at the risk of developing cervical cancer and its precursors (Castellsagué et 
al., 2007).  
According to the cell type involved, cervical cancer can be histologically divided into 
three categories: squamous cell carcinoma, adenocarcinoma and adenosquamous 
carcinoma. Most reported cases of cervical cancer are squamous cell carcinomas, 
while only about 11.4% are ascribed to adenocarcinomas or adenosquamous 
carcinomas (Vizcaino et al., 1998). The role of human papillomavirus (HPV) as 
etiologic agent for cervical carcinogenesis was initially hypothesized in mid-1970s 
(zur Hausen et al., 1974; zur Hausen, 1976 and 1977). In early 1980s, zur Hausen 
and co-workers reported the isolation of HPV16 and HPV18 DNA directly from 
cervical carcinoma biopsies for the first time (Dürst et al., 1983; Boshart et al., 1984). 
Meanwhile, HPV DNA has been detected in as much as 99.7% of invasive cervical 
squamous cell carcinomas worldwide (Bosch et al., 1995; Walboomers et al., 1999). 
Analysis of pooled data from international case-control studies has also shown that 
about 93% of invasive cervical adenocarcinomas and adenosquamous carcinomas 
are infected with HPV (Castellsagué et al., 2006). Although other risk factors are also 
contributive (Castellsagué and Muñoz, 2003), the causal relation between HPV 
infection and cervical carcinogenesis has been undoubtedly recognized and 
accepted (zur Hausen, 2002; Bosch et al., 2002), based on lines of molecular 
epidemiologic evidence from retrospective case-control and prospective cohort 
studies (Koutsky et al., 1992; Muñoz et al., 1992; Schiffman et al., 1993; Bosch et al., 
1995; Kjær et al., 1996; Ho et al., 1998; Walboomers et al., 1999; Liaw et al., 1999; 
Woodman et al., 2001). As a consequence of this well-established concept, recently 
a variety of prophylactic vaccines against HPV infection have been developed and 
applied, in order to prevent the global burden of cervical cancer fundamentally (Villa 
et al., 2005; Harper et al., 2006; Future II Study Group, 2007; Garland et al., 2007). 
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Over 100 distinct types of HPV have been identified so far (de Villiers et al., 2004), 
causing a wide spectrum of proliferative epithelial lesions from benign warts to 
malignant carcinomas (zur Hausen, 2002). Among them, about 40 types are 
classified as mucosotropic (or genital) HPVs, which all infect mucosal epithelial cells 
of the genital tract. Other HPV types belong to the category of cutaneous HPVs, 
which are generally found in common skin warts, Epidermodysplasia verruciformis 
(EV) lesions or immune-suppressed individuals (de Villiers et al., 2004). Based on 
the prevalence in cervical squamous cell carcinomas, a subset of at least 15 genital 
types is epidemiologically classified as high-risk HPVs, which are significantly 
associated with cervical carcinogenesis (Muñoz et al., 2003). This group contains 
HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82. By contrast, 
12 low-risk genital types (especially HPV6 and HPV11) are common in genital warts, 
but rarely found in cervical cancer. Two high-risk HPV types, HPV16 and HPV18, are 
regarded as major contributors to cervical cancer, which account for about 70% 
(HPV16, 55%; HPV18, 15%) of the invasive cervical carcinomas reported worldwide 
(Clifford et al., 2003; Smith et al., 2007).  
 
1.2  HPV genome organization and transcription map 
The genomic information of HPV is compacted into circular double-stranded DNA 
with a size of about 8 kb, enclosed by a non-enveloped icosahedral capsid shell. The 
HPV16 DNA genome encodes eight open reading frames (ORFs) and can be divided 
into three subgenomic regions: early, late and non-coding region (Figure 1-1). The 
early region contains six ORFs, E1, E2, E4, E5, E6 and E7, which are expressed in 
the early stage of HPV16 life cycle. The late region contains two ORFs L1 and L2, 
which are expressed in the late stage. Between the L1 and E6 ORFs, there is a 
segment (about 1 kb) of non-coding DNA named upstream regulatory region (URR) 
or long control region (LCR), which harbours the viral DNA replication origin and 
regulatory elements (promoter and enhancer) essential for viral gene expression.  
Two major promoters, p97 and p670, are responsible for HPV16 gene expression 
(Zheng and Baker, 2006). The common early primary transcript starts from the early 
promoter p97 and is terminated at the early polyadenylation site at position 4215. It is 
alternatively spliced into various polycistronic mRNA species with different coding 
potentials for the six early proteins including E6, E7, E1, E2, E4 and E5 (Figure 1-2; 
species A-N). Because the E4 ORF does not have an own start-codon, E4 is 
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translated as a fusion-protein named E1^E4 together with the five N-terminal amino 
acids from E1. The major late primary transcript starts from the late promoter p670 
(within ORF E7) and is terminated at the late polyadenylation site at position 7321. It 
is also spliced into different mRNA species important for the expression of the two 
late proteins L1 and L2 (Figure 1-2; species R-T).  
                                  
Figure 1-1: The genomic organization of HPV16 DNA. The HPV16 DNA genome (7906 bp; circular 
double-stranded DNA) and approximate positions of the eight HPV16-encoded ORFs are schematically 
presented. The long control region (LCR) is located between L1 and E6 ORFs. The HPV16 early (p97) 
and late (p670) promoters are marked as black arrows. The HPV16 early (PAE) and late (PAL) 
polyadenylation sites are also shown. The figure was taken from Doorbar (2006).  
       
Figure 1-2: The HPV16 transcription map and coding potential of individual mRNA species. The 
HPV16 genome is shown in linear form, starting with the upstream regulatory region (URR) and followed 
by early and late regions. Positions for early (p97) and late (p670) promoters as well as for early (AE) 
and late (AL) polyadenylation sites are shown. The eight HPV16 ORFs are illustrated with positions of 
start and stop codons. The ORF E4 is spliced to the 5’-end of E1 at position 880. Various mRNA 
species derived from different usage of promoters and alternative splicing sites are shown together with 
their protein-coding potentials. For each species, exons (heavy lines), introns (thin lines) and positions 
of alternative splicing sites are demonstrated. The figure was taken from Zheng and Baker (2006).  
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1.3  HPV productive life cycle 
The natural host cells of HPV are human keratinocytes of the stratified squamous 
epithelium (zur Hausen, 2002). HPV infection is thought to begin with the access of 
viral particles to cells of the basal layer (Figure 1-3), which are able to proliferate and 
differentiate (Fehrmann and Laimins, 2003). HPV DNA replication is strictly 
dependent on the cellular DNA replication machinery, but also requires the viral 
proteins E1 and E2. E1 is a DNA helicase highly conserved among different HPV 
types, which binds to a consensus motif in the viral DNA replication origin, but with 
relatively weak affinity (Hughes and Romanos, 1993; Dixon et al., 2000). The E2 
protein as a replication factor helps to recruit E1 on its target site and facilitates the 
initial binding between them (Mohr et al., 1990).  
At the latent stage of infection, the HPV DNA genome is moderately replicated in 
synchrony with cellular DNA synthesis (Figure 1-3). The subsequent productive 
stage of HPV infection is tightly coupled with epithelial differentiation (Doorbar, 
2006). During the upward differentiation from basal cells to differentiated 
keratinocytes in the upper layers (Figure 1-3), the vegetative viral DNA amplification 
occurs, which is followed by the synthesis of capsid proteins and assembly of 
infectious virion particles (Doorbar, 2006). In normal epithelia, daughter basal cells 
exit from cell cycle and undergo terminal differentiation, as soon as they migrate into 
the suprabasal layers (Madison, 2003). However, in HPV-infected cells the 
differentiation process is retarded, the S-phase entry is activated, but the cell cycle is 
arrested at the G2/M boundary, thereby providing an environment permissive for 
both viral and genomic DNA replication (Cheng et al., 1995; Sherman et al., 1997; 
Davy and Doorbar, 2007). The re-entry of host cells into S-phase is believed to result 
from the transforming activities of viral oncoproteins E6 and E7, but the underlying 
mechanism for G2/M-arrest remains unclear. E7 promotes cell cycle progression, 
through direct association with the tumor suppressor protein pRB and the concurrent 
release of oncogenic transcription factor E2F (Dyson et al., 1989; Münger et al., 
1989a; Chellappan et al., 1992; Boyer et al., 1996). E6 binds to and induces the 
ubiquitin-mediated degradation of tumor suppressor protein p53, thereby disrupting 
the p53-mediated apoptotic pathways (Werness et al., 1990; Scheffner et al., 1990; 
Scheffner et al., 1993). Expression analysis suggested that E4 and E5 proteins may 
also contribute to viral genome amplification, but less is known about their functions 
(Doorbar, 2006). 
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As cells move to the upper epithelial layers (Figure 1-3), capsid proteins L1 and L2 
are expressed from late transcripts driven by the late promoter (p670 for HPV16), 
whose activation is believed to depend on cellular differentiation (Bedell et al., 1991; 
Higgins et al., 1992). Progeny virions are released from the tissue by regular 
desquamation, after the infected cells arrive at the epithelial surface (Fehrmann and 
Laimins, 2003).  
     
Figure 1-3: HPV16 productive life cycle and the molecular events involved. The stratified 
epithelium with different layers is schematically demonstrated on the left. Featured molecular events 
during the productive HPV16 infection are shown as arrows in the middle. Different stages of HPV16 life 
cycle are shown on the right. E6 and E7 (red circles) expressed from the early promoter p97 are present 
in the lower layers. Dark blue circles indicate the nuclei of normal, uninfected epithelial cells. Late 
events including viral DNA amplification and expression of capsid proteins (L1 and L2) are driven by the 
use of late promoter p670. The expression of E4 gene (green) is upregulated at this stage. The figure 
was taken from Middleton et al (2003). 
 
 
1.4  The natural history of HPV infection 
It has been estimated that up to 80% of the general female population carry HPV at a 
certain time of life (Brown et al., 2005). Fortunately, most infections are transient and 
not destined to develop cervical cancer (Ho et al., 1998; Moscicki et al., 1998; 
Woodman et al., 2001). Cervical carcinogenesis is a multi-stage process (Snijders et 
al., 2006), which generally takes over 10 years from the first infection with high-risk 
HPVs to invasive carcinomas (Wallin et al., 1999). Cervical cancer develops from 
stepwise, morphologically distinguishable pre-cancerous lesions (Holowaty et al., 
1999). There are two nomenclature systems widely applied to define the different 
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grades of cervical pre-cancerous lesions (Figure 1-4): the cervical intraepithelial 
neoplasia (CIN) terminology defined by histopathological features (Richart, 1967), 
and the squamous intraepithelial lesion (SIL) system based on cytological 
abnormality (Solomon et al., 2002).  
In general, about 80% of HPV infections are effectively cleared by host immune 
response (Ho et al., 1998; Franco et al., 1999; Baseman and Koutsky, 2005). From 
the other 20% of persistent infections, only few may progress to invasive cervical 
carcinomas ultimately (Ostör, 1993; Holowaty et al., 1999). It seems that low-grade 
lesions (CIN1 or low-grade SIL) represent the cytopathology of productive HPV 
infection (Peh et al., 2002; Middleton et al., 2003), and they often regress 
spontaneously (Cox et al., 2003; Moscicki et al., 2004). In contrast, high-grade 
lesions (CIN2/CIN3 or high-grade SIL) are considered as critical precursors to 
cervical cancer (Schiffman et al., 2007). However, only 10-20% of high-grade 
cervical pre-cancerous lesions will eventually progress to malignancy for unclear 
reasons (Nobbenhuis et al., 2001). In order to avoid over- and under-treatment in 
clinical practice, it is of particular interest to distinguish between cervical lesions with 
low and high risk for neoplastic progression. 
Persistent infection with high-risk HPVs is the necessary risk factor for cervical 
cancer and its precursors (Remmink et al., 1995; Moscicki et al., 1998; Nobbenhuis 
et al., 1999; Schlecht et al., 2001; Kjær et al., 2002). The two oncoproteins E6 and 
E7 of high-risk HPVs are obligatory for the induction and maintenance of transformed 
phenotypes in cervical cancer cells (von Knebel Doeberitz et al., 1992; Münger and 
Howley, 2002). However, E6 and E7 activities are not sufficient for the development 
of malignant transformation (zur Hausen, 2000 and 2002). Although in vitro studies 
have shown the efficient immortalization of primary human keratinocytes by high-risk 
HPV E6 and E7 (Münger et al., 1989b; Hawley-Nelson et al., 1989; Hudson et al., 
1990; Halbert et al., 1991), the HPV-immortalized cells are not tumorigenic in nude 
mice, unless the co-expression of additional cellular oncogenes (DiPaolo et al., 1989; 
Dürst et al., 1989; Pei et al., 1993; Narisawa-Saito et al., 2008). Therefore, it is 
suggested that in addition to the transforming activities of high-risk HPV oncogenes, 
the accumulation of yet unclear genetic and/or epigenetic alterations of host cells is 
also required for cervical malignant transformation. 
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Figure 1-4: Classification of cervical pre-cancerous lesions. The morphological abnormalities 
observed in cervical pre-malignant lesions (dysplasia and carcinoma in situ) and invasive carcinomas 
are schematically demonstrated. The correlation between CIN and SIL nomenclature systems for the 
classification of cervical pre-cancerous lesions is shown. (micro = microinvasive; inv = invasive). The 
figure was taken from Snijders et al (2006). 
 
 
1.5  HPV DNA integration in cervical carcinogenesis 
HPV DNA integration into the host cell genome is a frequent event during cervical 
carcinogenesis (Pett and Coleman, 2007), which has been associated with 
neoplastic progression from pre-malignant lesions to invasive carcinomas (Dürst et 
al., 1985; Cullen et al., 1991; Daniel et al., 1995; Klaes et al., 1999; Tonon et al., 
2001; Hopman et al., 2004; Hudelist et al., 2004). Integrated HPV DNA could be 
found in up to 88% of HPV16-positive and almost 100% of HPV18-positive cervical 
carcinomas (Cullen et al., 1991; Klaes et al., 1999; Kalantari et al., 2001). In clinical 
practice, HPV DNA integration has been shown to correlate with poor prognosis of 
cervical cancer and low-level of disease-free survival (Unger et al., 1995; Vernon et 
al., 1997; Kalantari et al., 1998).  
The integration of HPV into cellular DNA is thought to be mediated by non-
homologous DNA recombination mechanisms (Pett and Coleman, 2007). Upon 
integration, the episomal HPV DNA becomes linearized and inserted into human 
chromosomes (Schwarz et al., 1985). The breakpoints of HPV DNA are located in 
the E1 or E2 ORF from the early region, and in the L1 or L2 ORF from the late 
region, respectively (Figure 1-5). HPV DNA integration often results in disruption or 
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deletion of the E2 ORF, while the URR region together with E6 and E7 oncogenes 
are always retained (Schwarz et al., 1985). The transcription of integrated HPV DNA 
is activated by enhancer elements in the URR and started from the early promoter 
(Figure 1-5). Since the canonical HPV early polyadenylation site is missing, the 
transcription is terminated at the next possible polyadenlyation site in downstream 
cellular sequences. Finally, viral-cellular hybrid transcripts mainly for the expression 
of E6 and E7 oncoproteins are produced (Schneider-Gädicke* and Schwarz, 1986; 
Baker et al., 1987). 
           
Figure 1-5: Structure and expression of integrated HPV DNA. Upon integration, the circular HPV 
DNA is broken in ORF E1 or E2 from the early region, and in ORF L1 or L2 from the late region. Since 
the URR, promoter and E6/E7 region are always retained, transcription can start from the viral early 
promoter (p), continue into flanking cellular sequences and stop at an appropriate cellular 
polyadenylation site (pa). The viral-cellular hybrid transcript is used for the expression of viral 
oncoproteins E6 and E7. The figure was kindly provided by Elisabeth Schwarz (DKFZ, Heidelberg). 
 
 
Previous data have suggested that integrated HPV DNA provides a selective growth 
advantage for the host cells, in comparison with episomal DNA (Jeon et al., 1995). 
HPV DNA integration leads to the permanent incorporation of HPV DNA into the 
human genome, thereby enabling the constitutive expression of E6 and E7 
oncogenes for cellular transformation. The multifunctional viral E2 protein acts as a 
repressor of HPV early gene expression (Bernard et al., 1989; Romanczuk et al., 
1990). Since the E2 ORF is often disrupted in the integrated HPV DNA, HPV DNA 
integration may induce the over-expression of HPV oncogenes (Romanczuk and 
Howley, 1992). It has also been shown that the viral-cellular hybrid transcripts from 
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integrated HPV DNA have longer half-lives than the normal HPV early transcripts 
from episomal DNA (Jeon and Lambert, 1995). 
The HPV DNA integration sites identified so far are dispersed all over the human 
genome (Wentzensen et al., 2004; Kraus et al., 2008). There are no specific target 
sequences on human chromosomes for HPV DNA integration. In general, HPV DNA 
integration occurs preferentially in transcriptionally active regions and common fragile 
sites (Choo et al., 1996; Wentzensen et al., 2002; Thorland et al., 2003). As a 
consequence, the expression of cellular genes at or near the HPV integration sites 
could be influenced via insertional mutagenesis. In the context of cervical 
carcinogenesis, it may involve the activation of cellular proto-oncogenes or the 
inactivation of tumor suppressor genes. One well-documented example of insertional 
mutagenesis in cervical cancer is the down-regulation of the potential tumor 
suppressor gene APM-1 (ZBTB7C), which is induced by DNA integration of the rare 
high-risk HPV type 68 (Reuter et al., 1998). Another remarkable example is the over-
expression of c-myc proto-oncogene in several cervical carcinoma cell lines, which is 
associated with HPV DNA integration into the c-myc locus (Peter et al., 2006). It has 
been estimated that the myc locus is the most recurrent HPV integration site, which 
has been observed in about 10% of cervical carcinomas analysed until 2006 (Peter 
et al., 2006). Thus, HPV-induced insertional mutagenesis of particular cellular genes 
might enhance malignant progression in at least a subset of cervical cancers.  
 
 
1.6  Methods for HPV DNA integration analysis  
The determination of HPV integration sites can be achieved at the levels of 
chromosomes, genomic DNA and cDNA. At the chromosomal level, the integrated 
HPV DNA can be localized in specific chromosomal regions (cytogenetic bands) by 
in situ hybridization (Mincheva et al., 1987; Popescu et al., 1987; Couturier et al., 
1991). However, limited by the low resolution of this assay, it is not possible to 
identify which gene is located directly at or near the integration site. Therefore, in 
order to analyse the genetic context of integrated HPV DNA, integration sites have to 
be characterized at the DNA or cDNA sequence level.  
Since the integrated HPV DNA is co-transcribed together with downstream cellular 
DNA as a hybrid mRNA, the cellular sequences from this featured structure can be 
used to determine the HPV integration sites. Viral-cellular junction sequences were 
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obtained from cDNA libraries by cloning, hybridization and sequencing (Schneider-
Gädicke* and Schwarz, 1986). In later years, a method termed amplification of 
papilloma virus oncogene transcripts (APOT) has been applied to amplify the 3’ viral-
cellular junction sequences by RT-PCR (Klaes et al., 1999). However, the cDNA-
based assays have the common inherent limitation that the exact 3’ viral-cellular 
DNA junctions cannot be identified, because they are spliced out as intron during 
RNA processing (see Figure 1-5). Therefore, the most accurate determination of 
HPV integration sites should come directly from DNA sequence analysis. Earlier 
studies in this field were done with genomic DNA libraries, hybridization and 
sequencing (Baker et al., 1987). Later, several PCR-based methods for the 
identification of HPV integration sites have been published. Detection of integrated 
papillomavirus sequences (DIPS-PCR) is a ligation-mediated assay including 
restriction digestion, adapter ligation, linear amplification with HPV primer and PCR 
using nested HPV primer together with the adapter (Luft et al., 2001). Another 
ligation-mediated assay called restriction enzyme cleavage, self-ligation and inverse 
PCR (rliPCR) was also developed (Kalantari et al., 2001). Unlike DIPS-PCR and 
rliPCR, the restriction-site PCR (RS-PCR) is a semi-nested PCR assay, which does 
not require the digestion and ligation procedure (Sarkar et al., 1993; Thorland et al., 
2000). Details about the RS-PCR will be described in Section 2.1. 
Instead of determining HPV integration sites, an assay called E2-E6 quantitative 
PCR was developed to rapidly estimate the physical state of HPV16 DNA (episomal, 
integrated or a mixture of both) (Nagao et al., 2002; Peitsaro et al., 2002). As 
mentioned earlier, the percentages of integrated HPV DNA are positively correlated 
with pathologic grades of cervical lesions (Cullen et al., 1991; Daniel et al., 1995; 
Klaes et al., 1999; Tonon et al., 2001; Hopman et al., 2004; Hudelist et al., 2004). 
Accordingly, clinical pre-cancerous lesions often harbour a mixed form of episomal 
and integrated HPV DNA. Based on the assumption that ORF E2 is deleted or 
disrupted upon integration, the E2/E6 ratio obtained by quantitative PCR is thought to 
represent the percentage of integrated versus episomal HPV16 DNA (Figure 1-6), 
thereby implicating the physical state of HPV16 DNA in a given sample (Nagao et al., 
2002; Peitsaro et al., 2002). This method has been used in large-scale investigations 
to assess HPV DNA integration as a progression marker for cervical cancer (Arias-
Pulido et al., 2006; Briolat et al., 2007; Saunier et al., 2008). However, for accurate 
interpretation it is necessary to validate the HPV DNA integration status (after E2-E6 
quantitative PCR) at the DNA sequence level.  
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Figure 1-6: The principle of E2-E6 quantitative PCR. The structural difference between episomal and 
integrated HPV DNA is schematically represented, with the assumption that ORF E2 is deleted or 
disrupted in the integrated DNA. For better demonstration, the episomal HPV DNA is also shown in 
linear form. The blue line represents cellular DNA flanking the HPV integration site. Red arrows show 
the ORFs of E6, E7, E1 and E2. The E6 and E2 amplicons used in the quantitative PCR are marked in 
green. The E2/E6 ratio of 1 indicates purely episomal DNA, and the ratio of 0 indicates fully integrated 
DNA. E2/E6 ratios between 0 and 1 are interpreted as mixed HPV16 DNA. The figure was kindly 
provided by Elisabeth Schwarz (DKFZ, Heidelberg).  
 
 
1.7  CGE-DKFZ co-operation project 
The present study is part of a French-German co-operation project between 
Cancéropôle du Grand-Est (CGE) and DKFZ, aimed to improve the knowledge about 
HPV-induced cervical carcinogenesis. As a sub-project of this co-operation, our 
group in Heidelberg has been working on HPV16 DNA integration analysis in clinical 
cervical lesions together with two groups in France, one in Reims and the other in 
Besançon.  
Clinical samples were collected from women who participate in routine cervical 
screening programs carried out in Reims and Besançon. The great benefit of cervical 
screening is to discover cervical lesions at an early stage before malignant 
conversion, through a cytological procedure called Pap smear test (Papanicolaou 
and Traut, 1941). Since 1990s, the conventional Pap smear test has been replaced 
by liquid-based monolayer cytology systems (Hutchinson et al., 1991). The widely 
applied liquid-based ThinPrep Pap Test is also used in Reims and Besançon for 
primary screening (Clavel et al., 2001; Bory et al., 2002; Briolat et al., 2007; Saunier 
et al., 2008). With this method, samples are collected from the cervix using a 
cytobrush. After rinsing in the PreservCyt fixative, cells are fixated and preserved in 
the medium. For cytological test, an aliquot of liquid-fixed cells is spread on slide, 
stained and observed under a microscope, to detect cells with abnormal morphology 
(Hutchinson et al., 1991).  
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Besides the liquid-based cytology, additional analyses are performed in Reims and 
Besançon. For samples containing abnormal cells, the same slide preparations are 
also used to detect DNA aneuploidy, one of the hallmarks of cancer cells, using DNA 
image cytometry (Lorenzato et al., 2001). In order to increase the screening 
accuracy, HPV DNA testing for high-risk types has been applied in conjunction with 
cytological test (Clavel et al., 2001). The HPV testing is mainly done with the Hybrid 
Capture II assay, which is based on the specific binding of a mixture of RNA probes 
with high-risk HPV DNA from cell lysates (Lörincz, 1996). Because Hybrid Capture II 
cannot distinguish between individual HPV types, HPV genotyping is further 
performed using the Linear Array Test from Roche (Briolat et al., 2007). For those 
samples, which are classified as high-grade lesions by cytology and contain at least 
one of the high-risk HPV types, DNA and RNA samples are isolated for detailed 
molecular analysis. For HPV16 integration analysis, HPV16-positive DNA samples 
from high-grade lesions are sent to our group at DKFZ. In parallel, the estimation of 
HPV16 physical states by E2-E6 quantitative PCR is performed in Reims and 
Besançon (Saunier et al., 2008). 
 
 
1.8  Aims and outline of the thesis work 
The intention of our co-operation project was to evaluate HPV DNA integration as 
predictor for high-grade cervical pre-cancerous lesions and as neoplastic progression 
marker for cervical cancer development. The primary goal of this thesis work was to 
determine HPV16 DNA integration sites at the sequence level (viral DNA breakpoints 
and human genome target sequences) in selected pre-cancerous and cancerous 
lesions obtained from cervical scrapes within routine screening programs. For this 
purpose, two prerequisites had to be fulfilled. Firstly, a whole genome amplification 
(WGA) method tolerant to template DNA degradation was required to amplify the tiny 
amounts of often partially degraded clinical DNA samples derived from cervical 
scrapes. Secondly, it was intended to establish an adequate procedure that can 
identify viral-cellular junction sequences against a background of episomal HPV16 
DNA, especially for cervical pre-cancerous lesions.  
In the present study, it was initially planned to combine the phi29-based multiple 
displacement amplification (MDA) for WGA (Dean et al., 2002) with restriction-site 
PCR (RS-PCR) for junction sequence determination. However, by applying these 
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methods to DNA from HPV16-positive cell lines and clinical samples, it became 
apparent that phi29-MDA failed to amplify degraded DNA frequently isolated from 
cervical scrapes and RS-PCR seemed to be inappropriate for clinical samples 
containing episomal HPV16 DNA. Therefore, during the thesis work a novel 
alternative strategy for HPV16 integration analysis was developed and tested with 
cervical carcinoma cell lines as well as clinical DNA samples from cervical pre-
cancerous and cancerous lesions. The novel strategy, named ASP16, includes the 
robust PCR-based GenomePlex whole genome amplification (A), an HPV16 DNA 
enrichment-selection step (S) and high-throughput pyrosequencing (P) followed by 
bioinformatics analysis of the sequence data. Unique among methods for 
determination of HPV16 integration sites, ASP16 allows the simultaneous analysis of 
multiple DNA samples in one sequencing experiment. 
Based on the sequence data of HPV16 DNA integration, insertional mutagenesis of 
candidate cellular genes at or near the integration sites was investigated in the 
context of cervical carcinogenesis. Using RS-PCR, the HPV16 integration site in the 
cell line MRI-H186 was determined closely upstream of the c-myc proto-oncogene. 
Thus, cell line MRI-H186 turned out to be a remarkable example of HPV-induced 
insertional mutagenesis. Consequently, over-expression and mutations of the c-myc 
proto-oncogene associated with HPV16 DNA integration into the c-myc locus in MRI-
H186 were intensively further characterized in this work. For clinical samples 
analysed by ASP16, the cellular proto-oncogenes and tumor suppressor genes, 
whose expression might be directly affected by integrated HPV16 DNA, were 
predicted. In the context of the co-operation project, it is intended to interpret the 
HPV16 integration data in correlation with the molecular and clinical data assembled 
in Reims and Besançon to further validate HPV16 integration as marker for women 
with high-grade precursor lesions/cancer or at high risk for malignant progression 
and to further deepen the molecular understanding of cervical carcinogenesis.  
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2.   Results 
The experimental results of this thesis are divided into two parts. The first one 
describes the identification of HPV16 DNA integration sites with restriction-site PCR 
(RS-PCR) in the cervical carcinoma cell line MRI-H186, which turned out to be a 
remarkable example of insertional mutagenesis of the c-myc proto-oncogene. The 
second part is concerned with HPV16 DNA integration analysis in clinical DNA 
samples obtained from cervical scrapes, for which a novel strategy termed 
amplification-selection-pyrosequencing for HPV16 (ASP16) was developed. 
 
2.1  HPV16 DNA integration analysis with restriction-site PCR in cervical 
carcinoma cell lines 
At the beginning, it was planned to determine HPV16 DNA integration sites in clinical 
samples using restriction-site PCR (RS-PCR). As illustrated in Figure 2-1, this 
method includes two rounds of PCR (Sarkar et al., 1993; Thorland et al., 2000). For 
the first round, an HPV16 L1/L2 or E1/E2 primer is used in combination with eight 
restriction-site oligonucleotides (RSOs) in different reactions to amplify the 5’ or 3’ 
viral-cellular junction. The RSO primer contains the recognition sequence of an 
HPV16 non-cutting restriction enzyme (Figure 2-1 and Section 4.12.3). The second 
round is a semi-nested PCR to increase amplification specificity, for which a nested 
HPV16 primer works together with the same RSOs. Before dealing with clinical 
samples, genomic DNA from cell lines was used as template to establish the RS-
PCR. This involved the HPV16-positive cervical carcinoma cell lines SiHa, CaSki, 
MRI-H186 and MRI-H196. Among them, the chromosomal integration site of HPV16 
DNA in SiHa had been reported previously, and both the 5’ and 3’ viral-cellular 
junction sequences were determined (Baker et al., 1987; Meissner, 1999). For the 
other three cell lines, HPV16 DNA integration sites had not been characterized 
before at the DNA sequence level.  
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Figure 2-1:  Schematic demonstration of viral-cellular junctions and restriction-site PCR (RS-
PCR). Definition of the 5’ and 3’ viral-cellular junctions is shown in panel A. The procedure of RS-PCR is 
outlined in panel B. The RSO primer contains the T7-adapter sequence, a random sequence of ten 
nucleotides (N10), and the recognition sequence (Xs in blue) of an HPV16 non-cutting restriction 
enzyme.  
 
 
 
2.1.1  Identification of the 3’ viral-cellular junction sequence in SiHa  
Previous studies had shown that only one integration site of HPV16 DNA is present 
in SiHa cells, which is located in chromosomal region 13q22.1 (Baker et al., 1987; 
Meissner, 1999). The breakpoints of integrated HPV16 DNA are located at position 
3133 at the 3’ terminus and position 3385 at the 5’ terminus (Baker et al., 1987). For 
establishment of the RS-PCR, it was tested whether the 3’ viral-cellular junction 
sequence of SiHa can be re-identified. The first-round PCR was performed using 
primer HPV16-1546-26D in combination with eight individual RSO-primers in 
separate reactions, respectively (Thorland et al., 2000). For the second-round PCR, 
the nested primer HPV16-1588-26D was used to increase PCR specificity of the 
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HPV16 part (Thorland et al., 2000). In parallel, applicability of the unique T7-adapter 
sequence instead of the full-length RSO-primers in the 2nd PCR was also examined. 
The 2nd-PCR products were checked by gel electrophoresis, and then hybridized with 
the HPV16-complete DNA probe (Figure 2-2A and B). The final PCR products of two 
positive reactions, RSO-BamHI and RSO-SacI (red arrows in Figure 2-2A), were 
cloned. After the selection by Southern hybridization, nine clones positive for HPV16 
were sequenced completely. As a result, all clones contained the same 3’ viral-
cellular junction sequence of SiHa DNA (Figure 2-2C and D), which is identical with 
the published data (Baker et al., 1987; Meissner, 1999). The consensus sequence 
derived from the nine clones is shown in Appendix 1. 
In conclusion, the 3’ viral-cellular junction sequence of SiHa DNA (Figure 2-2D) could 
be re-identified with RS-PCR. The cellular parts of the RS-PCR amplicons (Figure 2-
2C) were overall long enough for database searching to localize the junction 
sequences on human chromosomes. Concerning the specificity of priming in the 2nd 
PCR, the T7-adapter (Figure 2-2A) exhibited more reliability than the full-length RSO-
primers (Figure 2-2B), and therefore was used in successive experiments.  
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Figure 2-2: Identification of the 3’ viral-cellular junction sequence in SiHa by RS-PCR. RS-PCR 
was performed using either T7-primer (panel A) or RSO (panel B) in combination with HPV16-1588-26D 
for the 2nd-round PCR reaction. In both cases, gel analysis (top) of the 2nd-PCR products and Southern 
hybridization (bottom) with the HPV16-complete DNA probe are shown. The SmartLadder was used as 
size marker. Nine clones (panel C) were obtained from the 2nd-PCR products of RSO-BamHI and RSO-
SacI (red arrows in panel A) and were sequenced. The structure of the viral-cellular junction identified 
by RS-PCR is schematically demonstrated in panel D. The dashed arrows show the orientation of the 
viral and cellular DNA involved. 
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2.1.2  Identification of HPV16 DNA integration sites in cell lines MRI-H186, MRI-
H196 and CaSki 
 
MRI-H186: 
It was shown in previous experiments that the HPV16 DNA is integrated in 
chromosomal region 8q24 near the c-myc proto-oncogene in MRI-H186 (Wanschura, 
1992). However, the exact junction sequences were unknown. For determining the 3’ 
viral-cellular junction sequence of MRI-H186 DNA with RS-PCR, the HPV16 primers 
used for the two-round reaction were exactly the same as in SiHa (see Section 
2.1.1). To obtain the 5’ junction sequence, primers HPV16-6688-25U and HPV16-
5885-27U were used for the 1st and 2nd PCR, respectively (Thorland et al., 2000). As 
a result, both 3’ and 5’ viral-cellular junction sequences could be identified in MRI-
H186 (Figure 2-3). Altogether 15 clones (Figure 2-3C) containing the 3’ or 5’ viral-
cellular junction sequence of MRI-H186 were obtained from various 2nd-PCR 
products (red arrows in Figure 2-3A and B). The consensus sequences for both 
junctions derived from the 15 clones are shown in Appendix 1.  
As shown in Figure 2-3D, the breakpoints of HPV16 DNA are located at position 
2754 at the 3’ terminus and position 4871 at the 5’ terminus. The HPV16-E2 gene 
(position 2756 to 3853) is completely deleted in this DNA architecture. By database 
searching, the HPV16 integration site of MRI-H186 DNA was mapped to 
chromosomal band 8q24.21. A small deletion of 8 bp was observed in the flanking 
cellular sequences around the integration site. Since the c-myc gene starts at 
position 128817498 of chromosome 8 (NC_000008.9), it became clear that this 
human proto-oncogene is located directly downstream and in close proximity to the 
integrated HPV16 DNA (see more details in Section 2.2).   
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Figure 2-3: Identification of the 3’ and 5’ viral-cellular junction sequences in MRI-H186 by RS-
PCR. The 2nd-PCR products and Southern hybridization with the HPV16-complete probe are shown for 
the 3’-junction (panel A) and 5’-junction RS-PCR (panel B). The SmartLadder was used as size marker. 
Fifteen clones (panel C) obtained from the final products of seven PCR reactions (red arrows in panel A 
and B) were sequenced. Panel D shows the structures of the 5’ and 3’ junctions based on the sequence 
data. 
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MRI-H196: 
For MRI-H196, RS-PCR for the 3’ viral-cellular junction was carried out using primers 
HPV16-1546-26D and HPV16-2387-25D sequentially. RS-PCR for the 5’ junction 
was primed by HPV16-6688-25U and HPV16-6653-25U (Thorland et al., 2000). 
Altogether four clones (Figure 2-4C) from two 2nd-PCR products (red arrows in Figure 
2-4A and B) were sequenced. The cloned 3’-junction was sequenced completely, 
and the breakpoint of HPV16 DNA is located at position 3858 (Figure 2-4D). This 
leaves the HPV16-E2 gene (position 2756 to 3853) intact. A small DNA insertion 
“TTAC” was found at the junction site between HPV16 (position 3858) and cellular 
DNA (position 47967861). The consensus sequence for the 3’ junction of MRI-H196 
is shown in Appendix 1. By contrast, the cloned 5’-junction could not be sequenced 
in full length for unknown reasons. Therefore, it was not possible to determine the 
exact breakpoints of HPV16 and the cellular DNA for this junction. The gap is 
estimated to be about 400 bp (Figure 2-4D). The partial sequences of the 5’ junction 
are shown in Appendix 1. The HPV16 integration site of MRI-H196 DNA was 
mapped to chromosomal band 11p11.2. By comparing the cellular sequence 
positions at the 5’ and 3’ junctions, a DNA deletion of about 1 Mb in the cellular target 
sequence was detected. 
 
 
 
CaSki: 
RS-PCR failed to determine any viral-cellular junction sequence of CaSki DNA. Only 
pure HPV16 amplicons from the E1/E2 region were obtained, which were caused by 
false priming of RSO primers onto the HPV16 DNA (data not shown). Every CaSki 
cell contains approximately 500 copies of integrated HPV16 DNA, and most of them 
are present as concatemers of the complete HPV16 genome (Yee et al., 1985; Baker 
et al., 1987). This feature is most likely the reason for the false priming as well as the 
failure to amplify and detect the much less-abundant viral-cellular junctions.  
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Figure 2-4: Identification of the 3’ and 5’ viral-cellular junction sequences in MRI-H196 by RS-
PCR. The 2nd-PCR products and Southern hybridization with the HPV16-complete probe are shown for 
the 3’-junction (panel A) and 5’-junction RS-PCR (panel B). The SmartLadder was used as size marker. 
Four clones (panel C) obtained from the final products of two PCR reactions (red arrows in panel A and 
B) were sequenced. Panel D shows the structures of the 5’ and 3’ junctions based on the sequence 
data. The precise viral-cellular DNA boundary of the 5’ junction is not known. The sequence gap 
(dashed red line) has a size of about 400 bp. 
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2.2  Genetic context of integrated HPV16 DNA in MRI-H186 
Because the integrated HPV16 DNA is located closely upstream of the c-myc gene in 
MRI-H186 cells, it was decided to clarify whether and to which extent this important 
cellular proto-oncogene is affected by HPV16 DNA integration.  
 
2.2.1  The viral-cellular DNA organization 
The human c-myc gene is mapped to chromosomal band 8q24.21, and the three 
exons of c-myc expand from position 128817498 to 128822853 (NC_000008.9) of 
the forward DNA strand. As displayed in Figure 2-5A, the HPV16 DNA in MRI-H186 
is integrated upstream and in sense orientation to the c-myc gene. The distance 
between the HPV16 DNA breakpoint at the 3’ junction and the transcription initiation 
site of c-myc is only 1709 bp.  
The integrated HPV16 DNA as determined by RS-PCR in MRI-H186 (see Section 
2.1.2) is designated as HPV16 integration variant A (Figure 2-5A). To verify the viral-
cellular DNA organization of HPV16 integration variant A, a series of long-PCR 
reactions was performed using different combinations of HPV16 and c-myc primers 
(table in Figure 2-5B). SiHa DNA was used as a control for the uninterrupted c-myc 
allele. As shown by the agarose gel in Figure 2-5B, all PCR products agreed with the 
expected sizes. Both the 5’ and 3’ junctions were confirmed by junction-specific PCR 
(reactions 8 and 10). Combining c-myc primers 128815697-F and 128816053-R, 
which are located directly upstream (5’) and downstream (3’) of integration variant A, 
a PCR product of the expected size (6.1 kb) was obtained (reaction 2). In addition, a 
small PCR product representing the c-myc wild-type allele was amplified not only 
from SiHa DNA as expected (reaction 1), but also in reaction 2 with MRI-H186 DNA 
as template. This result implied that either a normal chromosome 8 exists in MRI-
H186 cells or that the mutated chromosome 8 with integrated HPV16 DNA also 
harbors an uninterrupted c-myc allele. 
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Figure 2-5: Long-PCR analysis to examine the genetic context of HPV16 integration variant A in 
MRI-H186. The junction sequences obtained from RS-PCR were combined to predict the genetic 
context (panel A) of HPV16 integration variant A and flanking cellular sequences. The genomic 
positions at the HPV16 integration junctions and of the three c-myc exons are given (NC_000008.9). 
The c-myc wild-type allele without integrated HPV16 DNA is shown above. The blue lines with the 
flanking arrows indicate the positions of the PCR products and their primers outlined in the table of 
panel B. The numbers correspond to the PCR numbers in the table. Five primer combinations (table in 
panel B) were used in long-PCR to test the predicted DNA structure in MRI-H186 (SiHa as control). 
PCR products are shown on the gel. The numbers above the lanes correspond to the PCR numbers in 
the table. The red arrow indicates the 6.1-kb band containing the HPV16 integration variant A. The 
!/Hind III (leftmost) and SmartLadder (rightmost) were used as size marker. (a.e. = as expected) 
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2.2.2  HPV16/c-myc transcripts 
To investigate how HPV16 integration variant A might affect c-myc gene expression 
in MRI-H186, putative transcripts were predicted based on the architecture of 
integrated HPV16 DNA and c-myc gene (Figure 2-6A). The URR-E6-E7 region of 
HPV16 is entirely retained in MRI-H186 and therefore ensures expression of the viral 
oncogenes E6 and E7. The downstream-located c-myc transcription unit is fully 
intact. For that reason, transcription can be initiated at the HPV16 early promoter 
p97, and then continues through the 3’ viral-cellular junction and the downstream c-
myc gene, until it is terminated at the c-myc poly-A signal. RNA splicing will generate 
a viral-cellular hybrid transcript (HPV16-myc mRNA), which contains HPV16-E6 and 
E7 as well as exons 2 and 3 of c-myc. In addition, because the c-myc promoter P1 is 
maintained, the normal c-myc mRNA is also expected in MRI-H186. RT-PCR was 
applied to examine whether the two predicted transcripts are produced in MRI-H186 
cells. In Figure 2-6B, the primer pairs and products are summarized in the table, and 
the experimental results are shown on the gel photo. With the exception of PCR 
numbers 7 and 8, all primers used are located in different exons, so that cDNA 
templates can be distinguished from DNA contamination. Not intended to amplify E6 
splicing variants (see Figure 1-2), only primers in E7 (HPV16-811-F and HPV16-856-
F) were selected for the HPV16 part. As a result, the lengths of cDNA amplicons 
checked on gel consisted with the expected sizes and thereby proved the existence 
of the two transcripts. 
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Figure 2-6: Prediction and RT-PCR analysis of HPV16/c-myc transcripts in MRI-H186. According to 
the viral-cellular DNA organization (top), two transcripts with different coding potentials were predicted 
(panel A). The dashed lines indicate the introns removed by splicing. In panel A, the numbered lines 
below the DNA and RNA structures indicate the primer pairs and RT-PCR products. The existence of 
the transcripts was checked by RT-PCR with six different primer pairs in altogether twelve reactions 
(table in panel B). Negative results were expected from reactions 1, 3 and 5 (because no product could 
be generated in SiHa using an HPV16 primer together with a c-myc primer) as well as from reaction 2 
(because the 128817900-R in c-myc exon 1 does not bind to the HPV16-myc mRNA sequence). The 
RT-PCR products were checked on agarose gel. The reactions 4 and 6 (red arrows on gel photo) clearly 
showed the existence of the HPV16-myc hybrid mRNA. The 100 bp DNA Ladder (leftmost) and 
SmartLadder (rightmost) were used as size marker. (a.e. = as expected) 
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2.3  Expression level of c-myc in MRI-H186 
2.3.1  c-myc Northern blot analysis 
To detect myc-containing transcripts, Northern blot analysis was carried out using all 
three c-myc exons as DNA probes. Among them, only the c-myc exon 1 probe can 
distinguish between the HPV16-myc and the normal c-myc mRNA. For interpretation 
of c-myc expression level, poly-A+ mRNA from HeLa and CaSki cells was used for 
comparison with MRI-H186. It had been reported previously that c-myc gene is over-
expressed in HeLa and CaSki cells (Dürst et al., 1987). Interestingly, the Northern 
blot analysis revealed that c-myc expression is strongly elevated in MRI-H186, even 
if compared with HeLa and CaSki (Figure 2-7). The normal c-myc mRNA (exons 1 to 
3) has a length of 2362 nt. The HPV16-myc mRNA has a size of 2590 nt if E6 is 
present, or of 2408 nt if the spliced E6* is generated. Thus, the HPV16-myc and c-
myc transcripts cannot be distinguished by size on Northern blot. In order to estimate 
the relative amount of the two transcripts in MRI-H186 cells, signal intensities 
produced with the three c-myc exon probes were compared to each other. The signal 
intensity produced by the exon 1 probe is very similar to the intensities from exon 2 
and exon 3 probes. Since exon 1 is only present in the normal c-myc mRNA, but not 
in the HPV16-myc mRNA, it can be concluded that the normal c-myc mRNA is the 
predominant myc-containing transcript in MRI-H186.  
Strikingly, an extra RNA band was observed in MRI-H186, which hybridized with c-
myc exon 1 and exon 2, but not with exon 3 (red arrows in Figure 2-7). This RNA is 
shorter than the normal c-myc mRNA as well as the HPV16-myc hybrid mRNA, and 
is expressed in a notable amount. Identification of the structure and origin of this 
RNA will be explained in Section 2.4, together with the Northern blot analysis using 
HPV16-specific DNA probes. 
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Figure 2-7: c-myc transcript level in MRI-H186. Poly-A+ mRNA was isolated from total RNA of HeLa, 
MRI-H186 and CaSki. Three Northern blots were prepared in parallel using equal amounts of the 
isolated mRNA, and hybridized with the c-myc exon 1, 2 and 3 DNA probes, respectively. The blots 
were post-hybridized with the GAPDH probe as sample-loading control. The red arrows show an 
unexpected band, which is only positive for c-myc exons 1 and 2, but not for exon 3. 
 
2.3.2  c-MYC Western blot analysis  
The Northern blot analysis showed that in MRI-H186 the normal c-myc mRNA is 
produced in large amount, compared to HeLa and CaSki. In the next step, the protein 
expression level was examined by Western blot analysis.  
Translated from the AUG start-codon at the beginning of c-myc exon 2, the c-MYC 
oncoprotein, also named c-MYC-2 or p64, is composed of 439 amino acids. In 
addition, an alternative start codon CUG at the end of exon 1 is also active and gives 
rise to a c-MYC isoform called c-MYC-1 or p67, which is longer than c-MYC-2 with 
15 additional residues at the N-terminus. This unusual CUG start-codon is not as 
efficient as the classic AUG, and therefore the c-MYC-1 protein is normally translated 
at a negligible scale.  
With an anti-c-MYC antibody (clone 9E10) directed against an epitope at the C-
terminus (see Section 4.6), c-MYC protein expression levels were analysed in MRI-
H186 and other cell lines. Consistent with the up-regulation at RNA level, c-myc is 
also over-expressed at protein level in MRI-H186, compared to the non-cancerous 
cell line HaCaT as well as the cervical carcinoma cell lines C4-I, C4-II and MRI-H196 
(Figure 2-8). Elevated c-MYC protein levels were also observed in HeLa cells as 
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expected, and in the HPV-negative cervical carcinoma cell line C33A. Unlike the 
great difference on Northern blots (see Figure 2-7), the c-MYC protein in MRI-H186 
is expressed in similar amount as in HeLa. 
In conclusion, the human c-myc gene is over-expressed at both RNA and protein 
levels in MRI-H186, associated with HPV16 DNA integration into this locus.  
     
Figure 2-8: Expression level of c-MYC protein in MRI-H186. The c-MYC protein levels of various 
cancerous and non-cancerous cell lines were assessed by Western blot using antibody 9E10 directed 
against the C-terminus of human c-MYC protein. MRI-H186 cell lysates were prepared from two 
individual cell cultures to check reproducibility. GAPDH protein was used as an internal sample-loading 
control. 
 
2.4  HPV16 transcript pattern in MRI-H186 
Due to similar sizes the expected HPV16-myc hybrid mRNA (see Figure 2-6) seems 
to co-migrate with the normal c-myc mRNA on Northern blot, as deduced from the c-
myc Northern blot shown in Figure 2-7. To directly visualize the HPV16-myc mRNA, 
Northern blot experiments were performed using HPV16-specific probes. Three DNA 
probes were used for detection, covering the complete HPV16 genome, the E6-E7 
region and the E2 region, respectively. Besides MRI-H186, the HPV16-positive cell 
lines SiHa and CaSki were included in the analysis. In addition, it had to be clarified 
whether the extra-RNA hybridizing with c-myc exons 1 and 2 (see Figure 2-7) 
contains HPV16 sequences. The Northern results are shown in Figure 2-9. 
The HPV16 transcript patterns are strongly different among the three cell lines. 
CaSki shows multiple robust bands on Northern blots, whereas the HPV16 
transcripts of SiHa cells are hardly visible. For MRI-H186, hybridization with the 
HPV16-complete probe revealed three major mRNAs, which are indicated by the 
green, blue and red arrows in Figure 2-9. The mRNA indicated by the blue arrows 
seems to be the HPV16-myc hybrid mRNA, because it hybridized with the E6-E7 
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probe but not with E2. The mRNA with the strongest hybridization signal (red arrows) 
has a size very similar to the extra-RNA observed on the c-myc Northern blots. The 
mRNA hybridized with HPV16-complete and E2, but not with E6-E7. These results 
strongly suggested that a transcript containing sequences from the c-myc exon 1, 
exon 2 and HPV16-E2 could be existent in MRI-H186. The RNA band marked by the 
green arrows on the Northern blots seems to hybridize with HPV16-complete and E2, 
but not with E6-E7. The structure of this transcript has not been unravelled.  
 
Figure 2-9: HPV16 transcript pattern in MRI-H186. Three Northern blots were prepared in parallel 
using poly-A+ mRNA. The blots were hybridized with three HPV16 DNA probes corresponding to the 
indicated different regions in the HPV16 genome, respectively. The Northern blot hybridized with the c-
myc exon 1 probe was taken from Figure 2-7 for comparison with the HPV16 Northern blots. The red 
arrows indicate the mRNA hybridizing with c-myc exons 1 and 2 as well as HPV16-E2. The blue arrows 
implicate the HPV16-myc hybrid mRNA. The green arrows indicate another mRNA hybridizing with 
HPV16-E2, but without further sequence information. The 28S and 18S rRNA bands were used as 
internal size marker. The blots were post-hybridized with the GAPDH probe as sample loading control. 
 
2.5  Identification of myc-HPV16 hybrid mRNA in MRI-H186 
In the c-myc and HPV16 Northern blot analysis, a novel transcript in MRI-H186 
became apparent, which is composed of c-myc exons 1 and 2 as well as HPV16-E2 
sequences (see Sections 2.3.1 and 2.4). Rapid amplification of cDNA ends (RACE) 
analysis was carried out in order to clarify the precise structure of this transcript. 
Details about the RACE procedure are explained in Materials and Methods (see 
Section 4.27). After the synthesis of 5’ or 3’-RACE-ready cDNA, eight PCR reactions 
for the 5’ and 3’ RACE of MRI-H186 were performed using the universal adapter 
UPM in combination with eight different gene-specific primers, respectively. These 
primers have forward orientation for 3’-RACE or reverse orientation for 5’-RACE, and 
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are specific for HPV16-E7 or E2 and c-myc exon 1 or exon 2 (Figure 2-10A). Final 
products of all eight reactions (Figure 2-10B) were cloned and sequenced. 
Altogether, 32 sequences were obtained. After sequence comparison with the 
HPV16 genome as well as the c-myc cDNA reference (Accession number: 
NM_002467), 13 non-redundant sequences were obtained (Figure 2-10C).  
With these experiments the novel transcript hybridizing with HPV16-E2 and c-myc 
probes could be identified. It is a myc-HPV16 hybrid transcript composed of c-myc 
exon 1, a truncated variant of exon 2, and the 3’-terminal part of HPV16-E2 (Figure 
2-10D). The normal c-myc exon 2 is 774 nt long (128819675 – 128820448), whereas 
the truncated variant is only 195-nt long (128819675 – 128819869). The truncated c-
myc exon 2 is joined to the 3’ part of the HPV16 early region starting with the splice 
acceptor at position 3358 in E2/E4, and terminating with the poly-A signal at position 
4215. Between the c-myc and HPV16 parts, the three nucleotides “AAG” are found in 
the hybrid mRNA. The origin of this tri-nucleotide sequence will be described later in 
Section 2.6. The RACE cDNA sequence of the myc-HPV16 mRNA was confirmed by 
convenient RT-PCR using primer 128817576-F (in c-myc exon 1) in combination with 
HPV16-3572-R (in HPV16-E2) followed by cloning and sequencing (data not shown). 
The cDNA sequence of myc-HPV16 mRNA is shown in Appendix 2. 
In addition to myc-HPV16, an HPV16-myc-HPV16 mRNA was also revealed by 
RACE (Figure 2-10C and D). It differs from the myc-HPV16 mRNA by replacing the 
myc-exon1 with HPV16-E6* (position 97–226). This mRNA is probably not expressed 
to a notable level in MRI-H186, because no corresponding band (below myc-HPV16 
mRNA) was detected on Northern blots (see Figures 2-7 and 2-9). The existence of 
HPV16-myc-HPV16 mRNA was proven by RT-PCR using primer pair HPV16-103-F 
(in E6 and E6*) and HPV16-3572-R (in E2) followed by cloning and sequencing (data 
not shown).  
Additional transcripts identified by RACE include the HPV16-myc and the normal c-
myc mRNA as expected (see Section 2.2.2). Furthermore, HPV16 early transcripts 
were also found. These results strongly suggested that MRI-H186 cells may harbor 
integrated HPV16 copies containing an intact HPV16 early region. The HPV16 early 
transcripts were verified by RT-PCR using primers HPV16-103-F and HPV16-3572-R 
followed by cloning and sequencing (data not shown).  
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Figure 2-10: Identification of mRNA variants in MRI-H186 by RACE. Positions of gene-specific 
primers for RACE are shown in panel A. Final PCR products of the eight RACE reactions are shown on 
agarose gel (panel B). The SmartLadder was used as size marker. Thirteen non-redundant sequences 
each containing at least two exons are shown in panel C (Ex = exon; tr = truncated). The structures of 
two novel myc-HPV16 hybrid transcripts and HPV16 early transcripts identified by RACE are shown in 
panel D. The HPV16 transcript map was taken from Zheng and Baker (2006). 
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2.6  Genetic origin of the myc-HPV16 hybrid mRNA 
The structures of the novel myc-HPV16 hybrid transcript could not be deduced from 
the DNA architecture of HPV16 integration variant A (see Figure 2-5A). Therefore, 
the HPV16 integration variant responsible for expression of the myc-HPV16 hybrid 
mRNA had to be identified. For this purpose, long-PCR reactions with combinations 
of five different c-myc forward primers and one HPV16 reverse primer were 
performed (Figure 2-11). The HPV16 reverse primer has been chosen with a location 
in the L2 ORF, assuming that the integrated HPV16 DNA extends beyond the early 
region poly-A site (position 4215). Selected PCR amplicons (red arrows in Figure 2-
11B) were cloned and sequenced.  
 
    
Figure 2-11: Long-PCR analysis to amplify the DNA architecture responsible for the myc-HPV16 
mRNA. Based on the RACE results, the DNA structure for the myc-HPV16 hybrid mRNA was predicted 
(panel A).  Five c-myc forward primers were used in combination with the same HPV16 reverse primer 
for long-PCR (panel B). The !/HindIII was used as size marker. The PCR products of reactions 2 and 4 
(red arrows on gel photo) were cloned and sequenced.  
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The sequences revealed a new genomic viral-cellular junction in MRI-H186 cells. 
The HPV16 DNA in this architecture is named HPV16 integration variant B. At the 
junction site, the c-myc gene is disrupted at position 128819869 inside of exon 2, and 
connected with HPV16 DNA at position 2201 within the E1 region (Figure 2-12). This 
DNA rearrangement activates the splice donor sequence “AAG’GTA” located at 
HPV16 position 2201–2206, which matches perfectly to the consensus sequence of 
splice donors (A/C-A-G’G-T-A/G), but is not used in the context of HPV16 early gene 
transcription (see Figure 1-2). 
 
Figure 2-12: Genetic origin of the myc-HPV16 hybrid transcript. The structure of HPV16 DNA 
integration variant B is shown (top). The transcription procedure from DNA to myc-HPV16 mRNA is 
schematically demonstrated. (Do = splice donor; Ac = splice acceptor) 
 
 
2.7  The novel MycHPV16E2 fusion protein in MRI-H186 
2.7.1  Coding potential of myc-HPV16 hybrid mRNA  
The amino acid sequence encoded by the myc-HPV16 hybrid mRNA was predicted 
from the cDNA sequence. Because the fused HPV16 part harbors both the E2 ORF 
and the overlapping E4 ORF, it was of interest to determine whether translation 
initiated at the c-myc start codon will continue in frame with HPV16-E2 or E4. As 
shown in Figure 2-13, the myc-HPV16 hybrid transcript has the potential to encode a 
MycHPV16E2 fusion protein.  
The resulting fusion protein contains the first 60 amino acids of human c-MYC at the 
N-terminus, followed by the last 165 amino acids of HPV16-E2 at the C-terminus 
(Figure 2-13B). Both c-MYC and HPV16-E2 proteins are DNA-binding transcription 
factors with a similar domain organization, i.e., both start with a trans-activation 
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domain (TAD) and end with a DNA-binding domain (DBD), linked together by a 
flexibly structured hinge region. The MycHPV16E2 fusion protein contains the N-
terminal 60 residues of the c-MYC TAD and the complete HPV16-E2 DBD, 
connected by the HPV16-E2 hinge region. The sequence of the MycHPV16E2 fusion 
protein is shown in Appendix 2.  
 
       
Figure 2-13: Coding potential of the myc-HPV16 hybrid mRNA. The HPV16 E2 and E4 ORF in the 
region affected by HPV16 DNA integration were compared with the fusion ORF (panel A). The 
comparison indicates that the truncated c-MYC ORF is fused to the HPV16-E2 ORF. The triplet codons 
involved are underlined in different colours (blue for c-myc and red for HPV16). The structure of the 
MycHPV16E2 fusion protein is shown in panel B. (TAD = trans-activation domain; DBD = DNA-binding 
domain)   
 
2.7.2  Detection of MycHPV16E2 fusion protein 
According to the predicted sequence, the novel MycHPV16E2 fusion protein is 
composed of 225 amino acids with a calculated molecular weight of 25.6 kDa, if the 
AUG start codon is used for translation. For detection of this protein on Western blot, 
the anti-c-MYC antibody specific for a C-terminal epitope (see Section 2.3.2) is not 
suitable. Likewise, the HPV16-E2 antibody commercially available recognizes the N-
terminus of the E2 protein. Therefore, Western blot analysis was performed using a 
c-MYC antibody clone Y69 directed against an N-terminal epitope of c-MYC (see 
Section 4.6). This antibody should recognize both c-MYC and the MycHPV16E2 
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fusion protein. The results are shown in Figure 2-14. Indeed, MycHPV16E2 fusion 
protein was detected exclusively in MRI-H186 cell lysates, but not in other cell lines 
(Figure 2-14). 
    
Figure 2-14: Detection of MycHPV16E2 fusion protein by Western blot. The c-MYC antibodies 
specific for the N-terminus (clone Y69) or the C-terminus (clone 9E10) were used for detecting the c-
MYC-related signals. The MRI-H186 cell lysates from two individual preparations were analysed in 
parallel. GAPDH protein was used as an internal sample-loading control. The red arrow points to the 
MycHPV16E2 fusion protein.  
 
 
2.8  Comprehensive analysis of HPV16 integration variants in MRI-H186 
The DNA and RNA analysis mentioned before clearly demonstrated that at least two 
HPV16 DNA integration variants exist in MRI-H186, and both are located in the c-
myc region. Integration variant A refers to the DNA structure identified by RS-PCR 
(see Section 2.2.1). Integration variant B is the DNA structure from which the 
MycHPV16E2 fusion protein derives (see Section 2.6). In addition, the c-myc wild-
type allele unchanged by HPV16 DNA integration is also existent in MRI-H186 (see 
Section 2.2.1). This section is concerned with further investigation of HPV16 DNA 
integration variants existent in MRI-H186, through the combination of Southern blot 
and long-PCR. It involves the identification of novel HPV16 integration variants and 
characterization of their flanking cellular sequences. 
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2.8.1  HPV16 integration variants A and A+ 
Southern blot analysis was performed with genomic DNA digested with HindIII and 
XbaI, respectively. Both enzymes are HPV16 non-cutter, and therefore have 
recognition sites in the flanking cellular sequences. Deduced from the DNA 
sequence of integration variant A, cleavage should produce HPV16-cellular hybrid 
fragments of 16.8 kb (HindIII) and 12.8 kb (XbaI), respectively (Figure 2-15A). After 
hybridization with the HPV16-complete DNA probe, however, two bands from each 
digestion were observed on the blot (Figure 2-15B). These results indicated that 
there are two major HPV16 integration variants in MRI-H186. The two lower bands 
were compatible with the expected fragments (HindIII and XbaI) of integration variant 
A. The two larger bands with sizes greater than 23 kb for HindIII and about 20 kb for 
XbaI, should represent another integration variant. 
 
Figure 2-15: Southern blot analysis of HPV16 DNA in MRI-H186. Recognition sites for HindIII and 
XbaI flanking the HPV16 integration variant A are shown in panel A. MRI-H186 genomic DNA cleaved 
by HindIII or XbaI was blotted and hybridized with the HPV16-complete probe (panel B). Positions for 
the 23.1-kb band of !/Hind III and the 10-kb band of SmartLadder marker are marked for size 
determination. 
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As mentioned in Section 2.5, RACE assay suggested that at least one copy of the 
complete HPV16 genome is available in MRI-H186. The size difference between the 
smaller and the larger fragment from each digestion on Southern blot is about 8 kb 
(see Figure 2-15). Therefore, it was assumed that the larger Southern fragments 
contain the same viral-cellular junctions as integration variant A, but include 
additionally a complete HPV16 genome. This hypothetical structure was named 
HPV16 integration variant A+ and is shown in Figure 2-16. The calculated sizes of 
A+ would be 24.7 kb (16.8 kb + 7.9 kb) for HindIII and 20.7 kb (12.8 kb + 7.9 kb) for 
XbaI, in agreement with the bands detected on Southern blot (see Figure 2-15).  
In order to test the assumption, it was first attempted to amplify the complete 
integration variant A+ by long-PCR using cellular primers 128815697-F and 
128816053-R (positions shown in Figure 2-16). However, the expected product of 14 
kb was not obtained, probably because it is too long to be amplified. Furthermore, 
the same primers also bind to integration variant A as well as to the c-myc wild-type 
allele, and therefore favored the generation of these shorter amplicons of 6.1 kb and 
357 bp, respectively (data not shown). To overcome this problem, long-PCR was 
performed with combinations of cellular and HPV16 primers located in E2 or L2 
(Figure 2-16), since this region is deleted in integration variant A. As a result, the two 
PCR amplicons 1 and 2 with overlapping sequences in the HPV16-E2/L2 region 
were successfully amplified and cloned. One clone of each amplicon was fully 
sequenced and the sequence alignment was in complete agreement with the 
predicted structure of integration variant A+ (Figure 2-16). 
 
Figure 2-16: Long-PCR analysis of HPV16 integration variant A+ in MRI-H186. The predicted 
structure of integration variant A+ as well as the recognition sites for HindIII and XbaI are shown. The 
locations of the two overlapping amplicons 1 and 2 are indicated below.  
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Since integration variant A+ was not obtained in one piece by long-PCR, further 
Southern blot analysis was performed to confirm the predicted structure. Besides the 
HPV16 non-cutter (HindIII), an HPV16 single-cutter NcoI was used, in order to divide 
variant A+ into shorter fragments, which are suitable for size determination on 
Southern blot. Cleaving at position 863 of HPV16 DNA, NcoI cuts twice within variant 
A+ and provides three fragments: an entire HPV16 genome (7.9 kb), and two viral-
cellular junctions identical to those found in variant A (Figure 2-17A). Southern blot 
analysis was performed using MRI-H186 DNA cleaved by HindIII and NcoI in single 
and double-digestions. The blots were hybridized with three probes: HPV16-
complete, HPV16-E2 and c-myc exon 3. The expected and experimentally observed 
results are compiled as diagrams, table and autoradiographs in panels A, B and C of 
Figure 2-17, respectively. The bands observed on the blots agreed with the predicted 
fragment patterns of integration variants A and A+. In particular, the 7.9-kb NcoI 
fragment (F9) representing the complete HPV16 genome was detected with both the 
HPV16-complete and E2 probes. In addition, the c-myc wild-type allele previously 
identified by PCR (see Section 2.2.1) was detectable by the c-myc exon 3 probe 
(fragments F1, F2 and F3).  
 
It needs to be noticed that unexpected HPV16-E2 hybridization signals were found at 
positions similar to those of integration variant A. These bands are labelled as “X” in 
Figure 2-17C with HPV16-E2 probe. Since integration variant A is supposed to be 
absolutely negative for E2, it should hybridize only with probes HPV16-complete and 
c-myc exon 3 (fragment F4). This paradox can be explained by two possible reasons: 
either there could be another unknown HPV16 integration variant in MRI-H186, or 
the HPV16-E2 probe cross-hybridizes with integration variant A. The latter possibility 
was ruled out, because the HPV16-E2 probe did not hybridize with the cloned 
integration variant A (data not shown).  
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       * Only fragments hybridizing with at least one of the three DNA probes are mentioned. 
           The Southern blots are shown in Figure 2-17C on next page. 
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Figure 2-17: Southern blot analysis to verify the structure of HPV16 integration variants A and A+ 
as well as the c-myc wild-type allele in MRI-H186. The structures of c-myc wild-type allele and 
integration variants A and A+ as well as the recognition sites of HindIII and NcoI are demonstrated in 
panel A. For each DNA architecture, the total number, the expected sizes and the probe specificity of 
cleaved fragments (single or double-digested) were calculated and shown in panel B. Three Southern 
blots were prepared in parallel with MRI-H186 genomic DNA cut by Hind III, Nco I or both, and 
hybridized with the probes indicated (panel C). The expected fragments are designated by numbers 
from F1 to F9 (in red). Positions of !/Hind III (leftmost) and SmartLadder (rightmost) markers are 
marked for size determination. 
 
 
2.8.2  HPV16 integration variants B and A-B 
The HPV16 integration variant B is the DNA template of the myc-HPV16 hybrid 
mRNA (see Figure 2-12). To detect this DNA architecture on genomic DNA Southern 
blot, the structure of the integrated HPV16 as well as its flanking cellular sequences 
to the next recognition sites of HindIII or NcoI needed to be further characterized. In 
variant B, a truncated c-myc exon 2 is fused to the downstream HPV16 DNA broken 
at position 2201 at the junction site. According to previous PCR data, the HPV16 
sequence continues at least until position 5125 in the L2 ORF (see Section 2.6, 
Figure 2-11). In order to localize the 3’ junction of variant B, a series of long-PCR 
reactions were performed using the c-myc forward primer 128819700-F (in exon 2) in 
combination with eleven HPV16 reverse primers covering almost the complete 
HPV16 genome (Figure 2-18). PCR products of expected sizes were observed in 
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reactions 1 to 7 until the reverse primer position 1098, but no amplification products 
were obtained from reactions 8 to 11 (Figure 2-18C). The results suggested that the 
3’ breakpoint of HPV16 integration variant B is located between positions 1098 and 
1332.  
 
Figure 2-18: Long-PCR analysis to delimit the 3’ breakpoint of HPV16 integration variant B. 
Positions of c-myc primer 128819700-F and the eleven reverse primers (R1-R11) throughout the HPV16 
genome are shown in panel A. The expected sizes of PCR products are given in the table of panel B. 
The long-PCR results are shown in panel C. The !/HindIII (leftmost) and SmartLadder (rightmost) were 
used as size marker. The observed amplicon sizes are included in the table of panel B (a.e. = as 
expected). The red line (in panel B) and arrow (in panel C) show the boundary between the positive and 
negative PCR results.  
 
After delimiting the 3’ HPV16 breakpoint, the next challenge was to identify the exact 
3’ viral-cellular junction sequence. The experiment was based on the assumption that 
insertion of integration variant B has not caused severe deletions in the c-myc gene, 
as observed in variants A and A+. Various long-PCR reactions were performed using 
the same forward primer 128819700-F as before in combination with reverse primers 
specific for c-myc exon 2 or exon 3. All primer combinations failed to amplify the 3’ 
junction of integration variant B (data not shown). At that time, however, a novel 3’ 
junction sequence was identified by Martine Peter (Institut Curie, Paris) using DIPS-
PCR (see Section 2.9). In this sequence (Appendix 1), HPV16 DNA is broken at 
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position 1223 and linked to position 128744999 of chromosome 8. This position is 
located about 72.5 kb upstream of the c-myc gene. Since the 3’ HPV16 breakpoint 
falls into the region between positions 1098 and 1332 determined by long-PCR, a 
tentative structure of variant B was assembled by combining the results from long-
PCR and DIPS-PCR (Figure 2-19).  
 
Figure 2-19: Predicted structure of HPV16 integration variant B. The results of long-PCR (see 
Figure 2-18) and DIPS-PCR (Martine Peter, Paris) were combined to predict the complete structure of 
integration variant B. The DNA regions determined by the two approaches are underlined. 
 
 
To test the predicted structure, seven long-PCR reactions were designed for direct 
amplification of the complete variant B (Figure 2-20). Positive PCR products were 
expected only from four reactions (no. 2, 3, 4 and 7), while the other three served as 
negative controls. PCR products were obtained in all four reactions albeit at rather 
low yield, and hybridized with HPV16-complete DNA probe. Three of them showed 
the expected sizes on the gel. One of them (7.3 kb, lane 4) was cloned and 
sequenced. The sequence (data not shown) agreed with the predicted DNA structure 
of variant B.  
The PCR product of reaction 2 showed a size of about 4.4 kb, in contrast to the 
expected size of 11.3 kb (Figure 2-20B). To clarify the structure of this fragment, the 
PCR product 2 was cloned and sequenced. According to the sequence (data not 
shown), this product turned out to be a novel HPV16 integration variant, which 
contains the same 5’ junction as variant A (chr8-128815779/HPV16-4871) and the 3’ 
junction of variant B (HPV16-1223/chr8-128744999). Therefore, this novel variant is 
named A-B (Figure 2-20C).  
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Figure 2-20: Long-PCR amplification of HPV16 integration variants B and A-B in MRI-H186. 
Primer positions of PCR reactions 2, 3, 4 and 7 for amplification of integration variant B are shown in 
panel A. Seven long-PCR reactions were performed (panel B, left), and the products were blotted and 
hybridized with HPV16-complete probe (panel B, middle). The primers as well as the expected and 
observed sizes of the PCR reactions are described in the table (panel B, right part). Negative PCR 
results were expected for PCR 1 (because the HPV16-1470-F sequence is not present in variant B), for 
PCR 5 (because the 128821823-F sequence is not present in variant B), and for PCR 6 (because the 
128744774-F sequence is not present in variant B and HPV16-209-R has the “wrong” orientation). The 
!/HindIII and SmartLadder were used as size marker. The PCR product of lane 4 (panel B) was cloned 
and sequenced. The sequence indicated a novel integration variant A-B (panel C). PCR reactions 1, 5 
and 6 were expected to be negative, because the forward primers cannot hybridize. (a.e. = as expected) 
 
 
2.8.3  HPV16 integration variant C  
An HPV16-myc-HPV16 hybrid mRNA was discovered by RACE assay (see Section 
2.5). This transcript contains HPV16-E6* (position 97–226) instead of c-myc exon 1, 
followed by the truncated c-myc exon 2 and the 3’ part of HPV16-E2. The transcript 
structure implied that at the DNA level another HPV16 integration variant (called C) 
should be located upstream of c-myc exon 1 and variant B. It was assumed that 
variant C has the same 3’-junction as variant A (Figure 2-21A). Long-PCR assays 
were designed and performed to test the assumption (Figure 2-21B). The expected 
7-kb amplicon specific for the juxtaposed variants C_B was not obtained. Instead, a 
2.3-kb amplicon was produced (Figure 2-21B, reaction 1). This product was also 
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expected because the primer pair used also binds to variants A, A+ and C. The 
amplicon from these templates is only 2.3 kb and preferentially amplified in the PCR 
reaction. In reaction 2, the 4.4-kb band of template C_B was observed with expected 
size, besides the 7.7-kb band from variant A+. In reaction 3, the forward primer 
HPV16-2881-F cannot bind to the predicted structure of integration variant C. As 
expected, no C_B specific product was found on the gel, but only the PCR product 
from A+. Comparison between PCR 2 and 3 clearly delimits the 3’ HPV16 breakpoint 
of integration variant C between positions 2701 and 2881, compatible with position 
2754. The 4.4-kb product of PCR 2 was cloned and sequenced. The sequence (data 
not shown) confirmed the predicted DNA arrangement of variants C_B, as shown in 
Figure 2-21A.  
The 5’ junction of variant C has not been determined. Nevertheless, variant C can be 
easily distinguished from variants A and A+ by the downstream cellular sequences. 
For variant C the downstream cellular sequence extends for 4082 bp until position 
128819869 including c-myc exon 1 and truncated exon 2, while for variants A and A+ 
the cellular sequences extend further including all three c-myc exons (see Section 
2.8.1). 
 
Figure 2-21: Identification of HPV16 integration variant C in MRI-H186 by long-PCR. The predicted 
structure of integration variant C based on RACE assay together with integration variant B is shown in 
panel A. Primer positions of three long-PCR reactions are marked by arrows. The expected long-PCR 
products and their DNA templates (integration variants) are listed in panel B (a. e. = as expected). Gel 
analysis of PCR products is shown. The !/HindIII (leftmost) and SmartLadder (rightmost) were used as 
size marker. 
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2.8.4  HPV16 integration variants D and E 
The identification of yet another integration variant was absolutely unexpected 
because it was obtained from a PCR reaction using primer pair 128816664-F and 
128816053-R. This combination was originally considered as a negative control for 
amplifying integration variant A, because the forward primer is downstream from the 
reverse primer. Nevertheless, a robust band of around 5 kb was observed on the gel 
(data not shown). The fragment was cloned and sequenced completely. The 
sequence showed a novel HPV16 integration variant called D (Figure 2-22A). It 
contains the same 3’ junction (HPV16-2754/chr8-128815788) as in variants A and 
A+, while its 5’ HPV16 breakpoint is not at position 4871, but at position 7848. With 
this breakpoint, only the 3’ segment of the URR containing the core promoter is 
retained upstream of the E6/E7 oncogenes, while the enhancer segment is deleted. 
Whether the E6/E7 genes are transcribed from this integration variant remains 
unknown. The 5’ junction is featured by an additional DNA re-arrangement: a 159-bp 
fragment (position 128805467–128805625) originally located about 12 kb upstream 
from c-myc gene is inserted between position 128818697 (c-myc) and position 7848 
(HPV16). 
The structure shown in Figure 2-22A also revealed that the upstream and 
downstream cellular regions of HPV16 integration variant D share common 
sequences of 2910 bp (128815788–128818697). This raised the possibility that 
variant D is preceded by another integrated HPV16 copy. Long PCR was performed 
with the assumption that the suspected upstream HPV16 integration variant (called 
E) contains the same 3’-junction at position 2754 as D. The experimental design and 
the results are shown in Figure 2-22B. The primer pairs for PCR 1 and 2 are 
expected to produce amplicons of 5.7 kb and 4.5 kb from variants E_D as template, 
respectively. These sizes should be clearly distinguishable from the amplicons of 7.8 
kb and 6.5 kb, expected from template A+. The primer pair for PCR 3, however, 
should only be able to amplify a product of 6.4 kb from template A+. The PCR results 
are in full agreement with the expectation (Figure 2-22B). However, PCR yield of the 
two E_D specific fragments was very low, and thus they were difficult to clone. To 
further verify the existence of integration variant E, diagnostic cleavage reactions 
with XbaI were performed (Figure 2-22C). XbaI has a recognition site in the cellular 
sequence between E and D, but not in the amplified HPV16 sequences of variant A+. 
After XbaI cleavage, the sub-fragments expected for variants E_D were obtained. 
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Figure 2-22: Determination of HPV16 integration variants D and E in MRI-H186. Panel A shows the 
structure of variant D and primer positions for the PCR reaction from which variant D was cloned. The 
blue line indicates the extra cellular sequence at the 5’ junction. Three long-PCR reactions were 
performed to test the predicted DNA structure of E_D (panel B). Primer positions and expected size of 
PCR products are given in the table (a. e. = as expected; n. a. = not applicable). In panel C, the results 
of XbaI digestion of PCR products 1 to 3 are shown. The recognition site of XbaI for variants E_D is 
marked by the red arrow. 
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2.8.5  Summary of HPV16 integration variants identified in MRI-H186 
A collection of seven HPV16 integration variants (A, A+, B, C, A-B, D and E) together 
with their flanking cellular sequences have been identified in MRI-H186, mainly by 
RS-PCR, long-PCR and Southern blot analysis. The structures are schematically 
outlined in Figure 2-23 and Table 2-24. Variants A and A+ are regarded as the two 
major HPV16 DNA integrates in MRI-H186 mainly because they are visible as very 
strong bands on genomic Southern blots (see Section 2.8.1). Furthermore, either the 
5’ or 3’ viral-cellular junction of variants A and A+ (the junction sequences are 
identical in A and A+) is also available in all other integration variants except in 
variant B. This suggests that all integration variants in MRI-H186 may originate from 
a primary integration event, which could be A or A+.  
It needs to be noticed that not all HPV16 integration variants existent in MRI-H186 
have been fully characterized. The 5’ junction sequences of variants C and E remain 
unclear, and some weak bands on Southern blots (see Figure 2-17C) are still difficult 
to explain. Even for variants B and A-B, which have been amplified and fully 
sequenced, the expected restriction fragments have not been clearly identified on 
Southern blots. Furthermore, the order of all the integration variants on chromosome 
8 is not known. 
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Figure 2-23: Summary of HPV16 DNA integration variants identified in MRI-H186. The schematic 
demonstration of all HPV16 integration variants characterized in MRI-H186 is shown. Positions of 
HPV16 and chromosome 8 (NC_000008.9) at the junction sites are given. The vertical blue bars and the 
numbers above indicate the c-myc exons (tr = truncated). The 5’ junction of variants C and E were not 
determined. The downstream cellular sequences of variants A and A+ contain the intact c-myc gene 
(position 128817498 to 128822853).  
Table 2-24: Summary of HPV16 DNA integration variants identified in MRI-H186. 
HPV16 
integration 
variant 
5’-junction 
(cellular pos. 
HPV16 pos.) 
3’-junction 
(HPV16 pos. 
cellular pos.) 
Length of 
HPV16 part Comments 
A 
 
chr8-128815779 
HPV16-4871 
HPV16-2754 
chr8-128815788 5789 bp 
major variant 
c-myc exons 1+2+3 
HPV16-myc mRNA 
A+ 
chr8-128815779 
HPV16-4871 
HPV16-2754 
chr8-128815788 13695 bp 
major variant 
c-myc exons 1+2+3 
HPV16-myc mRNA 
HPV16 mRNAs 
B 
chr8-128819869 
HPV16-2201 
HPV16-1223 
chr8-128744999 6929 bp 
minor variant 
c-myc exons 1+2(tr) 
myc-HPV16 mRNA 
MycHPV16E2 protein 
C unknown HPV16-2754 chr8-128815788 unknown minor variant 
A-B chr8-128815779 HPV16-4871 
HPV16-1223 
chr8-128744999 4259 bp minor variant 
D chr8-128818697 HPV16-7848 
HPV16-2754 
chr8-128815788 2813 bp minor variant 
E unknown HPV16-2754 chr8-128815788 unknown minor variant 
C_B tandem 
   HPV16-myc-HPV16 mRNA 
c-myc exons 1+2(tr) in cellular 
linker sequence (4081 bp; pos. 
128815788–128819869) 
E_D tandem 
   c-myc exon 1 in cellular  
linker sequence  
(2909 bp + 159 bp = 3068 bp;  
pos. 128815788-128818697 and 
pos. 128805467–128805625) 
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2.9  Supplementary data from Jérôme Couturier and Martine Peter 
In order to obtain additional information about the molecular mechanisms of HPV16-
induced insertional mutagenesis of c-myc proto-oncogene in MRI-H186, cooperation 
was arranged with Jérôme Couturier and Martine Peter from the Institut Curie (Paris, 
France). Using methods established in their laboratories and employed for their 
analysis of HPV16/18 integration in the c-myc region of cervical carcinoma samples 
(Couturier et al., 1991; Peter et al., 2006), they performed additional experiments 
with MRI-H186 cells, namely fluorescence in situ hybridization on MRI-H186 
chromosomes, spectral karyotyping, DIPS-PCR and quantitative PCR for copy 
number determination in the c-myc region. The data obtained from Paris are 
summarized in this section.  
 
2.9.1  Fluorescence in situ Hybridization analysis 
Since multiple HPV16 DNA integration variants and the wild-type c-myc allele have 
been identified in MRI-H186 (see Section 2.8.5), it was interesting to find out whether 
MRI-H186 cells contain a normal chromosome 8 negative for integrated HPV16 
DNA, or other HPV16 integration events outside of chromosome 8. To answer these 
questions, a dual-color fluorescence in situ hybridization (FISH) was performed by 
Jérôme Couturier. The chromosomes of MRI-H186 were hybridized with a blend of 
the c-myc and the HPV16 DNA probe labelled by different fluorescence dyes, 
respectively. The fluorescence signal of each dye was measured individually and 
merged together for evaluation. As shown in Figure 2-25, integrated HPV16 DNA is 
always co-localized with the c-myc gene in MRI-H186. There was definitely no 
HPV16 signal found on other chromosomes in this cell line, and no chromosome 8 
without integrated HPV16 DNA was observed. Only two chromosomes 8 were 
detected in each MRI-H186 cell and both were positive for HPV16. Taken together, 
the FISH assay indicated that the HPV16 DNA integration variants co-localize with 
the c-myc sequences on chromosome 8.  
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Figure 2-25: Dual-color FISH assay to demonstrate the co-localization of HPV16 DNA integrates 
and the c-myc gene. DAPI was used to visualize DNA/chromosomes (in blue). The HPV16 DNA probe 
was labelled with FITC (green light emission), while the c-myc probe was labelled with Spectrum 
Orange (red light emission). Cells were hybridized with a mixture of these three fluorescent dyes. The 
white light signal (red + green + blue = white) indicates the co-localization of HPV16 and c-myc. The 
experiments were performed and the figures were provided by Jérôme Couturier (Institut Curie, Paris). 
 
 
2.9.2  Spectral karyotyping 
In addition to FISH assay, the R-band karyotyping analysis of MRI-H186 cells was 
also performed by Jérôme Couturier. The cells appeared to be near-tetraploid and 
highly differed in the numbers of individual chromosomes. It was not possible to 
obtain a modal chromosome number for this cell line (Jérôme Couturier, personal 
communication). Therefore, a representative karyotype of MRI-H186 cells is shown 
in Figure 2-26. In agreement with the FISH results, only two chromosomes 8 were 
found in MRI-H186 cells, although other chromosomes showed great heterogeneity 
in their numbers. 
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Figure 2-26: R-band karyotype of MRI-H186 cells. The MRI-H186 cells showed overall near-
tetraploidy. Only two chromosomes 8 (indicated by the red circle) are present in these cells. The 
experiments were performed and the figure was provided by Jérôme Couturier (Institut Curie, Paris). 
 
 
2.9.3  DIPS-PCR 
In parallel with our RS-PCR analysis, the DIPS-PCR assay was performed by 
Martine Peter to determine the HPV16 DNA integration site in MRI-H186. Sequence 
data from DIPS-PCR revealed two viral-cellular junction sequences of MRI-H186 
DNA. One 5’-junction is identical with the chr8-128815779/HPV16-4871 determined 
by RS-PCR (see Section 2.1.2). The other one is the 3’-junction of the integration 
variants B and A-B (see Section 2.8.2). 
 
 
2.9.4  c-myc quantitative PCR 
The genomic Southern analysis suggested that the HPV16 integration variants 
(especially A and A+) together with the flanking cellular sequences seem to be co-
amplified in MRI-H186, because of the strong hybridization signals (see Figure 2-17). 
To determine the exact copy number of amplified DNA, quantitative PCR using ten 
amplicons throughout the 8q24.21 region was performed by Martine Peter (methods 
and primers as described in Peter et al., 2006). Two peaks of DNA copy number 
were detected from the 8q24.21 region in MRI-H186 (Figure 2-27). The higher peak 
with 26 copies represents the amplicon Q8 within the c-myc exon 1. This amplicon 
involves the c-myc wild-type allele as well as the flanking cellular sequences of 
almost all HPV16 integration variants characterized so far except the minor variant A-
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B. The lower peak reflects the copy number of amplicons Q5 and Q6, which are 
located very close to each other. This cellular region is located about 14 kb 
downstream of the 3’-junction of integration variants B and A-B (see Section 2.8.5).  
 
Figure 2-27: Determination of DNA copy numbers in chromosomal region 8q24.21 by quantitative 
PCR. Start positions* of the ten amplicons and the copy numbers determined by qPCR are shown in the 
table. The chart shows the copy numbers (Y-axis) and chromosomal locations (X-axis) of all the ten 
amplicons. The experiments were performed and the figures were provided by Martine Peter (Institut 
Curie, Paris). 
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2.10  Development of the novel amplification-selection-pyrosequencing 
strategy for HPV16 DNA integration analysis (ASP16) 
The major goal of the thesis work was to determine HPV16 DNA integration sites in 
pre-cancerous and cancerous lesions obtained from cervical scrapes. In general, two 
fundamental challenges are recognized for clinical DNA samples. Firstly, the amount 
of DNA obtained from cervical scrapes is rather low, approximately 1 µg per sample. 
From each sample, we obtained about 100 ng of DNA for HPV16 integration 
analysis. In order to get enough template DNA for PCR-based determination of 
HPV16 integration sites, DNA samples have to be amplified accordingly. Secondly, 
clinical DNA samples are often degraded to some extent, during the preservation 
stage between cervical scraping and DNA isolation. These problems called for a 
reliable DNA whole genome amplification (WGA) method, which should tolerate DNA 
degradation. To combine the WGA with integration analysis, a novel strategy named 
amplification-selection-pyrosequencing for HPV16 (ASP16) was developed in this 
thesis, which mainly consists of three steps as follows: 
Step 1 – Amplification (A): whole genome amplification of clinical DNA sample. 
Step 2 – Selection (S): selection of HPV16-containing DNA from the WGA library. 
Step 3 – Pyrosequencing (P): use of the next-generation DNA sequencing platform 
from Roche/454.  
 
2.10.1  ASP16 Step 1 – Amplification 
For the first step of ASP16 strategy, the GenomePlex whole genome amplification 
(GP-WGA) system from Sigma-Aldrich was applied according to the manufacturer’s 
instruction. This is a PCR-based method tolerant to DNA degradation, because 
genomic DNA templates are fragmented at the very beginning (Langmore, 2002). 
This advantage is of particular interest for clinical DNA samples. The principal steps 
of GP-WGA are outlined in Figure 2-28. Genomic DNA is randomly fragmented into 
PCR-amplifiable sizes by chemical digestion and heating. Then, the denatured DNA 
fragments are exposed to a mixture of degenerate primers, which all contain the 
same GenomePlex universal adapter (GPUA) sequence at their 5’ ends. Through a 
stepped isothermal amplification, DNA fragments are converted into the so-called 
OmniPlex library, which represents the whole genomic DNA input. In this library, all 
DNA fragments of 400 bp on average carry the uniform GPUA at both 5’ and 3’ ends. 
!"#$%&#'''(*'
'
Finally, the OmniPlex library is used as template for whole genome DNA 
amplification, which is achieved by PCR using GPUA as primer. To reduce 
amplification bias, PCR is performed with a limited number of thermal cycles (14 
cycles). The input for GP-WGA can be as little as 10 ng of genomic DNA, which is 
easily obtainable from cervical scrapes. In the end, the DNA template will be 
amplified about 500-fold to a yield of around 5 µg. 
               
Figure 2-28: The GenomePlex whole genome amplification (GP-WGA) system. The procedure of 
GP-WGA is schematically demonstrated. Details about individual steps are explained in the text. The 
figure was taken from the Whole Genome Amplification Advisor provided by Sigma-Aldrich. 
 
To test GP-WGA performance, four reactions were done with different HPV16-
positive genomic DNA templates, respectively (Figure 2-29B). These included two 
cervical carcinoma cell lines (MRI-H186, MRI-H196) and two clinical pre-cancerous 
lesions (50073, 55246). The DNA quality of them was checked on agarose gel before 
WGA. Compared with the “intact” DNA of cell lines, the clinical samples exhibited a 
smear of moderately degraded DNA (Figure 2-29A). Robust products were obtained 
from all four GP-WGA reactions (Figure 2-29B). The observed product sizes ranged 
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between 200 bp and 2 kb, with the majority smaller than 1 kb. No difference in GP-
WGA performance was found between intact DNA from cell lines and partially 
degraded DNA from clinical samples. With regard to allelic bias, a series of PCR 
using MRI-H186 and 50073 GP-WGA products as templates was performed to 
detect DNA regions in relation to HPV16 integration analysis (Figure 2-29C). PCR 
primers used in this assay are specific for HPV16-E6, HPV16-E2, c-myc and GAPDH 
genes. For MRI-H186, junction-specific PCR for both 5’ and 3’ viral-cellular junctions 
was also done (Figure 2-29C). All ten reactions showed final PCR products with the 
expected sizes. To conclude, the GP-WGA system is able to amplify the whole 
genome of moderately degraded clinical DNA samples.  
             
Figure 2-29: The performance of GenomePlex whole genome amplification (GP-WGA). Panel A 
shows DNA of cell lines MRI-H186 and MRI-H196 compared with DNA of altogether eight clinical 
samples including 50073 and 55246. “Intact” genomic DNA has a size of 50-100 kb, which runs on 0.8% 
agarose gels as a band above the 23.1-kb !/HindIII fragment. Smears from top to bottom on gel indicate 
partially degraded genomic DNA of clinical samples. The !/HindIII was used as size marker. Panel B 
shows the final products of four GP-WGA reactions. For each reaction, 4 µl from totally 75 µl was 
checked on gel. Ten PCR reactions, six for MRI-H186 (left) and four for 50073 (right), are shown in 
panel C. The PCR amplicons included the following: HPV16-E6 (184 bp), HPV16-E2 (395 bp), c-myc 
(356 bp), MRI-H186 5’ viral-cellular junction (338 bp), MRI-H186 3’ viral-cellular junction (448 bp) and 
GAPDH (173 bp). The 100 bp DNA Ladder was used as size marker.  
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2.10.2  ASP16 Step 2 – Selection 
The GP-WGA system has shown promise to amplify partially degraded clinical DNA 
samples. However, it was expected that the combination of GP-WGA and RS-PCR is 
not suitable for determination of HPV16 DNA integration sites in cervical pre-
cancerous lesions for two reasons. Firstly, the average length of GP-WGA products 
(about 400 bp) is too short for RS-PCR, because the latter requires cellular 
sequences to be relatively long for the specific binding of RSO-primers onto target 
sites. Secondly, RS-PCR had been shown to be inappropriate for DNA samples with 
high percentage of HPV16 episome/concatemer versus integrated DNA, such as the 
CaSki cell line (see Section 2.1.2). Therefore, an alternative procedure was 
developed in this thesis in order to amplify HPV16-containing sequences from GP-
WGA products.  
The GP-WGA library contains three species of DNA molecules: cellular genomic 
DNA, pure HPV16 DNA and HPV16-cellular junction DNA. For DNA sequencing, the 
rare HPV16-cellular junction DNA together with the pure HPV16 DNA need to be 
enriched against the huge background of cellular genomic DNA (Figure 2-30). 
           
Figure 2-30: Three species of DNA molecules existent in GP-WGA libraries of HPV16-positive 
DNA samples. (GPUA= GenomePlex universal adapter) 
 
As mentioned in Section 2.10.1, the GPUA plays an essential role for the GP-WGA 
procedure and defines the termini of all final WGA products. Therefore, the 
applicability of GPUA in combination with HPV16-specific primers for amplification 
and selection of HPV16-containing sequences from GP-WGA libraries was 
examined. Information about the exact sequence of GPUA is not given by the 
manufacturer. To unravel the GPUA sequence, an aliquot of MRI-H186 GP-WGA 
product was directly cloned into the pSC-A vector. Altogether 14 clones were 
randomly chosen and sequenced completely (data not shown). The 14 sequences 
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represent different regions of human genomic DNA, while they all carry the GPUA at 
both 5’ and 3’ ends as a common feature. The deduced GPUA sequence is shown in 
Figure 2-31.  
                     
Figure 2-31: The GenomePlex universal adapter (GPUA) sequence. DNA sequences in green and 
red represent the GPUA sequence and its complementary strand, respectively.  
 
Based on the sequence knowledge, it was then tested whether GPUA can be used 
as primer together with HPV16 primer for direct PCR amplification of HPV16-
containing DNA. Three PCR reactions were performed with MRI-H186 GP-WGA 
product as template (Figure 2-32). GPUA was used as cellular primer (reverse or 
forward) in combination with an HPV16 E1 forward primer (HPV16-2573-F) and an 
L2 reverse primer (HPV16-5125-R), respectively. Both HPV16 primers can bind to 
the integrated HPV16 DNA in MRI-H186. It was therefore expected that HPV16-
containing DNA would be specifically amplified with these primer combinations. As 
control, GPUA was used as both forward and reverse primer. The PCR results are 
shown in Figure 2-32. A DNA smear was observed in all three reactions, and 
obviously no HPV16 enrichment had occurred. Therefore, it was concluded that the 
combination of GPUA and HPV16 primer is not suitable for PCR amplification of 
HPV16-containing DNA directly from the GP-WGA library.  
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Figure 2-32: PCR for direct amplification of HPV16 DNA from the GP-WGA library. Primer 
combinations and gel analysis of three PCR reactions with MRI-H186 WGA product as template are 
shown. The 100 bp DNA Ladder was used as size marker.  
 
Since the direct PCR amplification using GPUA together with HPV16 primer had 
failed, a more efficient approach for HPV16 DNA selection from GP-WGA libraries 
was required. As alternative, it was attempted to enrich HPV16 sequences by primer 
extension using 5’-biotinylated HPV16-specific primers (Figure 2-33). The resultant 
single-stranded DNA should be HPV16-positive and contain GPUA only at the 3’ 
end. The single-stranded DNA products were purified from template DNA (GP-WGA 
library) after primer extension, using the biotin-streptavidin selection system with 
streptavidin-coated BioMag magnetic beads (see Section 4.35.2). In the next step, 
the single-stranded intermediates were converted into double-stranded DNA by PCR 
using GPUA and nested HPV16 primer in combination.  
Taken together, the procedure designed to select HPV16-containing DNA from GP-
WGA libraries is composed of linear amplification by primer extension, single-
stranded DNA selection by biotin-streptavidin, and double-stranded DNA synthesis 
by PCR (Figure 2-33). This procedure should strongly reduce the genomic DNA 
background, and the final products are supposed to contain pure HPV16 DNA and 
HPV16-cellular junction DNA (see Figure 2-30).  
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Figure 2-33: HPV16 DNA enrichment from the GP-WGA library. The GPUA and its complementary 
strand are shown in green and red, respectively. Positions of HPV16 primers are marked by black half-
arrows. (S=streptavidin-coated magnetic bead; B=biotin; 5’-B=biotin labelled at the 5’ end of HPV16 
primer).   
 
2.10.3  ASP16 Step 3 – Pyrosequencing 
After HPV16 DNA enrichment, the next challenge was an effective way of DNA 
sequencing. Two aspects had to be taken into consideration. Firstly, HPV16 DNA 
breakpoints could be located anywhere within E1/E2 and L1/L2 regions, while the 
average size of GP-WGA products is only about 400 bp. Therefore, in order to cover 
all possible locations of viral-cellular junctions, multiple HPV16 primers with 
appropriate intervals have to be used. Secondly, clinical DNA samples contain not 
only integrated HPV16 DNA but also episomal HPV16 DNA to different extents. The 
two inherent problems are not well compatible with classical cloning and Sanger 
sequencing, which are time-consuming, laborious and expensive. In these aspects, 
the so-called “next-generation” sequencing technologies became more promising.  
In 2006 and 2007, three next-generation sequencing systems were introduced, 
including Genome Sequencer FLX (Roche/454), Genome Analyzer (Illumina/Solexa) 
and SOLiD (Applied Biosystems) (Mardis, 2008; Shendure and Ji, 2008). A common 
strength of them is the massively parallel sequencing, which can provide huge 
amounts of sequence data in a single machine-run within hours. The Genome 
Sequencer FLX (GS-FLX) was chosen as a platform for the novel ASP16 strategy. 
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An essential aspect for this decision was the read length of about 250 bases, while 
the read lengths of the other systems are below 100 bases (Mardis, 2008; Shendure 
and Ji, 2008). The GS-FLX is mainly based on two principal techniques: emulsion 
PCR (emPCR) and pyrosequencing (Margulies et al., 2005). The emPCR precedes 
pyrosequencing, and it is used to amplify the template DNA for signal augmentation. 
Each DNA molecule bound to a magnetic bead is encapsulated into an emulsion 
sphere and clonally amplified to millions of identical copies (Figure 2-34A). The size 
of template DNA for emPCR is limited to about 400 bp, which fits the average length 
of GP-WGA products. The beads are deposited into a picotiter-plate for sequencing. 
Unlike Sanger sequencing, the pyrosequencing is a method featured on “sequencing 
by synthesis”. The pyrophosphates generated by DNA polymerization are 
quantitatively converted into light signals, without disrupting DNA elongation (Figure 
2-34B). This technique makes it possible to sequence every single DNA molecule 
within a mixture of templates individually and simultaneously. The final effect of the 
whole procedure is: one DNA molecule = one bead = one sequence read.  
 
Figure 2-34: Emulsion PCR and pyrosequencing. Panel A describes the workflow of emulsion PCR. 
The figure was taken from http://www.454.com. Panel B shows the principle of pyrosequencing. The 
figure was taken from http://www.pyrosequencing.com.  
 
In order to bind DNA onto magnetic beads in emPCR and to sequence PCR 
amplicons with GS-FLX, primers used in the nested-PCR step of HPV16 DNA 
enrichment (see Figure 2-33) have to be equipped with Roche-A and Roche-B 
adapter sequences. For ASP16 experiments, Roche-A was fused to the nested 
HPV16 primers, while Roche-B was coupled with GPUA (see Section 4.12.5). To 
utilize the GS-FLX system at its full capacity, a blend of multiple DNA samples can 
be sequenced simultaneously in one machine-run. To apply this possibility, each 
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DNA sample needs to be equipped with a molecular tag of unique character to 
differentiate between samples. Totally 24 distinct barcodes with a length of four 
nucleotides each were designed to represent different DNA samples in the ASP16 
experiments (see Section 4.12.5). The 24 barcodes were individually joined with the 
GPUA primer, which is common to all nested PCR reactions.  
In summary, the multiplex nested PCR in the HPV16 selection procedure was made 
compatible with sample pooling and GS-FLX pyrosequencing by a special primer 
design. All nested HPV16 primers have a bipartite structure carrying the Roche-A 
sequence at the 5’ end. The GPUA primers have a tripartite structure composed of 
Roche-B, 4nt-barcode and GPUA in 5’ to 3’ direction (see Figure 2-35). The whole 
experimental procedure of the ASP16 strategy is outlined in Figure 2-35.  
          
Figure 2-35: Summary of the amplification-selection-pyrosequencing strategy for HPV16 
integration analysis (ASP16). The details are explained in the text.  
!"#$%&#'''+1'
'
2.11  The first ASP16 experiment (ASP16-1) 
To test the whole concept of ASP16 for the first time, a set of 28 HPV16-positive 
DNA samples was prepared for pyrosequencing. This included four cervical 
carcinoma cell lines, three cytologically normal clinical samples and 21 cervical pre-
cancerous lesions (Table 2-36).  
Table 2-36: Information about DNA samples used in experiment ASP16-1. 
!"#$%&'()*+"#' !%*,&"'(%*"' -".$/0'1#%2"'%' !%*,&"'34'56%#7/2"8'
!" #$%!&'!" ()*+," -"
'" ##%!'.#" ()*+," !/'"
0" #1%.0#" ,)*+," !/0"
$" #1%&!" 2*34*" -"
1" #$%!5&5" 6789:;" -"
." #$%'#!&" 6789:;" !/."
<" #$%''<<" 6789:;" -"
5" =>+%(!5." ?@8AB?:;"?:8?B679:"?@;;";B6@" !/5"
&" =>+%(!&." ?@8AB?:;"?:8?B679:"?@;;";B6@" !/&"
!#" 3:*CB" ?@8AB?:;"?:8?B679:"?@;;";B6@" !/!#"
!!" *B(:" ?@8AB?:;"?:8?B679:"?@;;";B6@" !/!!"
!'" 05&10" 3+D0" !/!'"
!0" 0&#.!" 3+D0" !/!0"
!$" $!&.'" 3+D0" !/!$"
!1" $00!<" 3+D0" !/!1"
!." $$$&1" 3+D0" !/!."
!<" $$&.&" 3+D0" !/!<"
!5" $.!!." 3+D0" !/!5"
!&" $.!.5" 3+D0" !/!&"
'#" $..$1" 3+D0" !/'#"
'!" 11'$." 3+D0" !/'!"
''" 11.#'" 3+D0" !/''"
'0" 11.!&" 3+D0" !/'0"
'$" $<.0#" 3+D0" !/'$"
'1" $<..$" 3+D0" !/!"
'." $<5&5" 3+D0" !/$"
'<" $&!0." 3+D0" !/1"
'5" $&'0!" 3+D0" !/<"
 
a HGSIL=high-grade squamous intraepithelial lesion; LGSIL=low-grade squamous intraepithelial lesion;  
  ASCUS=atypical squamous cells of undetermined significance; CIN3=cervical intraepithelial neoplasia  
  grade 3.  
* Four samples were not included in the DNA mixture for pyrosequencing, due to their poor performance  
   in the HPV16 DNA enrichment procedure, see Figure 2-39. 
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Primer design for HPV16 early and late regions 
In the first ASP16 experiment (ASP16-1), it was planned to obtain both the 5’ and 3’ 
viral-cellular junction sequences of each DNA sample simultaneously. As described 
earlier, HPV16 DNA enrichment requires multiple HPV16 primers to cover the E1/E2 
and L1/L2 regions completely. Therefore, 16 biotin-labelled HPV16 primers, eight 
(EP-1 to EP-8) for E1/E2 and eight (LP-1 to LP-8) for L1/L2, were designed for linear 
amplification (Figure 2-37 and Table 2-38). Similarly, 16 nested HPV16 primers (EP-
N1 to EP-N8; LP-N1 to LP-N8) were used for multiplex PCR (Figure 2-37 and Table 
2-38). Sequences of the primers are shown in Section 4.12.5. The primer interval 
was about 400 bp, which is in accordance with the average length of GP-WGA 
product and the size limit of template DNA for emPCR. 
 
 
 
Figure 2-37: Primers used in experiment ASP16-1 to cover the early and late regions of 
integrated HPV16 DNA. Locations of 16 biotin-labelled HPV16 primers (LP-1 to LP-8; EP-1 to EP-8) for 
linear amplification are schematically demonstrated. The nested HPV16 primers for multiplex PCR are 
not shown. The exact positions of HPV16 primers are shown in Table 2-38. Primer sequences are given 
in Section 4.12.5. (LP=primer in the HPV16 late region; EP=primer in the HPV16 early region) 
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Table 2-38: Positions of HPV16 primers used in experiment ASP16-1. 
9:;' </.$=$/0.' 6$/=$0>&%="2'<#$*"#' </.$=$/0.' (".="2'<#$*"#' </.$=$/0.'
?@' 5.1"E7"'5!$"
?<A@' 5!#"50!" ?<A(@' 51<"5<<"
?<AB' !'.!"!'5'" ?<A(B' !'<1"!'&."
?<AC' !1.'"!15'" ?<A(C' !1<."!1&<"
?<AD' !&05"!&1&" ?<A(D' !&1!"!&<'"
?<AE' '05&"'$!!" ?<A(E' '$#0"'$'$"
?<AF' '<#1"'<'." ?<A(F' '<'0"'<$'"
?B' '<1."E7"0510"
?<AG' 0!#!"0!''" ?<A(G' 0!'!"0!$0"
?<AH' 01$'"01.0" ?<A(H' 0111"01<."
-@' 11.!"E7"<!1."
-<A@' .&'&#.&1!" -<A(@' .5&&#.&!5"
-<AB' .10!#.11'" -<A(B' .$50#.1#1"
-<AC' .!.1#.!5." -<A(C' .!'##.!0&"
-<AD' 1<$$#1<.." -<A(D' 1<!##1<'&"
-B' $'0<"E7"1.15"
-<AE' 1'&.#10!5" -<A(E' 1'51#10#$"
-<AF' $5&5#$&!<" -<A(F' $5<!#$5&#"
-<AG' $$<5#$1#!" -<A(G' $$$1#$$.."
-<AH' $'<!#$'&#" -<A(H' $'01#$'1$"
 
The positions of totally 32 HPV16 primers (16 biotinylated primers and 16 nested primers) as well as the 
HPV16 ORFs involved are shown. Overall, the distance between two neighbouring primers is about 400 
bp. (EP=early primer; EP-N=nested early primer; LP=late primer; LP-N=nested late primer) 
 
Whole genome amplification and HPV16 DNA enrichment 
At first, the GP-WGA was performed with 24 (serial number 1 to 24) out of the 28 
DNA samples, respectively. For each amplified DNA sample, two linear 
amplifications (E and L) as well as two subsequent multiplex-PCR reactions (E and 
L) for the HPV16 early and late regions were carried out individually. In each single 
reaction, eight HPV16 biotinylated primers (for linear amplification) or nested primers 
(for PCR) were used in a multiplex way. Aliquots of all 48 multiplex-PCR products 
were checked on gel and hybridized with the HPV16-complete DNA probe (Figure 2-
39). Staining intensities on gel and signal intensities on Southern blot showed large 
differences among samples. In particular for samples no. 1 to 7, only primer dimers 
were observed on the gel, and almost no HPV16 hybridization signals were detected 
on Southern blot (Figure 2-39, upper part). This was probably due to the poor DNA 
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quality of the seven samples, because the GP-WGA products of them were obviously 
shorter than other samples (data not shown). Overall, Southern hybridization 
correlated well with gel analysis in respect of signal intensity, which indicated the 
success of HPV16 DNA enrichment. Furthermore, signal intensities on Southern blot 
seem to correlate with HPV16 DNA copy number in the cell. For example, there is no 
difference in DNA quality among the three cell lines (no. 8 to 11), but the 
hybridization intensities were clearly different among them. The strongest signals 
came from CaSki (no. 10), which contains about 500 copies of HPV16 DNA per cell 
(Yee et al., 1985; Baker et al., 1987). By contrast, very weak signals were found in 
SiHa (no. 11), which harbors only 1 – 2 copy of integrated HPV16 DNA per cell (Yee 
et al., 1985; Baker et al., 1987).  
Because of the poor product amounts and hybridization intensities, the samples no. 
1, 4, 5 and 7 were eliminated from analysis and replaced by samples no. 25 to 28 
(see Table 2-36). Thus, altogether 24 samples (sample-IDs 1B1 to 1B24) containing 
48 multiplex-PCR reactions were purified separately and subjected to further 
analysis.  
 
Figure 2-39: Gel analysis and Southern hybridization of final products after HPV16 DNA 
enrichment. Panel A shows the 48 final products of HPV16 DNA enrichment (for HPV16 Early and Late 
regions) from 24 DNA samples (serial number 1 to 24). The final products of samples no. 25 to 28 are 
not shown. For each reaction, 3 µl of PCR product was checked on agarose gel prior to DNA 
purification. The 100 bp DNA Ladder was used as size marker. Gel was blotted and hybridized with the 
HPV16-complete DNA probe (panel B). 
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The concentration of purified multiplex-PCR products was between 13 and 50 ng/µl. 
For pyrosequencing, 100 ng of each purified DNA from altogether 48 reactions were 
mixed together. DNA concentration of this mixture was determined as 21 ng/µl. The 
DNA mixture was checked on agarose gel, and appeared to be a smear from 100 bp 
to over 600 bp with a peak at the position about 150 bp (Figure 2-40). 
                                                
Figure 2-40: Gel analysis of the DNA mixture for pyrosequencing in ASP16-1. About 120 ng (6 µl) 
of the DNA mixture for pyrosequencing was checked on agarose gel. The !/Hind III (leftmost) and 100 
bp DNA Ladder (rightmost) were used as size marker. 
 
Pyrosequencing 
The emPCR amplification and GS-FLX pyrosequencing (see Figure 2-34) of the DNA 
sample mixture were performed by the DKFZ Genomics and Proteomics Core 
Facility. Sequencing can be primed with either Roche-A or Roche-B. To make sure 
that every sequence read has a barcode, Roche-B was chosen as sequencing 
primer for the ASP16 experiments, because the barcodes are located directly 
downstream of Roche-B. Dependent on experimental requirements, three formats of 
picotiter-plates are available as sequencing devices (Figure 2-41). Each plate has a 
unique capacity, and can be further divided into physically separated small regions. 
For the experiment ASP16-1, the device 25x75 with one medium region was applied. 
 
Figure 2-41: Sequencing devices available for different applications with GS-FLX. The picotiter-
plate marked in red was used for the experiment ASP16-1 (*used for ASP16-2). The figure was taken 
from http://www.454.com. 
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Altogether 73283 sequence reads were obtained from ASP16-1. The entire data set 
amounted to 8.3 Mb, which did not reach the capacity of 16.8 Mb (see Figure 2-41). 
The average read length (Roche-B primer of 19 nt omitted) was 113 nt, which is a 
rather low value in comparison with the capacity of 250 nt. The average read length 
plus Roche-B (113+19=132 nt) agreed with the major DNA size observed on gel (see 
Figure 2-40). The overall distribution of sequence length is shown in Figure 2-42. The 
log-scale histogram shows that sequence reads from 50 to 300 nt were obtained by 
GS-FLX pyrosequencing in ASP16-1. Most sequences fell into the range between 65 
and 145 nt, as demonstrated by the linear-scale histogram.  
 
 
Figure 2-42: Overall length distribution of sequence reads from experiment ASP16-1. The X-axis 
represents increasing sequence lengths in 5-nt interval. The Y-axis shows the frequency (sequence 
number) of the corresponding read length. The length distribution is demonstrated in log scale (panel A) 
and linear scale (panel B). (Mo = more) 
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Bioinformatics data analysis 
The pyrosequence reads were analysed with bioinformatics tools developed by 
Sasithorn Chotewutmontri in our laboratory (Figure 2-43). The whole data set of 
ASP16-1 was first sorted into 24 sample categories, according to the 4-nt barcodes. 
For each sample, sequence reads were individually compared with the HPV16 
genome reference using the “BlastN” algorithm ($11nt) from NCBI. A cut-off value of 
28 nt was used to distinguish significant HPV16 sequences ($28nt) from unspecific 
sequences caused by false priming. The significant HPV16 sequences were then 
classified into four groups by length of the non-HPV16 part. Sequences from group 1 
have the longest non-HPV16 part, and are therefore the strongest candidates for 
viral-cellular junctions. Sequences from groups 1 to 3 were sequentially searched for 
matches in the human genome reference databases from NCBI using the 
“MegaBlast” algorithm ($28nt). Sequences from group 4 were not analyzed, because 
the non-HPV16 parts are too short for significant matches.  
Besides determining junction sequences, the programs were also applied to evaluate 
the specificity of individual nested HPV16 primers in ASP16 experiments. From each 
sample category, sequences were further sorted by the nested HPV16 primer 
sequences into 16 different groups. Within each primer group, number of significant 
HPV16 sequences versus total sequence number was compared.  
 
Figure 2-43: Bioinformatics data analysis of sequence reads obtained from ASP16-1. The 
individual steps are explained in the text. 
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To check the differences in sequence distribution among the 24 samples used for 
pyrosequencing, sequence numbers were calculated for each sample with four 
different filter criteria: total sequence number, HPV16 hit without cut-off, RA-HPV16 
primer hit, and HPV16 hit with 28-nt cut-off (Figure 2-44A). The total sequence 
number refers to the number of sequence reads assigned to a given sample by the 
barcode, but without any data filtering. The HPV16 hit without cut-off represents 
those sequence reads, which have a match of at least 11 nt with the HPV16 genome 
reference. The RA-HPV16 primer hit specifies the sequence reads carrying Roche-A 
(RA) plus HPV16 primer at the 3’ ends, which means they were sequenced 
completely. The HPV16 hit with 28-nt cut-off defines the significant HPV16 
sequences, which contain at least 28 nt of HPV16 sequences.  
As shown in Figure 2-44B and C, large differences in the total sequence number 
were observed among samples. For cell line CaSki (sample-ID 1B10), which harbors 
about 500 copies of HPV16 DNA per cell, 5895 sequence reads were obtained (the 
highest number in ASP16-1). Another cell line SiHa (sample-ID 1B11) with 1 – 2 
copy of HPV16 DNA per cell, contained 1750 sequence reads (a rather low number). 
The lowest sequence number 599 came from clinical sample 1B3, which had shown 
low yield in GP-WGA (data not shown) and no HPV16 hybridization signal (see 
Figure 2-39), probably due to the poor quality of original DNA. For each sample, 
there was no clear difference between total sequence number, HPV16 hits without 
cut-off and RA-HPV16 primer hits. This indicated that most sequence reads from 
ASP16-1 had been fully sequenced, and also agreed with the short read length (113 
nt on average). The performance of HPV16 DNA enrichment, reflected by the 
proportion of HPV16 hits with 28-nt cut-off to total sequence number, was different 
among samples. This might be caused by sample variations for example the poor 
DNA quality, but the exact reason still remains unclear. Nevertheless, HPV16-
containing DNA has been specifically enriched in many of the 24 samples, which 
suggested that overall the whole concept for HPV16 DNA enrichment works.  
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Figure 2-44: Sequence distribution of the 24 DNA samples in experiment ASP16-1. The general 
structure of the single sequence reads primed by Roche-B is shown in panel A. The absolute sequence 
numbers (panel B) and the relative numbers in percentage (panel C) compared to the total number of 
CaSki (1B10) are shown for each sample with four different filter criteria explained in the text. 
(RA=Roche-A; CF=cut-off; GPUA=GenomePlex universal adapter) 
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Identification of viral-cellular junctions 
For cell line MRI-H186 (sample-ID 1B8), altogether nine pyrosequence reads were 
identified in experiment ASP16-1, which represent the already known 3’ viral-cellular 
junction at HPV16-2754/chr8-128815788 (see Section 2.8.5). For the other three cell 
lines MRI-H196 (1B9), CaSki (1B10) and SiHa (1B11), however, no viral-cellular 
junction sequence was found in experiment ASP16-1. From the clinical samples, five 
potential junction sequences representing four unique viral-cellular junctions were 
obtained (Table 2-45). However, all the four junctions turned out to be false-positives, 
as determined by junction-specific PCR using an HPV16 primer together with a 
cellular primer (data not shown).  
 
Table 2-45: Potential viral-cellular junction sequences of clinical DNA samples obtained in 
experiment ASP16-1.  
!"I)"07"'34 !%*,&"'34 !"I)"07" ':"%2'-"0J=K 
-"0J=K'/L''
M<N@F',%#= 
M<N@F'4(O'
6#"%P,/$0= 
QK#/*/./*" 
#15500 !/< !#' 00 015< '# 
#.1!0$ !/< !#' 00 015< '# 
#$#&1& !/5 !#& 0. 0!1. & 
!#00.$ !/5 !!' 01 0!11 0 
#<#.5< !/!< !!0 0. !.!! < 
 
 
As the most important aspect, experiment ASP16-1 proved the concept of the ASP 
strategy, regarding the specificity of HPV16 sequence enrichment from whole-
genome DNA samples and the capability to identify viral-cellular junction sequences. 
The key problem revealed by ASP16-1 was the short read length (113 nt on average) 
versus long intervals between HPV16 primers (about 400 bp). This means that only 
about one-fourth of the HPV16 early and late regions could be sequenced under this 
experimental condition. For a more comprehensive coverage of HPV16 DNA, it was 
required either to reduce primer interval by introducing new primers, or to increase 
the average read length by experimental optimizations. 
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2.12  The second ASP16 experiment (ASP16-2) 
The most important modifications in the second experiment ASP16-2 were made in 
the HPV16 primer design, and in the decision to confine the integration analysis to 
the 3’ junction in the HPV16 early region. This decision was made because the 3’ 
junction downstream of the E6 and E7 oncogenes is more important for cervical 
carcinogenesis than the 5’ junction (see Figure 1-5). It was intended to reach 
complete sequence coverage of the E1/E2 region in the pyrosequencing step, 
thereby enhancing the probability to determine viral-cellular junction sequences. To 
shorten the intervals between the primers, eight new biotin-labeled HPV16 primers 
(EP-9 to EP-16) for linear amplification as well as eight new nested HPV16 primers 
(EP-N9 to EP-N16) for multiplex PCR were added into experiment ASP16-2. By 
doing this, the primer interval was overall decreased from 400 bp to 200 bp in the 
HPV16 E1/E2 region (Figure 2-46 and Table 2-47).  
 
 
 
Figure 2-46: Primers used in experiment ASP16-2 to cover the E1/E2 region of HPV16 DNA. The 
locations of 16 biotin-labelled HPV16 primers (EP-1 to EP-16) for linear amplification are schematically 
demonstrated. The nested HPV16 primers for multiplex PCR are not shown. The exact positions of 
HPV16 primers are shown in Table 2-47. Primer sequences are given in Section 4.12.5. (EP=primer in 
the HPV16 early region) 
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Table 2-47: Positions of HPV16 primers used in experiment ASP16-2. 
9:;' </.$=$/0.' 6$/=$0'<#$*"#' </.$=$/0.' (".="2'<#$*"#' </.$=$/0.'
?@' 5.1"E7"'5!$"
?<A@' 5!#"50!" ?<A(@' 51<"5<<"
?<AR' !#$."!#.." ?<A(R' !#.$"!#5$"
?<AB' !'.!"!'5'" ?<A(B' !'<1"!'&."
?<A@S' !0&$"!$!." ?<A(@S' !$!!"!$00"
?<AC' !1.'"!15'" ?<A(C' !1<."!1&<"
?<A@@' !<.#"!<5'" ?<A(@@' !<51"!5#1"
?<AD' !&05"!&1&" ?<A(D' !&1!"!&<'"
?<A@B' '!1!"'!<0" ?<A(@B' '!<$"'!&."
?<AE' '05&"'$!!" ?<A(E' '$#0"'$'$"
?<A@C' '10&"'1.!" ?<A(@C' '1.&"'1&!"
?<AF' '<#1"'<'." ?<A(F' '<'0"'<$'"
?B' '<1."E7"0510"
?<A@D' '&!'"'&00" ?<A(@D' '&00"'&10"
?<AG' 0!#!"0!''" ?<A(G' 0!'!"0!$0"
?<A@E' 00!5"000&" ?<A(@E' 000&"00.!"
?<AH' 01$'"01.0" ?<A(H' 0111"01<."
?<A@F' 0<.'"0<50" ?<A(@F' 0<<5"0<&5"
 
 
 
 
A collection of 21 HPV16-positive DNA samples was chosen for experiment ASP16-2 
(Table 2-48). The three cervical carcinoma cell lines MRI-H186 (sample-ID 2B1), 
MRI-H196 (2B2) and SiHa (2B3) had already been included in ASP16-1. The 18 
clinical DNA samples (sample-IDs 2B4 to 2B21) consisted of six cervical carcinomas 
and twelve high-grade pre-cancerous lesions (mostly classified as CIN3). 
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Table 2-48: Information about the DNA samples used in experiment ASP16-2. 
!%*,&"'34'
56%#7/2"8' !%*,&"'(%*"' -".$/0'1#%2"'
%'
M<N@F'?%#&>'<#$*"#'T$U'5?<T8'
)."2'L/#',>#/."I)"07$0J'
'/!" =>+%(!5." ?@8AB?:;"?:8?B679:"?@;;";B6@" FG=%!"H"FG=%'"
'/'" =>+%(!&." ?@8AB?:;"?:8?B679:"?@;;";B6@" FG=%!"H"FG=%'"
'/0" *B(:" ?@8AB?:;"?:8?B679:"?@;;";B6@" FG=%!"
'/$" #<?!0$" ?@8AB?:;"?:8?B679:" FG=%!"H"FG=%'"
'/1" #<?0.5" ?@8AB?:;"?:8?B679:" FG=%!"H"FG=%'"
'/." #<?05!" ?@8AB?:;"?:8?B679:" FG=%!"
'/<" #<?<!1" ?@8AB?:;"?:8?B679:" FG=%!"
'/5" #<?<!." ?@8AB?:;"?:8?B679:" FG=%!"
'/&" #<?<!&" ?@8AB?:;"?:8?B679:" -"
'/!#" .!$50" 3+D0" FG=%!"
'/!!" .'&<0" 3+D0" FG=%!"
'/!'" .0!<&" 3+D0" FG=%!"
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a CIN3 = cervical intraepithelial neoplasia grade 3 
* Due to weak or absent HPV16 hybridization signals (see Figure 2-49B), neither EPM-1 nor EPM-2 
  reactions were included in the pyrosequencing step of experiment ASP16-2. 
 
 
In experiment ASP16-2, the GP-WGA and HPV16 DNA enrichment (including linear 
amplification and multiplex PCR) were prepared separately for all 21 DNA samples. 
For each sample, two linear amplifications and two multiplex PCR reactions were 
performed with different HPV16 primer mixtures. The early primer mix 1 (EPM-1) 
contained biotinylated primers EP-1 to EP-8 for linear amplification or nested primers 
EP-N1 to EP-N8 for multiplex PCR. The EPM-2 contained EP-9 to EP-16 for linear 
amplification or EP-N9 to EP-N16 for multiplex PCR. The primer positions in the 
HPV16 E1/E2 region are shown in Figure 2-46 and Table 2-47. The final products of 
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totally 42 reactions were purified individually. From each reaction, an aliquot of 
purified DNA was checked on gel and analyzed by Southern hybridization with the 
HPV16-complete DNA probe (Figure 2-49). The gel analysis showed clear 
differences between reactions with EPM-1 and EPM-2. EPM-1 gave rise to DNA 
smears from about 100 bp to 600 bp, whereas EPM-2 has mainly produced short 
products of about 100 bp, which most likely represent primer dimers. On Southern 
blot the majority of EPM-1 reactions showed strong HPV16 hybridization signals. By 
contrast, only 9 out of 21 EPM-2 reactions hybridized with the HPV16 probe. Finally, 
altogether 25 reactions including 19 EPM-1 and six EPM-2 reactions were pooled for 
pyrosequencing (Table 2-48 and Figure 2-49). 
 
Figure 2-49: Gel analysis and Southern hybridization of DNA samples after HPV16 DNA 
enrichment in experiment ASP16-2. Panel A shows the 42 final products after HPV16 DNA 
enrichment from all 21 DNA samples. The first number refers to the sample ID (see Table 2-48), and the 
second number indicates EPM-1 and EPM-2, respectively. For each reaction, about 100 ng of purified 
PCR product was checked on agarose gel. The 100 bp DNA Ladder was used as size marker. The gel 
was blotted and hybridized with the HPV16-complete DNA probe (panel B). Reactions marked in red 
were mixed for pyrosequencing.  
 
The final concentration of the pooled DNA was determined as 19 ng/µl. As shown in 
Figure 2-50, the majority of DNA was found in the size range between 100 and 200 
bp, with an additional smear up to about 500 bp. In order to get more sequence 
reads, the pyrosequencing for ASP16-2 was performed using one large region in the 
70x75 picotiter-plate (see Figure 2-41).  
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Figure 2-50: Gel analysis of the DNA mixture for pyrosequencing in experiment ASP16-2. 150 ng 
of the DNA mixture for pyrosequencing was checked on agarose gel. The 100 bp DNA Ladder was used 
as size marker. 
 
The pyrosequencing outcome of experiment ASP16-2 is summarized in Table 2-51, 
in comparison with the capacity of the sequencing device applied. Altogether 223942 
sequence reads were obtained in ASP16-2, and the average read length was 88 nt.  
               Table 2-51: Summary of the sequence data obtained from experiment ASP16-2.  
                 
 
The distribution of sequence length in ASP16-2 is shown in Figure 2-52. Most 
sequences were shorter than 105 nt. Striking was a unique peak at the position of 55 
nt, which contained more than 37000 sequence reads (about 16.5% of all 
sequences). The DNA band of 74 nt (55 plus Roche-B of 19 nt) corresponding to this 
peak had not been observed before on agarose gel (see Figure 2-50). The length of 
74 nt is even shorter than the minimal length defined by the fusion-primers used for 
ASP16, which is about 80 nt containing Roche-A (19 nt), HPV16 primer (about 20 
nt), GPUA (18 nt), barcode (4 nt) and Roche-B (19 nt). This implied that the aberrant 
74-nt product should be some kind of primer dimer. The nature of this peak (primer 
dimer) has been clarified and will be explained later in Figure 2-56. 
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Figure 2-52: Overall length distribution of sequence reads from experiment ASP16-2. The X-axis 
represents increasing sequence lengths in 5-nt interval. The Y-axis shows the frequency (sequence 
number) of the corresponding read length. The length distribution is demonstrated in log scale (panel A) 
and linear scale (panel B). The red arrows point to the striking 55-nt peak. (Mo = more) 
 
The 223942 sequences obtained from experiment ASP16-2 were analyzed using the 
programs described in Figure 2-43. Sequence distribution within each of the 19 
samples used for pyrosequencing is shown in Figure 2-53, according to the four filter 
criteria: total sequence number, HPV16 hit without cut-off, RA-HPV16 primer hit, and 
HPV16 hit with 28-nt cut-off. Overall, the total sequence number of each sample was 
quite similar to each other, within the same category of either EPM-1 or EPM-1+2 
(Figure 2-53A and B). Each sample contained 40–60 % of significant ($28nt) HPV16 
sequences (Figure 2-53C). These results indicated that the HPV16 DNA enrichment 
procedure is able to effectively select HPV16 sequences from whole-genome DNA. 
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Figure 2-53: Sequence distribution of the 19 DNA samples analyzed in ASP16-2. The absolute 
sequence numbers (panel A) and the relative numbers in percentage (panel B) compared to the total 
number of sample 2B15 are shown for each sample with four different filter criteria. Panel C shows the 
absolute percentage of significant ($28nt) HPV16 sequences for each sample (CF=cut-off; RA=Roche-
A; EPM=HPV16 early primer mix) 
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To assess the specificity of the individual HPV16 primers, the percentage of 
significant ($28nt) HPV16 sequences among the 19 samples was calculated for each 
nested HPV16 primer (EP-N1 to EP-N16) and illustrated as box plot (Figure 2-54). 
The median values showed large differences in specificity among the primers. Most 
of them worked specifically and gave rise to more than 60% of significant HPV16 
sequences. Only two primers, EP-N1 and EP-N10, turned out to be very unspecific.  
       
Figure 2-54: Percentage of significant HPV16 sequences among the nested HPV16 primers (EP-
N1 to EP-N16) across the 19 DNA samples analyzed in ASP16-2. The five-number summary (Min, 
Q1, Median, Q3, Max) of sequence distribution is demonstrated by cyan boxes and grey lines outside. 
The blue line connects the median percentages of all primers. The red circles indicate the two unspecific 
primers EP-N1 and EP-N10.  
 
To understand how EP-N1 and EP-N10 have impaired the experimental outcome, 
sequence numbers of RA-HPV16 primer hits and significant (!28nt) HPV16 hits were 
listed for all 19 samples and 16 nested HPV16 primers (Table 2-55). For EP-N1, 
15584 sequence reads in total were obtained from the 19 samples, while only 58 of 
them were significant HPV16 sequences. Inspection of the sequences revealed that 
most of them contained exactly the 21-nt EP-N1 sequence (HPV16 pos. 857 – 877), 
and then continued with non-HPV16 sequences from various cellular target sites 
(data not shown). These results imply that the HPV16 primer EP-N1 might have the 
tendency to target repetitive sequences of human genomic DNA, and therefore 
should be eliminated from further ASP16 experiments. By contrast, taking EP-N2 as 
example for a specific HPV16 primer, 14962 sequence reads were obtained from all 
19 samples, and 13271 of them (about 89%) were significant HPV16 sequences.  
For EP-N10, 38302 sequences from six samples were obtained, but only 27 of them 
passed the 28-nt cut-off criterion (Table 2-55B). Therefore, about 17% (38275 out of 
223942) of total sequence reads in ASP16-2 were unspecific products induced by 
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primer EP-N10. Based on these data, it also became obvious that EP-N10 is most 
likely responsible for the 55-nt peak in Figure 2-52. Sequence comparison of EP-N10 
and GPUA revealed a perfect complementarity of 8 nt at their 3’ ends (Figure 2-56). 
Priming would create a primer dimer of 74 bp, which has a read length of 55-nt in 
experiment ASP16-2. These results clearly point to the fact that HPV16 primers with 
long stretches complementary to GPUA at 3’ ends should be omitted. 
 
Table 2-55: Comparison between RA-HPV16 primer hits and significant HPV16 hits  
of each nested HPV16 primer for all 19 samples in ASP16-2. 
 
 
 
• CF=cut-off; N1-N16=EP-N1 to EP-N16; SN1-SN16=significant HPV16 hits of EP-N1 to EP-N16 
• The red boxes indicate the unspecific primers EP-N1 and EP-N10. 
• The green boxes indicate the specific primer EP-N2. 
• %N1=15584 hits, %SN1=58 hits; %N10=38302 hits, %SN10=27 hits 
• %N2=14962 hits, %SN2=13271 hits 
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Figure 2-56: Origin and sequence of the 74-bp primer dimer. The 74-bp primer dimer responsible for 
the 55-nt peak in Figure 2-52 was created by false priming between EP-N10 and GPUA. The DNA 
stretches marked in red show the 8-nt perfect match between EP-N10 and GPUA at their 3’ ends. There 
exist two variants of this primer dimer, which differ to each other only in one nucleotide marked by black 
arrows. (BC=barcode) 
 
Identification of HPV16-cellular junction sequences 
The primary goal of the ASP16 strategy is to identify unknown HPV16-cellular 
junction sequences from clinical DNA samples. After barcode sorting of the 
pyrosequencing data, significant ($28nt) HPV16 sequence reads were compared 
with the human genome reference sequence to search for viral-cellular junctions (see 
Figure 2-43). This was achieved by MegaBlast searching in NCBI databases with the 
standard criterion (28-nt cut-off of sequence match with human genome reference). 
In addition, for cell lines with already known viral-cellular junctions, pyrosequence 
reads could be compared directly with the known junction sequence. By doing this, 
pyrosequences with shorter cellular part (<28nt), which do not pass the standard 
searching criterion (28-nt cut-off), can be determined.  
 
MRI-H186: 
For cell line MRI-H186, two 3’ viral-cellular junctions have been determined before by 
RS-PCR and long-PCR (see Section 2.8.5). The major 3’ junction of MRI-H186 is 
located at HPV16-2754/chr8-128815788. In experiment ASP16-2, this junction 
should be found in sequence reads starting with the HPV16 primer EP-N6 (pos. 2723 
– 2742). The distance between the 3’ end of EP-N6 and the breakpoint is 12 nt. For 
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MRI-H186 (sample-ID 2B1), altogether 671 significant ($28nt) HPV16 sequence 
reads were assigned to primer EP-N6 (see Table 2-55A). With MegaBlast searching 
(28-nt cut-off for the cellular part), 150 out of 671 sequence reads (22%) representing 
the junction HPV16-2754/chr8-128815788 were identified (class 1 in Figure 2-57). By 
comparing all the 671 reads to the known junction sequence, 320 reads (48%) turned 
out to contain the junction HPV16-2754/chr8-128815788. From them, 170 junction 
sequences contained cellular parts shorter than 28 nt (class 2 in Figure 2-57), and 
therefore were not detected by MegaBlast searching. The remaining 351 significant 
HPV16 reads (671-320=351) contained purely HPV16 sequences. These sequences 
are in agreement with the previous finding that complete HPV16 genomes are 
present in MRI-H186 (integration variant A+, see Section 2.8.5). Taken together, the 
results for MRI-H186 demonstrate convincingly the capacity of the ASP16 strategy 
for identification of viral-cellular junction sequences.  
 
Figure 2-57: Viral-cellular junction sequences of MRI-H186 obtained from ASP16-2. For each 
class, one example of sequence reads is shown. The HPV16 sequence parts are shown in red. The 
cellular sequence parts (on chromosome 8) are shown in blue. Details about the two classes are 
explained in the text.  
 
The minor 3’ junction of MRI-H186 is located at HPV16-1223/chr8-128744999. In 
experiment ASP16-2, this junction is located between primers EP-N9 (pos. 1064 – 
1084) and EP-N2 (pos. 1275 – 1296). The distance between EP-N9 and the junction 
is 139 nt. Primed by EP-N9, altogether 931 RA-HPV16 primer hits and 639 
significant HPV16 hits were obtained (see Table 2-55B). The longest one of these 
sequences stops at the position 1219 of HPV16, thus not long enough to cross the 3’ 
junction at position 1223.'
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MRI-H196: 
For cell line MRI-H196, the 3’ viral-cellular junction HPV16-3858/chr11-47967861 
has been characterized by RS-PCR (see Section 2.1.2). In experiment ASP16-2, this 
junction should be expected from sequence reads starting with the HPV16 primer 
EP-N16 (pos. 3778 – 3798). The distance between the 3’ end of EP-N16 and the 
breakpoint is 60 nt. For MRI-H196 (sample-ID 2B2), 208 significant HPV16 reads 
were assigned to EP-N16 (see Table 2-55B). However, no junction sequence was 
obtained by MegaBlast searching. By direct comparison between the known junction 
sequence and the 208 individual reads, one sequence containing the junction 
HPV16-3858/chr11-47967861 was identified. As shown in Figure 2-58, the cellular 
part of this sequence read was only 6-nt long. This sequence is also the longest one 
of the 208 reads. The rest of significant HPV16 sequences were too short to reach 
the junction site, and therefore contained purely HPV16 sequences.  
 
Figure 2-58: Sequence comparison between the viral-cellular junction sequence and pure HPV16 
sequences of MRI-H196 obtained from ASP16-2. The 208 significant HPV16 sequences starting from 
EP-N16 were sorted according to their lengths (descending). The HPV16 sequences from the eight 
longest reads are shown in red. The cellular part (6 nt) of the longest sequence is shown in blue. 
 
SiHa: 
For cell line SiHa (sample-ID 2B3), the 3’ viral-cellular junction known as HPV16-
3133/chr13-74087558 (see Section 2.1.1) has been characterized before (Baker et 
al., 1987; Meissner, 1999). The known junction sequence could not be identified in 
experiment ASP16-2 for reasons demonstrated in Figure 2-59. Firstly, the HPV16 
primer EP-N7 (pos. 3121 – 3143) is located exactly at the junction site, and can bind 
onto DNA target only with the 5’ part (pos. 3121 – 3133). In agreement with the 
priming site, no sequence was obtained for SiHa with primer EP-N7 (see Table 2-
55A, row SN7). Secondly, the HPV16 primer EP-N14 (pos. 2933 – 2953), which is 
180-nt upstream of the junction site, was not included into the pyrosequencing for 
SiHa (see Table 2-48). Thirdly, the HPV16 primer EP-N6 (pos. 2723 – 2742) is 
located 391-nt upstream of the junction site. For SiHa, 168 significant HPV16 reads 
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were assigned to EP-N6 (see Table 2-55A), but none of them extended to the 
junction site. The longest sequence ended at position 2926 of HPV16.  
     
Figure 2-59: Limitations of HPV16 primers used in ASP16-2 preventing determination of the 3’ 
viral-cellular junction in SiHa. Details are explained in the text. 
In summary, the analysis of junction sites from cell lines clearly demonstrates that 
the ASP16 performance under the current conditions is extremely dependent on the 
distance between the 3’ end of HPV16 primer and the junction site (Table 2-60). The 
main reason is the short average read length (only 88 nt) obtained in ASP16-2. 
 
Table 2-60: Relationship between the distance of HPV16 primer to junction site and the yield of 
viral-cellular junction sequences. 
 
 
Clinical samples 
From the 16 clinical DNA samples analyzed in experiment ASP16-2, a collection of 
40 potential viral-cellular junction sequences representing 28 unique HPV16 DNA 
integration sites in 14 samples was obtained with MegaBlast searching (Table 2-61). 
To examine the potential junction sequences, junction-specific PCR assays were 
applied, for which an HPV16 forward primer was used in combination with a cellular 
reverse primer. Junction-specific PCRs were performed for all 28 potential junction 
sequences. Two integration sites could be confirmed by junction-specific PCR for 
cervical carcinomas 07c368 (sample-ID 2B5) and 07c381 (2B6), respectively. The 
experimental details will be explained later in Sections 2.13 and 2.14. All the other 
potential junctions were determined as false-positives.  
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Table 2-61: Potential viral-cellular junction sequences of clinical DNA samples obtained in 
experiment ASP16-2.  
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(The five sequences marked in blue represent two unique HPV16 DNA integration sites which were 
confirmed by junction-specific PCR. All other potential viral-cellular sequences could not be confirmed 
by junction-specific PCR.) 
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The original intention was to analyze only those clinical DNA samples by ASP16 
strategy, for which the HPV16 DNA physical state had been estimated using E2-E6 
quantitative PCR (see Figure 1-6) and which should contain a high percentage of 
integrated HPV16 DNA. For the samples included in experiment ASP16-2, however, 
the E2-E6 qPCR was actually performed after pyrosequencing. The results of E2-E6 
qPCR are shown in Table 2-62. According to the qPCR data, sample 2B6 (E2/E6 
ratio=0) should contain fully-integrated HPV16 DNA. Sample 2B5 (E2/E6 ratio=0.16) 
harbors mainly integrated HPV16 DNA (84%), although episomal DNA also co-
exists. By contrast, all the other clinical samples contain high percentages of 
episomal HPV16 DNA. The qPCR data consisted with the outcome of experiment 
ASP16-2, which has only shown the junction sequences for 2B5 and 2B6.  
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Table 2-62: Comparison between HPV16 physical states and ASP16-2 outcome for clinical DNA 
samples. 
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a E2/E6 ratio = 0%, fully integrated HPV16 DNA 
  E2/E6 ratio > 100%, experimental bias (estimation of HPV16 physical state not possible) 
  E2/E6 ratio between 0 and 100%, mixed (episomal + integrated) 
  E2/E6 ratio = 100%, fully episomal HPV16 DNA 
  (n.d. = not determined; E2/E6 qPCR was performed by Veronique Dalstein in Reims.) 
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2.13  HPV16 integration site of cervical carcinoma 07c368 (2B5)  
For clinical sample 2B5 (cervical carcinoma 07c368), three identical sequence reads 
derived from one potential viral-cellular junction were obtained in ASP16-2 (see 
Table 2-61). Starting with HPV16 primer EP-N3 (pos. 1576 – 1597), the HPV16 DNA 
breakpoint is located at position 1662 in the E1 gene, and the cellular DNA 
breakpoint on chromosome 1 at position 240761106 (NC_000001.10) (Figure 2-
63A). To check the authenticity of this DNA organization, junction-specific PCR was 
performed using different combinations of HPV16 and cellular primers (Figure 2-
63B). However, PCR products of expected sizes were not obtained. After Southern 
hybridization with HPV16-complete DNA probe, some positive signals were 
detectable on the blot. The PCR product of reaction 5 was cloned and sequenced. It 
turned out to be a novel viral-cellular junction sequence.  
Distinct from the pyrosequence junction obtained in ASP16-2, the novel cloned viral-
cellular junction has an HPV16 breakpoint at position 1910 in the E1 region and a 
cellular breakpoint at position 240760698 on chromosome 1 (NC_000001.10) (Figure 
2-64A). To check the authenticity of the novel junction in 2B5, another series of 
junction-specific PCR reactions was performed using the viral forward primer HPV16-
1793-F in combination with two cellular reverse primers (Figure 2-64B). PCR 
products with expected sizes were obtained from the GP-WGA library as template 
(reactions 1 and 4), and importantly also from the original 2B5 DNA as template 
(reactions 2 and 5), but not from MRI-H186 (reactions 3 and 6). The products were 
further confirmed by Southern hybridization with HPV16 DNA probe. Taken together, 
HPV16-1910/chr1-240760698 is the authentic viral-cellular junction of sample 2B5.  
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Figure 2-63: Junction-specific PCR for the potential viral-cellular junction in sample 2B5. The 
potential junction sequence of sample 2B5 obtained from ASP16-2 is shown in panel A (HPV16 
sequence underlined in red, cellular sequence underlined in blue). The junction-specific PCR and 
Southern hybridization (with HPV16 DNA probe) are shown in panel B. All six PCR reactions were 
performed using the 2B5 GP-WGA product as templates. The 100-bp DNA Ladder was used as size 
marker. (n.a.e.=not as expected) 
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Figure 2-64: Junction-specific PCR for the novel viral-cellular junction of sample 2B5. The 
structure of the novel viral-cellular junction of 2B5 is shown in panel A. The junction-specific PCR and 
Southern hybridization (with HPV16 DNA probe) are shown in panel B. Junction-specific PCR was 
performed with both 2B5 GP-WGA and 2B5 original DNA as template, respectively. MRI-H186 GP-WGA 
was used as negative control. The 100-bp DNA Ladder was used as size marker. (a.e. = as expected) 
 
In sample 2B5 (carcinoma 07c368), the integrated HPV16 DNA is located at 
chromosomal band 1q43 (Figure 2-65). A cellular gene called Gremlin2 or GREM2 
(HGNC-ID: 17655) is located directly at the integration site. The GREM2 gene 
contains two exons on the minus strand of chromosome 1, and encodes a BMP 
(bone morphogenic protein) antagonist family member. The integrated HPV16 DNA 
is inserted into the sole intron of GREM2 (Figure 2-65A). Another gene named RGS7 
(regulator of G-protein signaling 7; HGNC-ID: 10003) is located downstream of the 
integrated HPV16 DNA (Figure 2-65B).  
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Figure 2-65: Schematic demonstration of the HPV16 DNA integration site (A) in sample 2B5 and 
the genetic context (B) near the junction site. 
 
 
2.14  HPV16 integration site of cervical carcinoma 07c381 (2B6) 
For clinical sample 2B6 (cervical carcinoma 07c381), two identical sequence reads 
representing one potential viral-cellular junction were obtained in ASP16-2 (see 
Table 2-61). The detailed sequence analysis revealed a complicated structure of this 
potential junction, which contained HPV16 early sequence, fused to 45 bp of strongly 
rearranged HPV16 L1 sequences and the downstream cellular sequence from 
human chromosome 12 (Figure 2-66A). Starting with primer EP-N6 (pos. 2723 – 
2742), the HPV16 early sequence of this potential junction continues until position 
2783 in the overlapping region of E1 and E2 ORFs. The cellular DNA breakpoint at 
the junction site is position 57686270 (NC_000012.11) of chromosome 12.  
To examine the potential junction in sample 2B6, junction-specific PCR was 
performed using the viral forward primer HPV16-2701-F and the cellular reverse 
primer 57686333-R (Figure 2-66B; reactions 3 and 4). In addition, control reactions 
with either HPV16 (reaction 1) or cellular (reaction 2) primer pair alone were also 
done. PCR products with expected amplicon sizes of the potential junction were 
obtained from both the GP-WGA library as template as well as from the original 2B6 
DNA as template (reactions 3 and 4). The PCR products of reactions 3 and 4 were 
cloned and sequenced. The sequences of the two clones are identical to each other, 
and also in full agreement with the pyrosequence. These results proved that the viral-
cellular junction sequence of sample 2B6 obtained in ASP16-2 is authentic. 
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According to the E2-E6 qPCR data (see Table 2-62), the DNA sample 2B6 (E2/E6 
ratio=0) was estimated to be HPV16 fully-integrated. As expected, in reaction 1 with 
primer pair HPV16-2701-F and HPV16-2879-R, no PCR product was observed, 
because the HPV16 reverse primer cannot bind to the junction sequence. In reaction 
2 with cellular primers flanking the breakpoint 57686270, a band of expected size 
was detected, which suggests the existence of the related wild-type allele. 
 
 
Figure 2-66: Junction-specific PCR for the viral-cellular junction sequence in sample 2B6. The 
potential viral-cellular junction sequence of sample 2B6 obtained in ASP16-2 is shown in panel A 
(HPV16 early sequence in red, cellular sequence in blue, the re-arranged HPV16 L1 sequences in 
black). Junction-specific as well as control PCRs are shown in panel B. Junction-specific PCR was 
performed with both 2B6 GP-WGA and 2B6 original DNA as template, respectively. The 100-bp DNA 
Ladder was used as size marker. (a.e. = as expected) 
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Deduced from the viral-cellular junction sequence, in sample 2B6 (carcinoma 
07c381) the HPV16 DNA is integrated into chromosomal region 12q13.3. The cellular 
gene R3HDM2 (R3H domain containing 2; HGNC-ID: 29167) is located directly at the 
integration site. R3HDM2 is composed of 22 exons and is located on the minus 
strand of chromosome 12. The integrated HPV16 DNA of sample 2B6 is located in 
the intron 8 of R3HDM2 (Figure 2-67A). Three cellular genes with known functions 
including INHBC (inhibin, beta C; HGNC-ID: 6068), INHBE (inhibin, beta E; HGNC-
ID: 24029) and GLI1 (GLI family zinc finger 1; HGNC-ID: 4317), are situated 
downstream of the HPV16 integration site (Figure 2-67B). 
 
Figure 2-67: Schematic demonstration of the HPV16 DNA integration site (A) in sample 2B6 and 
the genetic context (B) near the junction site. The 22 exons of R3HDM2 are shown as blue bars in 
panel A. 
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3.   Discussion 
3.1  HPV16 DNA integration analysis in MRI-H186 
The present study has provided comprehensive insights into somatic DNA 
rearrangement and amplification in cervical carcinoma cell line MRI-H186, which are 
strongly coupled with HPV16 DNA integration. Altogether seven HPV16 integration 
variants have been identified in MRI-H186, and all variants are located on 
chromosomal band 8q24.21 in the c-myc region (see Section 2.8.5). Determined by 
signal intensities on Southern hybridization (see Figure 2-17), variants A and A+ are 
the two major products of integrated HPV16 DNA in MRI-H186. For the other five 
variants (B, C, A-B, D and E), no corresponding restriction fragments were 
detectable on Southern blots, although the flanking cellular sequences have been 
well characterized. This is most likely due to their low DNA copy number, compared 
to A and A+.  
Sequence comparison between the viral-cellular junctions of all integration variants 
has suggested that in MRI-H186 there was a primary HPV16 DNA integration event, 
from which all the other variants have originated. This primary event should be A or 
A+, because they carry exactly the same junction sequences, and almost all the 
other variants have been generated from A or A+ by secondary events. However, it is 
impossible to judge whether the integration event A preceded A+ or vice versa. 
Variant A might be initially inserted into the human genome. Then, this architecture 
could have been converted to A+ by gain of a complete HPV16 genome from co-
existing episomes (Figure 3-1). Otherwise, variant A+ might derive from a primary 
integration event of an HPV16 dimeric episome. The successive creation of A could 
be mediated by excision of a complete HPV16 genome from A+ (Figure 3-1).  
 
Figure 3-1: Possible conversions between HPV16 DNA integration variants A and A+ of MRI-
H186. The structures of variants A and A+ with positions of viral-cellular junctions are shown. Details 
about the hypothesis are explained in the text.  
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Assessed by spectral karyotyping, MRI-H186 cells exhibit overall near-tetraploidy, 
with big differences in the numbers of individual chromosomes (see Figure 2-26). 
Despite this heterogeneity, only two chromosomes 8 have been found in each of the 
cells analysed (Jérôme Couturier, personal communication). This observation 
correlates with the FISH assay (see Figure 2-25), in which the co-localized HPV16 
and c-myc signals were detected exclusively in the two chromosomes 8. As 
determined by quantitative PCR (see Figure 2-27), the copy number of c-myc gene is 
about 26 in each MRI-H186 cell (13 copies on each chromosome 8). The c-myc 
qPCR amplicon used for this assay is located in exon 1, which is present in the 3’ 
flanking cellular sequences of almost all integration variants characterized (except A-
B; see Section 2.8.5) as well as the c-myc wild-type allele, and therefore cannot 
distinguish between them. Most of the 26 c-myc copies, however, should be 
attributed to the two prominent integration variants A and A+ detected on Southern 
blot (see Figure 2-17). Taken together, these results have elucidated that HPV16 
integration variants A and A+ together with their flanking cellular sequences, which 
contain the intact c-myc transcription unit, are amplified in MRI-H186 cells.  
Co-amplification of integrated HPV16 DNA together with the flanking cellular 
sequences has also been reported for cervical carcinoma cell line HeLa (Lazo et al., 
1989). Each HeLa cell harbors 10 – 50 copies of integrated HPV18 DNA (Schwarz et 
al., 1985), which are primarily mapped to chromosomal band 8q24 (Dürst et al., 
1987; Lazo et al., 1989). The HPV18 integration site in HeLa is located about 500 kb 
upstream of the c-myc gene (Ferber et al., 2003). Southern analysis and 
chromosome in situ hybridization have shown that the integrated HPV18 DNA in 
HeLa is co-amplified with the flanking sequences from 8q24, but the co-amplicons do 
not involve the c-myc coding region (Lazo et al., 1989). Recently, another group has 
reported that integrated HPV DNA is co-amplified with flanking cellular sequences in 
three out of five cervical carcinoma cell lines with integration sites at the c-myc locus 
on 8q24.21, and this result was also verified in the original carcinomas (Peter et al., 
2006). Estimated by qPCR with primer pairs distributed in 8q24.21, the potential co-
amplification of integrated HPV DNA together with c-myc coding region was 
speculated, but the co-amplicons had not been validated by cloning and sequencing 
(Peter et al., 2006). In comparison with the published examples, the present study on 
MRI-H186 has shown for the first time at sequence resolution the direct juxtaposition 
and co-amplification of integrated HPV16 DNA together with the complete 
transcription unit of c-myc. Since material of the original carcinoma from which cell 
line MRI-H186 was established was not available, it was impossible to directly 
!"#$%##"&'(((),(
(
examine whether the HPV16 integration variants already existed in the primary 
tumor, or occurred later during the in vitro cell culture.  
 
Regarding gene expression, HPV16 DNA integration in the c-myc region gives rise to 
two major hybrid transcripts in MRI-H186, the HPV16-myc and the myc-HPV16 
mRNAs. Derived from integration variants A and A+, the HPV16-myc hybrid mRNA 
(see Figure 2-6) is a typical HPV-cellular co-transcript (see Figure 1-5). The HPV16-
myc mRNA in MRI-H186 is a polycistronic mRNA with coding potentials for viral 
oncoproteins E6 and E7, as well as the human c-MYC protein. However, it is 
believed that only the upstream ORFs (in this case E6 and E7) could be efficiently 
translated from such a polycistronic mRNA in eukaryotes (Kozak, 2005). Therefore, 
this mRNA probably does not affect the c-myc expression level directly. To our 
knowledge, an HPV16-myc hybrid mRNA like that in MRI-H186 has not been 
described in other cell lines, in which HPV16 DNA is integrated in the c-myc region. 
A comparable mRNA structure has been described for the viral-cellular hybrid mRNA 
identified in cervical carcinoma cell line ME180 (Reuter et al., 1998). In ME180, the 
integrated HPV68 DNA splits the cellular tumor suppressor gene APM-1 into two 
separate parts. The upstream part contains the untranslated exon 1, while the 
downstream part contains the protein-coding exons 2 and 3. A hybrid transcript 
composed of HPV68 E6, E7, and the complete APM-1 ORF is produced. But, similar 
to the HPV16-myc mRNA in MRI-H186, the hybrid mRNA in ME180 does not support 
the translation of APM-1 protein either (Reuter et al., 1998). 
The myc-HPV16 hybrid mRNA (see Figure 2-10), transcribed from integration variant 
B in association with the upstream cellular sequence, is a unique hallmark for MRI-
H186 cells. It is expressed to a considerable scale in MRI-H186, as the second most 
abundant mRNA on c-myc Northern blot (see Figure 2-7), and the major mRNA on 
HPV16 Northern blot (see Figure 2-9). Structures analogous to this novel transcript 
have never been reported for any HPV type. In general, the typical HPV integration 
events give rise to viral-cellular hybrid transcripts, such as the HPV16-myc mRNA 
mentioned earlier. The unusual cellular-viral hybrid transcripts, in this case the myc-
HPV16 mRNA, may only derive from secondary integration events by complicated 
DNA rearrangements. We speculated that the novel MycHPV16E2 in-frame fusion 
protein, as the end product of myc-HPV16 mRNA, might also be operative in cervical 
carcinogenesis, because it contains part of the trans-activation domain of c-MYC and 
the complete DNA-binding domain of HPV16 E2 (see Figure 2-13). 
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Functional analysis of the MycHPV16E2 fusion protein has been undertaken by Anna 
Tikidzhieva in the course of her Diplomarbeit (Tikidzhieva, 2009). It has been shown 
that the full-length E2 proteins of HPV16 and HPV18 can trans-activate a promoter 
through binding to the E2-binding sites (Phelps and Howley, 1987). However, for the 
early promoters of HPV16 (p97) and HPV18 (p105), the E2 proteins are actually 
repressors rather than activators of viral gene expression (Bernard et al., 1989; 
Romanczuk et al., 1990). This repression is thought to work in a dose-dependent 
manner, mediated by the occupancy status of E2-binding sites adjacent to viral 
promoter, and thereby sterically hinders the interaction between cellular transcription 
factors and their target sites for transcription initiation (Thierry and Howley, 1991; 
Tan et al., 1992; Tan et al., 1994; Demeret et al., 1994; Steger and Corbach, 1997). 
It has been suggested that the repression of viral oncogene expression caused by 
ectopic re-introduction of E2 protein leads to growth inhibition specifically in HPV-
positive cervical carcinoma cell lines (Hwang et al., 1993; Dowhanick et al., 1995; 
Desaintes et al., 1997; Goodwin et al., 1998; Francis et al., 2000). Further 
investigation using HPV16 E2 mutants has proven that both the N-terminal trans-
acting domain and C-terminal DNA binding domain of HPV16 E2 protein are required 
for the repression activity and cell death (Sakai et al., 1996; Nishimura et al., 2000). 
Transient transfection assays using luciferase reporter gene showed that in SiHa and 
HeLa cells exogenously expressed MycHPV16E2 protein trans-activates the co-
transfected heterologous TK promoter, which is fused directly downstream to tandem 
repeated E2-binding sites (Tikidzhieva, 2009). Therefore, it seems that the partial c-
MYC trans-activation domain at the N-terminus of MycHPV16E2 may be functional, 
because the DNA binding domain of HPV16 E2 has no trans-acting activity. Stable 
transfection assay have provided two stable clones from SiHa cells transfected with 
MycHPV16E2. One clone showed suppressed cell growth, but the other one did not 
show any obvious change compared to untransfected cells (Tikidzhieva, 2009). No 
stable clone could be isolated from HeLa cells transfected with MycHPV16E2, 
indicating that HeLa cell growth is not compatible with the presence of this protein 
(Tikidzhieva, 2009). From these results, it appears unlikely that the MycHPV16E2 
fusion protein has oncogenic activity. More likely, the fusion protein is a transcription 
activator that probably causes cell death in HPV-infected cells, similar to HPV16 E2 
protein. In MRI-H186 cells, the potential pro-apoptotic activity of endogenous 
MycHPV16E2 protein seems to be well tolerated. 
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Associated with HPV16 DNA integration into c-myc locus, the c-myc proto-oncogene 
is over-expressed at both mRNA and protein levels in MRI-H186 (see Figure 2-7 and 
2-8). The human c-MYC protein is a multi-functional regulator involved in several 
important cellular processes including proliferation, differentiation, growth and 
apoptosis (Meyer and Penn, 2008). Aberrant c-myc expression has been frequently 
observed in a panel of human cancers (Dang, 1999; Grandori et al., 2000). The c-
myc deregulation can be induced by gross genetic alterations such as viral 
insertional mutagenesis, chromosomal translocation and allelic amplification, or 
mediated by a variety of upstream cellular pathways (Meyer and Penn, 2008). 
Among them, c-myc over-expression caused by chromosomal translocation has 
been intensively characterized in human Burkitt’s lymphoma. In these tumors, the c-
myc locus on chromosome 8 is often juxtaposed to three different immunoglobin (Ig) 
loci on chromosomes 14, 2 and 22, respectively (Hecht and Aster, 2000). The 
translocation events lead to transcriptional regulation of c-myc promoters under the 
control of lymphocyte-specific Ig enhancers. In quiescent cells, the c-myc expression 
is negatively controlled by pausing of RNA polymerase II, which leads to premature 
termination of transcription (Eick and Bornkamm, 1986). By contrast, in Burkitt’s 
lymphoma cells the blocked transcriptional elongation is released, thereby 
upregulating the c-myc expression compared to untransformed cells (Strobl and Eick, 
1992). It has also been shown that Ig enhancers can modulate activities of 
promoters, which are located as far as about 500 kb apart (Chesi et al., 1998; Hecht 
and Aster, 2000). Therefore, it can easily be imagined that in MRI-H186 cells c-myc 
over-expression is caused by direct cis-activation of the c-myc promoter by the 
HPV16 enhancer (Figure 3-2), because the distance between HPV16 integration site 
and c-myc gene is only about 1.7 kb.  
 
Figure 3-2: Hypothesized direct cis-activation of c-myc promoter by HPV16 enhancer. The 
structure of integrated HPV16 DNA (taking the variant A as example) and the flanking c-myc 
transcription unit is shown. The green arrow indicates the cis-activation of c-myc promoter (P1) by the 
HPV16 enhancer in upstream regulatory region (URR). 
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Concerning the fact that HPV DNA integration often occurs in c-myc locus (Dürst et 
al., 1987; Couturier et al., 1991; Sastre-Garau et al., 2000; Wentzensen et al., 2002; 
Ferber et al., 2003; Peter et al., 2006; Kraus et al., 2008; Dall et al., 2008), insertional 
mutagenesis of c-myc might not be a rare event but contribute to cervical 
carcinogenesis in a subset (about 10%) of cases. In an earlier study including 35 
cervical carcinomas, DNA amplification and/or rearrangement of c-myc has been 
detected in about 90% of the samples (Ocadiz et al., 1987). Over-expression of c-
myc has been reported in about 33% of altogether 93 cervical carcinomas (Bourhis 
et al., 1990). c-myc over-expression was shown to correlate with increased tumor 
size, overall relapse and distant metastasis, altogether suggesting a significant role 
of c-myc in tumor progression (Bourhis et al., 1990). Recent functional studies have 
shown that c-MYC protein can increase telomerase activity and thereby promote 
cellular immortalization, in cooperation with HPV16 E6 and E7 oncoproteins 
(Veldman et al., 2003; Liu et al., 2007; Liu et al., 2008). These results implicate that 
in cervical carcinogenesis the c-MYC oncoprotein may play an essential role for 
tumor progression. 
 
3.2  The novel ASP16 strategy 
In the present study, a novel strategy named ASP16 is introduced for the first time. 
The ASP16 strategy has been developed and examined during the thesis work, in 
order to determine HPV16 DNA integration sites at the sequence level in clinical pre-
cancerous and cancerous lesions obtained from cervical scrapes. As proof of 
principle, two ASP16 experiments (ASP16-1 and 2) were performed in this thesis. 
Both experiments have clearly shown the successful whole genome amplification 
and the effective HPV16 DNA enrichment, starting with DNA samples isolated from 
cervical scrapes, which are generally of low quantity and often of poor quality. As far 
as we know, this is the first systematic attempt to identify HPV DNA integration sites 
in cervical scrapes. The PCR-based HPV DNA integration analyses (DIPS-PCR; RS-
PCR) published so far have been focused on cervical carcinoma specimens rather 
than pre-cancerous lesions (Luft et al., 2001; Ziegert et al., 2003; Thorland et al., 
2003; Ferber et al., 2003), probably because the DNA amounts obtained from the 
former are much more abundant than the latter. So far, HPV integration analysis of 
cervical scrapes has only been involved in the RT-PCR-based APOT assay at the 
cDNA level (Klaes et al., 1999; Wentzensen et al., 2002; Vinokurova et al., 2008; 
Kraus et al., 2008). However, due to RNA splicing, cDNA sequences do not usually 
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represent the viral-cellular DNA junctions directly. In comparison with the published 
techniques mentioned above, the novel ASP16 strategy seems to be the most 
plausible means for HPV16 DNA integration analysis in clinical samples from cervical 
scrapes, which requires only about 10 ng of genomic DNA input and tolerates the 
partial degradation of clinical DNA. For future applications, it is worthy of combining 
the ASP16 strategy at the DNA level and the APOT assay at the cDNA level for 
better experimental outcomes.  
 
Concerning HPV16 DNA integration sites, the known 3’ viral-cellular junction 
sequence of MRI-H186 cell line has been identified in the experiments ASP16-1 and 
2. This clearly demonstrates that the whole concept of ASP16 strategy works. Based 
on the results of ASP16-1, some modifications on the experimental design were 
made for ASP16-2, including focus on the HPV16 early region, addition of new 
HPV16 primers to reduce primer interval, and expansion of pyrosequencing device to 
increase the total number of sequence reads. As a consequence, the performance of 
ASP16 has been improved in ASP16-2. This has helped to obtain much more 
sequence reads representing the already known 3’ junction of MRI-H186, and to 
determine novel junction sequences from clinical DNA samples (carcinomas 2B5 and 
2B6) as well. However, the problem of short average sequence length versus long 
primer interval remains to be solved. It was originally expected that the use of HPV16 
early primer mix 2 (EPM-2) in ASP16-2 could reduce primer interval from about 400 
to 200 bp, in association with primer mix 1 (EPM-1) also used in ASP16-1. But, the 
results from ASP16-2 have revealed that EPM-2 was not efficient enough, because 
the EP-N10 forms primer dimer together with GPUA. For optimization, unspecific 
primers EP-N10 (from EPM-2) and EP-N1 (from EPM-1) should be eliminated from 
future experiments or replaced by new ones. Even if the primer interval will be 
decreased to 200 bp in the future, the average length of pyrosequence reads (around 
100 nt) obtained under the current experimental conditions is still too short. It is 
therefore necessary to remove primer dimers and PCR products shorter than 200 bp 
from the DNA mixture prepared for pyrosequencing.  
In the experiment ASP16-2, HPV16 DNA integration sites have been identified and 
confirmed in two (cervical carcinomas 2B5 and 2B6) out of sixteen clinical DNA 
samples. Although the overall yield of authentic viral-cellular junctions was rather 
low, the ASP16 performance correlated well with HPV16 physical states of the 
clinical samples. Estimated by E2-E6 qPCR (see Table 2-62), carcinoma samples 
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2B5 and 2B6 should contain mainly (2B5; E2/E6 ratio=0.16) or exclusively (2B6; 
E2/E6 ratio=0) integrated HPV16 DNA. All the other fourteen clinical samples 
including three carcinomas and eleven pre-cancerous lesions, for which no authentic 
junction sequence was obtained in ASP16-2, showed high percentages of episomal 
HPV16 DNA. We learn from these results that for future ASP16 experiments the 
clinical DNA samples with low E2/E6 ratios should be preferentially conducted, in 
order to determine the HPV16 integration sites more efficiently. In the ongoing 
experiments ASP16-3 and ASP16-4 (performed in the PhD work of Sasithorn 
Chotewutmontri; unpublished data), this aspect has been taken into consideration, in 
addition to the experimental modifications mentioned before. In the experiment 
ASP16-3 for instance, HPV16 DNA integration sites have been determined in some 
cervical pre-cancerous lesions (CIN3) including the sample BV66019 with fully 
integrated HPV16 DNA, which was initially included in ASP16-2 (sample-ID 2B18), 
but not used for the pyrosequencing (see Table 2-48 and Figure 2-49).  
 
Taken together, the novel ASP16 strategy has offered the first opportunity to 
systematically explore HPV16 integration sites in clinical DNA samples obtained from 
cervical scrapes, with particular respect to the low quantity and poor quality of 
template DNA. This unique feature is of great interest for the incorporation of HPV16 
DNA integration analysis into routine cervical screening programs, which continually 
provide pre-cancerous and cancerous lesions for investigation. Another potential 
DNA resource for ASP16 applications would be the large number of archival cervical 
biopsies collected previously and stored frozen over a long period of time, which 
therefore may not be compatible with the conventional methods applied for HPV 
integration analysis, such as DIPS-PCR, RS-PCR and APOT. In addition to viral-
cellular junctions, the majority of pyrosequence reads from ASP16 experiments are 
purely HPV16 DNA sequences, altogether covering the complete HPV16 E1/E2 
region. It has been suggested that mutations/variations of the HPV16 E2 gene 
associated with high-grade cervical pre-cancerous lesions and carcinomas may 
contribute to tumor progression by deregulating viral gene expression (Casas et al., 
1999; Giannoudis et al., 2001). In this context, the huge amount of sequence data 
from ASP16 experiments can be used to detect sequence variations including point 
mutations, small deletions/insertions and gross DNA rearrangements of the HPV16 
E1/E2 region. Based on the results of ASP16-2, one example of the mutation 
analysis has been illustrated by Nico Steinmeyer in his Diplomarbeit (Steinmeyer, 
2009). In this case, mutation within E1 ORF has resulted in an additional recognition 
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site for a restriction enzyme, and the new site was confirmed by specific cleavage of 
PCR-amplicons containing the point mutation (Steinmeyer, 2009). Finally, after the 
establishment and optimization of ASP16, this strategy will be extended to other 
high-risk HPV types especially for HPV18 (then will be named ASP18), which has 
been detected as integrated form in almost all HPV18-positive cervical carcinomas 
analysed (Cullen et al., 1991; Hudelist et al., 2004; Vinokurova et al., 2008).  
 
3.3  HPV16 DNA integration and insertional mutagenesis 
It is apparent that HPV integration events may put intact cellular genes under the cis-
control of viral regulatory elements. In some instances including c-myc discussed in 
Section 3.1, the aberrant regulation is strongly associated with activation of cellular 
proto-oncogene or inactivation of tumor suppressor gene (Reuter et al., 1998; Peter 
et al., 2006). Although a number of HPV integration sites have been identified in 
cervical carcinomas, less is known about the general role of insertional mutagenesis 
in cervical cancer progression. Based on the fact that integration sites are often 
mapped dozens to hundreds kb away from a protein-coding gene, some researchers 
argued that insertional mutagenesis might be a rare event and not important for 
cervical carcinogenesis (Wentzensen et al., 2002; Ziegert et al., 2003). Others, 
however, have argued that alterations of cellular gene expression caused by HPV 
integration may not be a rare event (Kraus et al., 2008). As seen from chromosomal 
rearrangements in Burkitt’s lymphoma, gene expression can be modulated by 
enhancers located about 500 kb apart. Furthermore, it has also been reported that 
integrated HPV DNA is frequently found near microRNA-coding genes (Calin et al., 
2004). These observations suggest that more efforts should be given in the future for 
investigating cellular candidate genes, whose expression may be affected by cis-
elements of integrated HPV DNA. 
 
In cervical carcinoma cell line MRI-H196, the integrated HPV16 DNA is mapped to 
chromosomal band 11p11.2 (see Section 2.1.2). The cellular gene ptprj (HGNC-ID: 
9673) is located about 34 kb downstream of the 3’ viral-cellular junction site (Figure 
3-3). PTPRJ belongs to the protein tyrosine phosphatase (PTP) family composed of 
at least 37 members, including the well-known tumor suppressor protein PTEN 
(Tonks, 2006). Deletion of ptprj followed by loss of hetorozygosity (LOH) has been 
detected in a variety of lung, colon and breast cancers, indicating its tumor 
!"#$%##"&'(((/02(
(
suppressor activity (Ruivenkamp et al., 2002). However, gain of ptprj DNA copy 
number has also been reported recently for one glioma case, but without any 
information about the ptprj expression level (Preusser et al., 2007). The HPV 
integration sites published to date have not shown any connection with ptprj 
(Wentzensen et al., 2004; Kraus et al., 2008). In MRI-H196 cells, expression of ptprj 
might be upregulated by HPV16 enhancer elements, because the distance of about 
34 kb is accessible for transcriptional cis-activation. On the other hand, there is also 
evidence from cell line ME180 implicating that tumor suppressor gene APM-1 is 
silenced by promoter hypermethylation associated with HPV68 DNA integration into 
the APM-1 gene (Elisabeth Schwarz, personal communication). The question here is 
whether this silencing effect may still be operative over a range of 34 kb in MRI-
H196. Furthermore, it needs to be clarified whether the 1-Mb deletion of cellular DNA 
between the 5’ and 3’ viral-cellular junctions (see Figure 2-4D) is homozygous, 
because this region contains several apoptosis-related genes including DDB2, 
MADD and PU.1.  
 
Figure 3-3: Schematic demonstration of the HPV16 DNA integration site in MRI-H196 and the 
genetic context near the junction site. 
 
In cervical carcinoma 07c368 (2B5), the integrated HPV16 DNA is mapped to 
chromosomal band 1q43 (see Figure 2-65). The HPV16 integration site is located in 
the intron between exons 1 and 2 of the cellular gene Grem2. This gene encodes 
Gremlin2 protein, which is an antagonist of the bone morphogenetic protein (BMP) 
family essential for skeletal formation (Avsian-Kretchmer and Hsueh, 2004; Yanagita, 
2005). BMPs belong to the tumor growth factor beta (TGF!) superfamily, which 
either act as negative regulators of tumor growth or promote cell invasiveness and 
metastasis toward distant tissues (Massagué et al., 2000; Derynck et al., 2001; Tobin 
et al., 2002; Elliott and Blobe, 2005; Pardali and Moustakas, 2007). A growing 
number of evidence has shown the correlation between BMPs over-expression and 
osteoblastic bone metastasis in human prostate and breast cancers (Hamdy et al., 
1997; Autzen et al., 1998; Masuda et al., 2003; Alarmo et al., 2008; Yuen et al., 
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2008). In accordance with this correlation, several BMP antagonists including 
Noggin, Gremlin1 and SOSTDC1 have been reported to be downregulated in human 
malignancies (Suzuki et al., 2005; Schwaninger et al., 2007; Yuen et al., 2008; Blish 
et al., 2008; van Vlodrop et al., 2010). In some instances, the inactivation of Gremlin1 
gene has been linked with promoter hypermethylation (Suzuki et al., 2005; van 
Vlodrop et al., 2010). For sample 2B5, it needs to be clarified whether Grem2 is 
inactivated and by which mechanism (LOH or methylation).  
 
In cervical carcinoma 07c381 (2B6), the HPV16 DNA integration site is mapped to 
chromosomal band 12q13.3 (see Figure 2-67). The transcription unit of the cellular 
R3HDM2 gene is disrupted by the integrated HPV16 DNA. It is impossible to 
speculate about the relevance to cervical carcinogenesis, because nothing is known 
about the function of R3HDM2 protein. By contrast, the cellular proto-oncogene GLI1 
located about 124 kb downstream of R3HDM2 became more interesting (see Figure 
2-67B). The GLI1 transcription factor is a member of the Kruppel zinc finger protein 
family, and belongs to the sonic hedgehog (SHH) signalling pathway (i Altaba et al., 
2002; di Magliano and Hebrok, 2003). The GLI1 gene was initially identified highly 
expressed in a malignant glioma, along with over 50-fold of GLI1 DNA amplification 
(Kinzler et al., 1987). Later studies have frequently shown the upregulation of GLI1 
and activation of SHH pathway in basal cell carcinoma of the skin (Dahmane et al., 
1997; Green et al., 1998; Nilsson et al., 2000). Recent data also suggest the role of 
GLI1 over-expression in metastases from esophageal squamous cell carcinoma and 
pancreatic cancer (Mori et al., 2006; Feldmann et al., 2007). Thus, it would be 
interesting to investigate the expression level of GLI1 and the metastasis status in 
sample 2B6.  
 
Each of the HPV16 DNA integration sites identified in the present study has a unique 
feature of flanking cellular sequences. This is consistent with the results of other 
groups (Wentzensen et al., 2004; Kraus et al., 2008). The cellular proto-oncogenes 
or tumor suppressor genes located near or at the junction sites belong to different 
signalling pathways. Unlike the ubiquitous contributions of oncogenic E6 and E7 in 
cervical carcinogenesis, insertional mutagenesis of cellular genes may involve 
different molecular mechanisms. The potential insertional mutagenesis events 
implicated in this study, especially from samples 2B5 and 2B6, suggest a possible 
role of HPV-induced insertional mutagenesis in cervical cancer progression. 
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4.   Materials and Methods 
4.1  Chemical reagents 
2’-deoxyadenosine-5’-triphosphate (dATP) 
2’-deoxycytidine-5’-triphosphate (dCTP) 
2’-deoxyguanosine-5’-triphosphate (dGTP) 
2’-deoxythymidine-5’-triphosphate (dTTP) 
Acetic acid glacial 
Agarose, for routine use 
Ammonium persulfate (APS), powder 
Ampicillin, sodium salt, powder 
Bacto agar 
Bacto tryptone 
Bacto yeast extract 
Blue dextran 
!-mercaptoethanol 
Bovine Serum Albumin (BSA) 
Bromophenol blue, sodium salt 
Roche Applied Science, Mannheim 
Roche Applied Science, Mannheim 
Roche Applied Science, Mannheim 
Roche Applied Science, Mannheim 
Sigma-Aldrich, München 
Sigma-Aldrich, München 
Roche Applied Science, Mannheim 
AppliChem, Darmstadt 
Becton Dickinson, Heidelberg 
Becton Dickinson, Heidelberg 
Becton Dickinson, Heidelberg 
Sigma-Aldrich, München 
Sigma-Aldrich, München 
NEB, Frankfurt am Main 
Serva, Heidelberg 
Chloroform 
Coomassie Brilliant Blue G-250 
DEPC 
Dimethylformamide (DMF) 
DMEM 
DMSO, cell culture grade 
EDTA, disodium salt dihydrate 
Ethanol absolute   
Ethidium bromide, powder 
Fetal Bovine Serum (FBS) Superior 
Ficoll 400 
Formaldehyde 
Formamide 
Glucose 
Glycerol 
Roth, Karlsruhe 
Bio-Rad, München 
AppliChem, Darmstadt 
Sigma-Aldrich, München 
Sigma-Aldrich, München 
AppliChem, Darmstadt 
Sigma-Aldrich, München 
Sigma-Aldrich, München 
Sigma-Aldrich, München 
Biochrom, Berlin 
Serva, Heidelberg 
Merck, Darmstadt 
Merck, Darmstadt 
Sigma-Aldrich, München 
Sigma-Aldrich, München 
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Glycine 
HEPES, free acid 
Hydrochloric acid (HCl), 37% w/v 
Isoamyl alcohol 
Isopropanol 
Kanamycin sulfate, powder 
Lithium Chloride (LiCl) 
Magnesium chloride (MgCl2) 
Magnesium sulfate (MgSO4) 
Methanol 
Milk powdered, blotting grade 
MOPS, free acid, powder 
NEN ["-32P]dCTP 
NP-40 
Penicillin-streptomycin, liquid 
Sigma-Aldrich, München 
Sigma-Aldrich, München 
Sigma-Aldrich, München 
Sigma-Aldrich, München 
Sigma-Aldrich, München 
AppliChem, Darmstadt 
Sigma-Aldrich, München 
Sigma-Aldrich, München 
Sigma-Aldrich, München 
Sigma-Aldrich, München 
Roth, Karlsruhe 
Sigma-Aldrich, München 
PerkinElmer, Rodgau-Jügesheim 
Sigma-Aldrich, München 
Invitrogen, Karlsruhe 
Phenol 
Polyvinylpyrrolidone 
Potassium chloride (KCl), powder 
Potassium phosphate monobasic (KH2PO4) 
Proteinase K 
Redivue ["-32P]dCTP 
RNase A 
RNaseZap spray 
Rotiphorese Gel 30 (37.5:1) 
RPMI 
Sarkosyl, sodium salt 
Sodium acetate, powder 
Sodium chloride (NaCl), powder 
Sodium citrate dihydrate 
Sodium deoxycholate 
Sodium dodecyl sulfate (SDS), powder 
Sodium hydroxide (NaOH), powder 
    Roth, Karlsruhe 
    Sigma-Aldrich, München 
    Sigma-Aldrich, München 
    Sigma-Aldrich, München 
    Merck, Darmstadt 
    GE Healthcare Europe, München 
    Qiagen, Hilden 
    Sigma-Aldrich, München 
    Roth, Karlsruhe 
    Sigma-Aldrich, München 
    Sigma-Aldrich, München 
    Sigma-Aldrich, München 
    Sigma-Aldrich, München 
    Sigma-Aldrich, München 
    Sigma-Aldrich, München 
    Sigma-Aldrich, München 
    Sigma-Aldrich, München 
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Sodium phosphate dibasic (Na2HPO4) 
TEMED 
Trizma base, powder 
TRIzol Reagent 
t-RNA 
Trypsine/EDTA 
Tween 20 
UltraPure water, DNase/RNase-free 
X-Gal 
Xylene cyanol FF, sodium salt 
Sigma-Aldrich, München 
Sigma-Aldrich, München 
Sigma-Aldrich, München 
Invitrogen, Karlsruhe 
Sigma-Aldrich, München 
Invitrogen, Karlsruhe 
Sigma-Aldrich, München 
Invitrogen, Karlsruhe 
Sigma-Aldrich, München 
Serva, Heidelberg 
 
 
 
 
4.2  Buffer solutions (frequently used) 
6! BPB DNA-loading buffer 
0.25% (w/v) bromophenol blue 
30% (v/v) glycerol 
store at 4 °C 
(BPB runs in the agarose gel  
at the position of about 0.5 kb) 
6! XC DNA-loading buffer 
0.25% (w/v) xylene cyanol 
30% (v/v) glycerol 
store at 4 °C 
(XC runs in the agarose gel  
at the position of about 5 kb) 
 
1 M Tris-HCl 
1 M Trizma base 
adjust pH with HCl 
autoclave 
0.5 M EDTA, pH 8.0 
0.5 M EDTA 
adjust pH with NaOH 
autoclave 
 
10! TE, pH 8.0 
100 mM Tris-HCl, pH 8.0 
10 mM EDTA, pH 8.0 
autoclave 
 
50! TAE buffer, per liter 
242 g of Trizma base  
57.1 ml of glacial acetic acid  
100 ml of 0.5 M EDTA, pH 8.0 
dissolve in deionized water 
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10! MOPS electrophoresis buffer 
0.2 M MOPS 
20 mM sodium acetate 
10 mM EDTA, pH 8.0 
dissolve in DEPC-treated water  
filter-sterilized, store in dark 
1! RNA-loading buffer 
50% (v/v) formamide 
2.2 M formaldehyde 
1! MOPS-buffer 
1% (v/v) Ficoll 400 
0.02% (w/v) bromophenol blue 
 
20! SSC 
3 M NaCl 
0.3 M sodium citrate 
adjust pH to 7.0 with HCl 
autoclave 
3 M sodium acetate, pH 5.2 
3 M sodium acetate 
adjust pH with glacial acetic acid 
autoclave 
 
 
10! PBS, per liter 
80 g NaCl 
2 g KCl 
14.4 g Na2HPO4 
2.4 g KH2PO4 
adjust pH to 7.4 with HCl 
autoclave 
10! TBS, per liter 
80 g NaCl 
2 g KCl 
30 g Trizma base 
adjust pH to 7.4 with HCl 
autoclave 
 
 
5! SDS-PAGE sample buffer 
10% (w/v) SDS 
10 mM !-mercaptoethanol 
20% (v/v) glycerol 
0.2 M Tris-HCl, pH 6.8 
0.05% (w/v) bromophenol blue 
5! SDS-PAGE running buffer 
125 mM Trizma base 
1 M glycine  
0.5% (w/v) SDS 
 
 
 
10! Western blotting buffer 
250 mM Trizma base 
2 M glycine 
 
Western stripping buffer 
62.5 mM Tris-HCl, pH 6.8 
2% (w/v) SDS 
0.1 M !-mercaptoethanol 
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4.3  Molecular weight size markers 
4.3.1 DNA markers 
            " /Hind III (500 ng/lane)                                 SmartLadder (5 µ l/lane) 
             (Invitrogen, Karlsruhe)                                        (Eurogentec, Köln) 
                                   
 
 
                        100 bp DNA Ladder (500 ng/lane; not for DNA quantitation) 
                                                        (Invitrogen, Karlsruhe) 
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4.3.2 Protein markers 
 BenchMark prestained protein ladder             PageRuler prestained protein ladder 
               (Invitrogen, Karlsruhe)                                      (Fermentas, St. Leon-Rot) 
                                            
 
 
4.4  Culture media 
4.4.1 Bacterial culture media 
LB medium 
1% (w/v) Bacto tryptone 
0.5% (w/v) Bacto yeast extract 
1% (w/v) NaCl 
dissolve in distilled water 
pH = 7.0 (adjust with 5 N NaOH) 
autoclave at 121 °C, store at RT 
LB agar (with selective antibiotics) 
LB contents + 1.5% (w/v) Bacto agar 
dissolve in water, adjust pH, autoclave 
cool to 50–60 °C, add antibiotics* 
pour into petri dishes, 25 ml/plate 
allow agar to solidify at RT 
store plates inverted at 4 °C 
 
(* final concentration: 100 µg/ml of ampicillin or 50 µg/ml of kanamycin) 
 
SOB medium 
2% (w/v) Bacto tryptone 
0.5% (w/v) Bacto yeast extract 
10 mM NaCl  
2.5 mM KCl 
adjust pH to 7.0, autoclave  
SOC medium 
SOB medium 
20 mM glucose (filter-sterilized) 
aliquot, store at –20 °C 
 
 
add filter-sterilized MgCl2/MgSO4 (10 mM each) 
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4.4.2 Cell culture media 
Complete DMEM culture medium 
500 ml DMEM 
50 ml FBS 
5 ml Penicillin-streptomycin* 
Complete RPMI culture medium 
500 ml RPMI 
50 ml FBS 
5 ml Penicillin-streptomycin* 
 
(* contains 50000 units of penicillin and 50000 µg of streptomycin in total)  
 
Cell freezing medium 
80% (v/v) complete cell culture medium 
10% (v/v) FBS 
10% (v/v) DMSO, cell culture grade 
 
 
4.5  Restriction endonucleases (frequently used) 
Enzyme Recognition Sequence Reaction Condition Manufacturer 
EcoR I 
(FastDigest) 
5’-G#AATTC-3’ 
3’-CTTAA$G-5’ 
1% FastDigest buffer; 
at 37°C 
Fermentas 
(St. Leon-Rot) 
Hind III 
5’-A#AGCTT-3’ 
3’-TTCGA$A-5’ 
1% React 2 buffer; 
at 37°C 
Invitrogen 
(Karlsruhe) 
Nco I 
5’-C#CATGG-3’ 
3’-GGTAC$C-5’ 
1% NEBuffer 3; 
at 37°C 
           NEB 
(Frankfurt am 
Main) 
Xba I 
5’-T#CTAGA-3’ 
3’-AGATC$T-5’ 
1% React 2 buffer; 
at 37°C 
Invitrogen 
(Karlsruhe) 
 
 
4.6  Antibodies 
4.6.1 Primary antibodies 
Anti-c-MYC, clone 9E10 (Roche Applied Science, Mannheim) 
Mouse monoclonal antibody (IgG); Working concentration: 1 µg/ml for Western blot;  
Epitope: the C-terminus of human c-MYC protein (AA 410–419, EQKLISEEDL) 
 
Anti-c-MYC, clone Y69 (Epitomics, Burlingame, U.S.A) 
Rabbit monoclonal antibody (IgG); Working dilution: 1:10000 for Western blot; 
Epitope: the N-terminus of human c-MYC protein (AA 1–20, MPLNVSFTNRNYDLDYDSVQ) 
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Anti-GAPDH (Abcam, Cambridge, UK) 
Rabbit polyclonal antibody (IgG); Working dilution: 1:1000 for Western blot; 
Immunogen: human GAPDH protein (native, full length)  
 
4.6.2 Secondary antibodies 
Peroxidase-conjugated AffiniPure Goat Anti-Mouse IgG (H+L) 
(Jackson ImmunoResearch Europe, Suffolk, UK) 
Working dilution: 1:10000 after rehydration in 1.5 ml of distilled water 
 
Peroxidase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) 
(Jackson ImmunoResearch Europe, Suffolk, UK) 
Working dilution: 1:10000 after rehydration in 1.5 ml of distilled water 
 
 
4.7  Commercial kits 
Advantage 2 PCR Kit 
Chemiluminescence Detection Kit 
Dynabeads Oligo (dT)25 
Expand HiFiPLUS PCR Kit 
Expand Long Range PCR Kit 
FastStart Taq DNA Polymerase Kit 
GenomePlex WGA 2 Kit  
illustra MicroSpin G-25 Columns 
Paq5000 DNA Polymerase Kit 
Qiagen Multiplex PCR Kit 
QIAquick Gel Extraction Kit 
QIAquick PCR Purification Kit 
Rediprime II DNA Labeling System 
SMART RACE cDNA Amplification Kit 
StrataClone PCR Cloning Kit 
SuperScript III Reverse Transcriptase Kit 
Taq DNA Polymerase Kit 
TOPO TA PCR Cloning Kit 
 
Becton Dickinson, Heidelberg 
AppliChem, Darmstadt 
Invitrogen, Karlsruhe 
Roche Applied Science, Mannheim 
Roche Applied Science, Mannheim 
Roche Applied Science, Mannheim 
Sigma-Aldrich, München 
GE Healthcare Europe, München 
Stratagene, La Jolla, U.S.A 
Qiagen, Hilden 
Qiagen, Hilden 
Qiagen, Hilden 
GE Healthcare Europe, München 
Becton Dickinson, Heidelberg 
Stratagene, La Jolla, U.S.A 
Invitrogen, Karlsruhe 
Invitrogen, Karlsruhe 
Invitrogen, Karlsruhe 
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4.8  Consumables 
BioMag streptavidin beads 
Biomax Light film 
Biomax MR film 
Cell culture flasks (25, 75, 175 cm2) 
Cell scraper, plastic 
Cuvettes, plastic 
Falcon tube (15 and 50 ml) 
Hybond-N+ nylone membrane 
Immobilon-P transfer membrane 
Microcentrifuge tube (1.5 & 2ml) 
Pasteur piptte, plastic 
PCR-tube, 0.5 ml, thin-walled 
Petri dish (for bacteria) 
Pipetting tips 
PP-tube (14 ml) 
Scalpel 
Sterile filter (0.22 & 0.45 µM)  
Whatman 3MM paper 
Polysciences, Heidelberg 
GE Healthcare Europe, München 
GE Healthcare Europe, München 
Greiner, Frickenhausen 
Greiner, Frickenhausen 
Eppendorf, Hamburg 
Becton Dickinson, Heidelberg 
GE Healthcare Europe, München 
Millipore, Schwalbach/Ts. 
Steinbrenner, Wisenbach 
Neolab, Heidelberg 
Neolab, Heidelberg 
Greiner, Frickenhausen 
Steinbrenner, Wisenbach 
Greiner, Frickenhausen 
Sterimed, Püttlingen 
Millipore, Schwalbach/Ts. 
Schleicher & Schuell, Dassel
 
 
4.9  Laboratory instruments 
Biofuge Pico 
CO2-incubator for cell culture 
Curix 60 film processor 
Electrophoresis chamber 
(for agarose gel) 
Film cassettes 
Heating block 
Magnetic particle concentrator 
Megafuge 1.0R 
Heraeus, Hanau 
Heraeus, Hanau 
AGFA Healthcare, Köln 
Renner, Dannstadt &  
Peqlab, Erlangen 
GE Healthcare Europe, München 
Eppendorf, Hamburg 
Invitrogen, Karlsruhe 
Heraeus, Hanau
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Mini-PROTEAN II Electrophoresis Cell  
Mini Trans-Blot Transfer Cell 
NanoDrop 1000 Spectrophotometer 
Pipettes 
Thermocycler PTC-200 
Ultrospec 3000 pro 
Vortex  
Bio-Rad, München 
Bio-Rad, München 
Thermo Fisher, Waltham, U.S.A 
Gilson, Düsseldorf 
MJ Research, Waltham, U.S.A 
GE Healthcare Europe, München 
Bender & Hobein, Zürich, Switzerland
 
 
4.10  Software 
HUSAR: Heidelberg Unix Sequence Analysis Resources (http://www.dkfz.de/menu/biounit) 
NCBI: National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov) 
Ensemble: European Bioinformatics Institute (EBI) databases (http://www.ensembl.org) 
Computer programs for ASP16 strategy: written by Sasithorn Chotewutmontri 
(unpublished, ongoing PhD thesis, DKFZ) 
 
 
4.11  Genome reference resources 
4.11.1 Human genome reference sequences 
Version:  NCBI Build 36.3 (March 2008) and Build 37.1 (August 2009) 
Organism: Homo Sapiens 
NCBI taxonomy ID: 9606 
 
4.11.2 HPV16 genome reference sequence 
The complete HPV16 DNA sequence was originally published in 1985 (Seedorf et al., 1985; 
GenBank accession number: K02718). This sequence was revised according to the 
corrections made by Los Alamos National Laboratory in 1995 and 1997. The final version of 
the revised HPV16 reference sequence (version 1997) is shown in Appendix 3. 
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4.12  Oligonucleotides 
4.12.1 HPV16 primers for routine PCR 
All primers were synthesized by Thermo Fisher Scientific (Ulm). The number in the name 
indicates the start position of each primer according to the HPV16 reference sequence. (F = 
forward; R = reverse) 
HPV16-103-F:      5’-AATGTTTCAGGACCCACAGG-3’ 
HPV16-209-R:      5’-GTTGCTTGCAGTACACACATTC-3’ 
HPV16-773-R:      5’-CTTTGTACGCACAACCGAAG-3’ 
HPV16-811-F:      5’-ATGGGCACACTAGGAATTGTG-3’ 
HPV16-817-R:      5’-TGCCCATTAACAGGTCTTCC-3’ 
HPV16-856-F:      5’-TAATCTACCATGGCTGATCCTG-3’ 
HPV16-1098-R:     5’-TTGTTTTGCTTCCTGTGCAG-3’ 
HPV16-1333-R:     5’-ATGGTGTTTCAGTCTCATGGC-3’ 
HPV16-1470-F:     5’-TGCAAAGGCAGCAATGTTAG-3’ 
HPV16-1551-F:     5’-TAAATCAACGTGTTGCGATTG-3’ 
HPV16-1565-F:     5’-GCGATTGGTGTATTGCTGC-3’ 
HPV16-1692-R:     5’-TAACACAACCATTCCCCATG-3’ 
HPV16-1793-F:     5’-CAAAATTGCGTAGTACAGCAGC-3’ 
HPV16-1805-R:     5’-CTACGCAATTTTGGAGGCTC-3’ 
HPV16-2171-F:     5’-GAGGTGATTGGAAGCAAATTG-3’ 
HPV16-2186-R:     5’-TGCTTCCAATCACCTCCATC-3’ 
HPV16-2450-R:     5’-CAACAGGGCACTGTAGCATC-3’ 
HPV16-2573-F:     5’-CTGGTACAGATTCTAGGTGGCC-3’ 
HPV16-2701-F:     5’-TTCTCAAGGACGTGGTCCAG-3’ 
HPV16-2879-R:     5’-TAGCACATTCTAGGCGCATG-3’ 
HPV16-2882-F:     5’-TATTACAAGGCCAGAGAAATGG-3’ 
HPV16-3384-F:     5’-TTATTAGGCAGCACTTGGCC-3’ 
HPV16-5125-R:     5’-TAGAGGTTAATGCTGGCCTATG-3’ 
HPV16-5398-R:     5’-TAGAGGGTACAGATGGTACCGG-3’ 
HPV16-5714-R:     5’-CATCCGTGCTTACAACCTTAG-3’ 
HPV16-6448-R:     5’-ATTTTCACCAACAGTACCAGCC-3’ 
HPV16-6955-R:     5’-CATCTTCTTTAGGTGCTGGAGG-3’ 
 
4.12.2 myc primers for routine PCR 
All primers were synthesized by Thermo Fisher Scientific (Ulm). The number in the name 
indicates the start position of each primer according to the human genome reference 
sequence of chromosome 8 (Accession number: NC_000008.9). (F = forward; R = reverse) 
128744774-F:      5’-AGGGACTCAATGAGTATGCATG-3’ 
128745226-R:      5’-ACCCATCAAATCCCTCTGC-3’ 
128815697-F:      5’-TTAAAGCTGAATTGTGCAGTGC-3’ 
128816053-R:      5’-ACGCTTCGACTTAGCTAGTTGC-3’ 
128816092-R:      5’-ACTGTATGTAACCCGCAAACG-3’ 
128816664-F:      5’-AACAGGCAGACACATCTCAGG-3’ 
128817197-F:      5’-TCAAACAGTACTGCTACGGAGG-3’ 
128817576-F:      5’-AGGGCTTCTCAGAGGCTTG-3’ 
128817900-R:      5’-TGTAAGTTCCAGTGCAAAGTGC-3’ 
128818442-F:      5’-TGGAGTAGGGACCGCATATC-3’ 
128819700-F:      5’-AACGTTAGCTTCACCAACAGG-3’ 
128819716-R:      5’-TTGGTGAAGCTAACGTTGAGG-3’ 
128821823-F:      5’-GAGGAGGAACAAGAAGATGAGG-3’ 
128821873-R:      5’-CTTTTCCACAGAAACAACATCG-3’ 
128822955-R:      5’-TCTTAAGACCACCCTCTGAAGG-3’ 
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4.12.3 Primers for restriction-site PCR 
All primers were synthesized by Thermo Fisher Scientific (Ulm). For HPV16 primers, the 
number in the name indicates the start position of each primer according to the HPV16 
reference sequence. All primer sequences were taken from Thorland et al (2000). Names and 
compositions of the RSO primers are explained in Section 2.1. (D = downstream or forward; 
U = upstream or reverse) 
HPV16-1546-26D:   5’-AGTAATAAATCAACGTGTTGCGATTG-3’ 
HPV16-1588-26D:   5’-GGACTTACACCCAGTATAGCTGACAG-3’ 
HPV16-2387-25D:   5’-TTTGTTTACAACCATTAGCAGATGC-3’ 
HPV16-6688-25U:   5’-AGTAGATATGGCAGCACATAATGAC-3’ 
HPV16-6653-25U:   5’-TGCGTGTAGTATCAACAACAGTAAC-3’ 
HPV16-5885-27U:   5’-ACTTATTGGGGTCAGGTAAATGTATTC-3’ 
 
RSO-BamHI:        5’-TAATACGACTCACTATAGGGAGANNNNNNNNNNGGATCC-3’ 
RSO-NheI:         5’-TAATACGACTCACTATAGGGAGANNNNNNNNNNGCTAGC-3’ 
RSO-SacI:         5’-TAATACGACTCACTATAGGGAGANNNNNNNNNNGAGCTC-3’ 
RSO-SalI:         5’-TAATACGACTCACTATAGGGAGANNNNNNNNNNGTCGAC-3’ 
RSO-NdeI:         5’-TAATACGACTCACTATAGGGAGANNNNNNNNNNCATATG-3’ 
RSO-PvuI:         5’-TAATACGACTCACTATAGGGAGANNNNNNNNNNCGATCG-3’ 
RSO-XbaI:         5’-TAATACGACTCACTATAGGGAGANNNNNNNNNNTCTAGA-3’ 
RSO-XhoI:         5’-TAATACGACTCACTATAGGGAGANNNNNNNNNNCTCGAG-3’ 
T7-primer:        5’-TAATACGACTCACTATAGGGAGA-3’ 
 
 
4.12.4 Primers for rapid amplification of cDNA ends 
All primers were synthesized by Thermo Fisher Scientific (Ulm). For HPV16 primers, the 
number in the name indicates the start position of each primer according to the HPV16 
reference sequence. For myc primers, the number indicates the start position of each primer 
according to the human genome reference sequence of chromosome 8 (Accession number: 
NC_000008.9). (F = forward; R = reverse) 
HPV16-683-F:      5’-CAGCTGGACAAGCAGAACCGGACAG-3’ 
HPV16-855-R:      5’-TGGTTTCTGAGAACAGATGGGGCAC-3’ 
HPV16-3386-F:     5’-ATTAGGCAGCACTTGGCCAACCACC-3’ 
HPV16-3565-R:     5’-TGCAGTGAGGATTGGAGCACTGTCC-3’ 
 
myc-128817671-F:  5’-TAATTCCAGCGAGAGGCAGAGGGAG-3’ 
myc-128818021-R:  5’-CGTCTAAGCAGCTGCAAGGAGAGCC-3’ 
myc-128819726-F:  5’-TGACCTCGACTACGACTCGGTGCAG-3’ 
myc-128820371-R:  5’-CGTCGAGGAGAGCAGAGAATCCGAG-3’ 
 
 
Sequences of the following primers were taken from user manual of the SMART RACE cDNA 
amplification kit.  
5’-CDS primer:    5’-(T)25VN-3’  (V = A, C or G) 
3’-CDS primer A:  5’-AAGCAGTGGTATCAACGCAGAGTAC(T)30VN-3’ 
UPM-long :        5’-CTAATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGT-3’ 
UPM-short :       5’-CTAATACGACTCACTATAGGGC-3’ 
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4.12.5 Primers for ASP16 strategy 
All primers for ASP16 strategy were synthesized by Sigma-Aldrich (Steinheim am Albuch). 
Details about the primer combinations are explained in Section 2.11 and 2.12.  
The following 24 primers were labeled with biotin at the 5’ end (5B), and contain only HPV16 
sequences. Start positions are given as numbers in primer names according to the HPV16 
reference sequence. (EP = early primer; LP = late primer; F = forward; R = reverse) 
EP-1(5B-810F):    5'-AATGGGCACACTAGGAATTGTG-3' 
EP-2(5B-1261F):   5'-GGGTATGGCAATACTGAAGTGG-3' 
EP-3(5B-1562F):   5'-GTTGCGATTGGTGTATTGCTG-3' 
EP-4(5B-1938F):   5'-ACAGATGGTACAATGGGCCTAC-3' 
EP-5(5B-2389F):   5'-TGGTTACAACCATTAGCAGATGC-3' 
EP-6(5B-2705F):   5'-CAAGGACGTGGTCCAGATTAAG-3' 
EP-7(5B-3101F):   5'-ACAGTGGAAGTGCAGTTTGATG-3' 
EP-8(5B-3542F):   5'-GACAGTGCTCCAATCCTCACTG-3' 
 
EP-9(5B-1046F):   5'-AGGCAGAAACAGAGACAGCAC-3' 
EP-10(5B-1394F):  5'-GAGAGGGTGTTAGTGAAAGACAC-3' 
EP-11(5B-1760F):  5'-GTGTGTCTCCAATGTGTATGATG-3' 
EP-12(5B-2151F):  5'-ATGTGATAGGGTAGATGATGGAG-3' 
EP-13(5B-2539F):  5'-TGCCCTCCATTATTAATTACATC-3' 
EP-14(5B-2912F):  5'-CATATTAACCACCAAGTGGTGC-3' 
EP-15(5B-3318F):  5'-CGGGTGGTCAGGTAATATTATG-3' 
EP-16(5B-3762F):  5'-CATATGATAGTGAATGGCAACG-3' 
 
LP-1(5B-6951R):   5'-TCTTTAGGTGCTGGAGGTGTATG-3' 
LP-2(5B-6552R):   5'-TGGGCATCAGAGGTAACCATAG-3' 
LP-3(5B-6186R):   5'-CCTGGATTTACTGCAACATTGG-3' 
LP-4(5B-5766R):   5'-AGTAGTCTGGATGTTCCTGCATG-3' 
LP-5(5B-5318R):   5'-ATAGAAGTAGGTGAGGCTGCATG-3' 
LP-6(5B-4917R):   5'-TAATCCTAGGCGTGCCACTG-3' 
LP-7(5B-4501R):   5'-CAGGAGCAAGTGTATCTGTAGCTG-3' 
LP-8(5B-4290R):   5'-AAGTTGGGTAGCCGATGCAC-3' 
 
The following 24 primers contain the 19-nt Roche-A (RA) sequence as 5’ parts and HPV16 
sequences as 3’ parts. Start positions of the HPV16 parts are given as numbers in primer 
names according to the HPV16 reference sequence. (EP-N = nested early primer; LP-N = 
nested late primer; F = forward; R = reverse) 
EP-N1(RA-857F):   5'-GCCTCCCTCGCGCCATCAG AATCTACCATGGCTGATCCTG-3' 
EP-N2(RA-1275F):  5'-GCCTCCCTCGCGCCATCAG TGAAGTGGAAACTCAGCAGATG-3' 
EP-N3(RA-1576F):  5'-GCCTCCCTCGCGCCATCAG ATTGCTGCATTTGGACTTACAC-3' 
EP-N4(RA-1951F):  5'-GCCTCCCTCGCGCCATCAG TGGGCCTACGATAATGACATAG-3' 
EP-N5(RA-2403F):  5'-GCCTCCCTCGCGCCATCAG AGCAGATGCCAAAATAGGTATG-3' 
EP-N6(RA-2723F):  5'-GCCTCCCTCGCGCCATCAG TAAGTTTGCACGAGGACGAG-3' 
EP-N7(RA-3121F):  5'-GCCTCCCTCGCGCCATCAG TGGAGACATATGCAATACAATGC-3' 
EP-N8(RA-3555F):  5'-GCCTCCCTCGCGCCATCAG TCCTCACTGCATTTAACAGCTC-3' 
 
EP-N9(RA-1064F):  5'-GCCTCCCTCGCGCCATCAG CACATGCGTTGTTTACTGCAC-3' 
EP-N10(RA-1411F): 5'-GCCTCCCTCGCGCCATCAG AGACACACTATATGCCAAACACC-3' 
EP-N11(RA-1785F): 5'-GCCTCCCTCGCGCCATCAG AGAGCCTCCAAAATTGCGTAG-3' 
EP-N12(RA-2174F): 5'-GCCTCCCTCGCGCCATCAG GTGATTGGAAGCAAATTGTTATG-3' 
EP-N13(RA-2569F): 5'-GCCTCCCTCGCGCCATCAG AATGCTGGTACAGATTCTAGGTG-3' 
EP-N14(RA-2933F): 5'-GCCTCCCTCGCGCCATCAG CCAACACTGGCTGTATCAAAG-3' 
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EP-N15(RA-3339F): 5'-GCCTCCCTCGCGCCATCAG GTCCTACATCTGTGTTTAGCAGC-3' 
EP-N16(RA-3778F): 5'-GCCTCCCTCGCGCCATCAG GCAACGTGACCAATTTTTGTC-3' 
 
LP-N1(RA-6918R):  5'-GCCTCCCTCGCGCCATCAG GCAATTGCCTGGGATGTTAC-3' 
LP-N2(RA-6505R):  5'-GCCTCCCTCGCGCCATCAG TGAACTGGCTAAATTTGCAGTAG-3' 
LP-N3(RA-6139R):  5'-GCCTCCCTCGCGCCATCAG TTCCCCTATAGGTGGTTTGC-3' 
LP-N4(RA-5729R):  5'-GCCTCCCTCGCGCCATCAG TGCGTGCAACATATTCATCC-3' 
LP-N5(RA-5304R):  5'-GCCTCCCTCGCGCCATCAG GGCTGCATGTGAAGTGGTAG-3' 
LP-N6(RA-4890R):  5'-GCCTCCCTCGCGCCATCAG CCCTGGTATGGGTGTGCTAC-3' 
LP-N7(RA-4466R):  5'-GCCTCCCTCGCGCCATCAG GTTCCCAATGGAATATACCCAG-3' 
LP-N8(RA-4254R):  5'-GCCTCCCTCGCGCCATCAG AGAACGTTTGTGTCGCATTG-3' 
 
The following 24 primers contain the 19-nt Roche-B (RB) sequence as 5’ parts and the 18-nt 
GenomePlex universal adapter (GPUA) sequence as 3’ parts. Between RB and GPUA, there 
are 24 different 4-nt barcode sequences unique for each primer. 
RB-GPUA-1:        5'-GCCTTGCCAGCCCGCTCAG TGAC TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-2:        5'-GCCTTGCCAGCCCGCTCAG AGAC TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-3:        5'-GCCTTGCCAGCCCGCTCAG TCAC TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-4:        5'-GCCTTGCCAGCCCGCTCAG ACAC TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-5:        5'-GCCTTGCCAGCCCGCTCAG TGTC TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-6:        5'-GCCTTGCCAGCCCGCTCAG AGTC TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-7:        5'-GCCTTGCCAGCCCGCTCAG TCTC TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-8:        5'-GCCTTGCCAGCCCGCTCAG ACTC TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-9:        5'-GCCTTGCCAGCCCGCTCAG CTGA TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-10:       5'-GCCTTGCCAGCCCGCTCAG CAGA TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-11:       5'-GCCTTGCCAGCCCGCTCAG CTCA TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-12:       5'-GCCTTGCCAGCCCGCTCAG CACA TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-13:       5'-GCCTTGCCAGCCCGCTCAG TAGC TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-14:       5'-GCCTTGCCAGCCCGCTCAG ATGC TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-15:       5'-GCCTTGCCAGCCCGCTCAG TACA TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-16:       5'-GCCTTGCCAGCCCGCTCAG ATCA TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-17:       5'-GCCTTGCCAGCCCGCTCAG TGCA TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-18:       5'-GCCTTGCCAGCCCGCTCAG TCGA TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-19:       5'-GCCTTGCCAGCCCGCTCAG AGCA TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-20:       5'-GCCTTGCCAGCCCGCTCAG ACGA TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-21:       5'-GCCTTGCCAGCCCGCTCAG CATC TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-22:       5'-GCCTTGCCAGCCCGCTCAG CTAC TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-23:       5'-GCCTTGCCAGCCCGCTCAG CTGC TGTGTTGGGTGTGTTTGG-3' 
RB-GPUA-24:       5'-GCCTTGCCAGCCCGCTCAG CAGC TGTGTTGGGTGTGTTTGG-3' 
 
4.12.6 Primers for junction-specific PCR of clinical samples 
All primers were synthesized by Thermo Fisher Scientific (Ulm). The number in the name 
indicates the start position of each primer according to the human genome reference 
sequence of chromosome 1 (NC_000001.10) or chromosome 12 (NC_000012.11). (F = 
forward; R = reverse) 
240760735-R:      5’-TTATTCTCAGCAGTTCCCAGC-3’ (NC_000001.10) 
240760912-R:      5’-AGCAGCTCCCAGGTCACTAG-3’  (NC_000001.10) 
240760944-F:      5’-ATATTCCCAATGCTTGGCAC-3’  (NC_000001.10) 
240761029-F:      5’-AAGTTCTAAGCGGATGGCTG-3’  (NC_000001.10) 
 
57686174-F:       5’-TCTGCAGCTTCCCAATAAGC-3’  (NC_000012.11) 
57686333-R:       5’-TGTCAGCCCATAGCTTTTAGC-3’ (NC_000012.11) 
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4.13  Human continuous cell lines 
All cell lines were provided by Elisabeth Schwarz and were obtained originally from the 
indicated sources. 
CaSki:   cervical carcinoma,  HPV16-positive,  ATCC 
MRI-H186:  cervical carcinoma,  HPV16-positive,  ATCC 
MRI-H196:  cervical carcinoma,  HPV16-positive,  ATCC 
SiHa:   cervical carcinoma, HPV16-positive,  ATCC 
C4-I:   cervical carcinoma,  HPV18-positive,  ATCC 
C4-II:   cervical carcinoma,  HPV18-positive,  ATCC 
HeLa:   cervical carcinoma,  HPV18-positive,  ATCC 
C33A:   cervical carcinoma,  HPV-negative,   ATCC 
HaCat: spontaneously immortalized keratinocytes, HPV-negative, Petra Boukamp (DKFZ) 
 
4.14  Clinical DNA samples 
The clinical DNA samples for HPV16 integration analysis were provided by our cooperation 
partners in Reims and Besançon. There, cervical scrapes were obtained from women 
participating in routine cervical screening programs. HPV16-positive high-grade cervical pre-
cancerous lesions and carcinomas were sent to our group in Heidelberg for molecular 
determination of HPV16 DNA integration sites. Performed in Reims and Besançon, DNA was 
isolated from clinical samples using the EZ1 DNA tissue kit and BioRobot EZ1 from Qiagen 
(Hilden), according to the manufacturer’s instructions.  
 
4.15  In vitro cultivation of mammalian adherent cells 
Taken from liquid-nitrogen tank, a vial of frozen cells (1 ml) was thawed quickly to 37°C. In a 
laminar flow hood, a 75-cm2 tissue culture flask was filled with 14 ml complete cell culture 
medium pre-warmed to 37°C. Cells were suspended by repeated pipetting, transferred into 
the flask and mixed by gently shaking. Cell suspension was spread on flask bottom and then 
horizontally incubated at 37°C, 5% CO2 and 95% relative humidity. Under this condition, 
adherent cells grow and expand to a monolayer culture. Cells were observed daily under a 
microscope, and medium was renewed every 2–3 days. For splitting, cells were rinsed briefly 
with 5 ml pre-warmed trypsine/EDTA solution, and incubated with another 3 ml solution at 
37°C for minutes. After detachment from the flask bottom, cells were diluted with 7 ml of 
complete culture medium and mixed well by pipetting intensively. Dependent on the desired 
dilution rates, an appropriate volume of the cell suspension was combined with fresh medium 
to a total volume of 15 ml. 
Tissue culture cells can be preserved in liquid nitrogen vapor phase over a long time. One 
175-cm2 flask of cells was trypsinized and centrifuged at 800 rpm for 10 min at 4°C. The 
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supernatant was discarded and the pellet was resuspended in 10 ml of complete medium. 
Centrifuged again, medium was removed and cells were dissolved with 5 ml of freezing 
medium. The cell suspension was mixed well and transferred into five sterile cryogenic vials 
(1 ml each). Cells were cooled slowly down to –80°C and stored in liquid-nitrogen tank. 
 
4.16  Genomic DNA isolation from cultured mammalian cells 
Medium was decanted and cells were washed twice with ice-cold PBS/EDTA. For a 175-cm2 
flask, 6 ml PBS/EDTA (1% PBS; 2 mM EDTA) and 3 ml of 3% lysis buffer (2% TE, pH 8.0; 3% 
sarkosyl, w/v) was applied. After shaking gently and briefly, the viscous lysate was collected 
into a 50 ml Falcon tube. Proteinase K was added at a final concentration of 0.2 mg/ml and 
incubated overnight at 55°C. Reaction was cooled down to RT, and 9 ml phenol* (50% 
phenol, 50% CIA) was added for deproteination. The reaction tube was placed into a mixer 
and rotated for 30 min. Centrifuged at 2000 rpm for 10 min at RT, the mixture was separated 
into a nucleic-acid containing upper aqueous phase and a lower organic phase. The aqueous 
phase (without interphase) was transferred into a new 50 ml Falcon tube using a plastic 
Pasteur pipette. To remove the residual phenol, CIA (chloroform : isoamyl alcohol = 24:1) was 
added into the aqueous phase with the same volume, rotated for 30 min and centrifuged for 
10 min. The aqueous phase was moved into another tube, and 1/10 volume of 3 M sodium 
acetate (pH 5.2) plus 2 volumes of ice-cold ethanol absolute was added for DNA precipitation. 
Centrifuged at 5000 rpm for 30 min at 4°C, the DNA pellet was washed with 10 ml of 70% 
ethanol and centrifuged for 10 min. Ethanol was decanted and the pellet was air-dried for 30 
min. Finally, the pellet was dissolved with 4 ml of 1% TE by overnight incubation at 4°C. 
Genomic DNA was stored at 4°C.  
Concentration of genomic DNA cannot be accurately determined by spectrophotometer, due 
to the high molecular weight. Instead, it was estimated by agarose gel electrophoresis 
together with the &/HindIII marker suitable for DNA quantitation. Samples were mixed with 6% 
BPB-buffer, loaded into a 0.8% agarose gel containing 0.5 µg/ml ethidium bromide, and 
separated with 1% TAE buffer. 
 
4.17  Polymerase chain reaction 
Polymerase chain reaction (PCR) is widely used for rapid amplification of specific target 
regions from trace amounts of DNA samples. All PCR reactions in this study were performed 
in a 50-µl format using the Thermocycler PTC-200 machinery with heated lid. Common 
materials for the reactions in one experiment were made as a homogenized master-mix to 
reduce pipetting error and to ensure comparable results among individual reactions. The final 
PCR products were examined by loading samples with 6% XC-buffer into a 1.5% agarose gel 
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for electrophoresis. The following commercial PCR systems were used for concrete 
experimental requirements, according to the manufacturer’s instructions. 
Taq DNA polymerase (Invitrogen, Karlsruhe) 
For routine PCR, up to 3 kb amplicon, non proof-reading, non hot-start 
Reaction components                                    Final conc. 
10! PCR buffer without Mg                                      1!         
50 mM MgCl2                                                       1.5 mM 
dNTP mix (10 mM each)                                  0.2 mM each 
forward primer (10 µM)                                        0.2 µM  
reverse primer (10 µM)                                        0.2 µM  
Genomic DNA template                                100 ng/reaction 
Taq DNA polymerase (5 U/µl)                          2 U/reaction 
Cycling condition 
Initial denaturation:         94 °C     for     3 min 
         Denaturation:         94 °C     for    30 sec  
              Annealing:         60 °C     for    30 sec 
              Extension:         72 °C     for   1 min/kb  
      Final extension:         72 °C     for    10 min   
                  Cooling:           4 °C         hold 
 
Paq5000 DNA polymerase: (Stratagene, La Jolla, U.S.A) 
Faster and cheaper than Taq, up to 6 kb, non proof-reading, non hot-start 
Reaction components                                    Final conc. 
10! Paq5000 Reaction Buffer                                 1! 
dNTP-mix (10 mM each)                                    0.2 mM 
forward-primer (10 µM)                                       0.2 µM  
reverse-primer (10 µM)                                       0.2 µM  
Genomic DNA template                                100 ng/reaction 
Paq5000 DNA polymerase (5 U/µl)                2.5 U/reaction 
Cycling condition 
Initial denaturation:         95 °C     for     3 min 
         Denaturation:         95 °C     for    30 sec  
              Annealing:         60 °C     for    30 sec 
              Extension:         72 °C     for   30 sec/kb  
      Final extension:         72 °C     for     5 min   
                  Cooling:          4 °C         hold 
35 cycles 
35 cycles 
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FastStart Taq DNA Polymerase (Roche Applied Science, Mannheim) 
Hot-start, high specificity and sensitivity, up to 3 kb, non proof-reading 
Reaction components                                         Final conc. 
10! PCR buffer with 20 mM MgCl2                              1!         
dNTP-mix (10 mM each)                                      0.2 mM each 
forward-primer (10 µM)                                            0.2 µM  
reverse-primer (10 µM)                                            0.2 µM  
Genomic DNA template                                     100 ng/reaction 
FastStart Taq DNA polymerase (5 U/µl)               2 U/reaction 
 
Cycling condition 
Initial denaturation:         95 °C     for    5 min 
         Denaturation:         95 °C     for   30 sec  
              Annealing:         60 °C     for   30 sec 
              Extension:         72 °C     for  1 min/kb  
      Final extension:         72 °C     for   7 min   
                  Cooling:           4 °C        hold 
 
 
Expand Long Range PCR System (Roche Applied Science, Mannheim) 
up to 25 kb amplicon, proof-reading, non hot-start 
Reaction components                                        Final conc. 
5! Buffer with 12.5 mM MgCl2                                     1!         
dNTP-mix (10 mM each)                                     0.5 mM each 
forward-primer (10 µM)                                           0.3 µM  
reverse-primer (10 µM)                                           0.3 µM  
Genomic DNA template                                   100 ng/reaction 
Expand Long Range Enzyme mix (5 U/µl)        3.5 U/reaction 
 
Cycling condition 
Initial denaturation:         94 °C     for     3 min 
         Denaturation:         94 °C     for    30 sec  
              Annealing:         60 °C     for    30 sec 
              Extension:         68 °C     for   1 min/kb  
      Final extension:         68 °C     for     7 min   
                  Cooling:           8 °C        hold 
 
35 cycles 
35 cycles 
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4.18  Restriction-site PCR 
Restriction-site PCR (RS-PCR) is applied to determine the integration site of HPV16 DNA 
from the human genome at the sequence level (Sarkar et al., 1993; Thorland et al., 2000). 
The essence of this method is the use of restriction-site oligonucleotide (RSO) primer, which 
contains a T7-adapter at the 5’ end, and the recognition site of an HPV16 non-cutting 
restriction enzyme at the 3’ end (see Section 2.1 and 4.12.3). A random sequence of ten 
nucleotides was placed in the middle for efficient primer binding. The RS-PCR assay consists 
of two sequential rounds of PCR. In the first round, an HPV16-specific primer targeting the 
HPV16 early or late region was applied together with eight RSO-primers respectively, at a low 
stringent annealing temperature. The second round is a stringent semi-nested PCR, for which 
a nested HPV16 primer was used together with T7-adapter as primer pair. Both rounds of 
PCR were performed using the Expand High Fidelity PCR system (Roche, Mannheim), 
according to the user manual. 
1st PCR 
Reaction components                                     Final conc.       
5! Buffer with 7.5 mM MgCl2                                   1!         
dNTP-mix (10 mM each)                                  0.2 mM each 
HPV16-primer (5 µM)                                           0.1 µM  
RSO-primer (50 µM)                                              2 µM  
Genomic DNA template                                 100 ng/reaction 
Expand HiFi Enzyme Blend (5 U/µl)                2.5 U/reaction 
 
2nd PCR 
Reaction components                                     Final conc.      
5! Buffer with 7.5 mM MgCl2                                   1!         
dNTP-mix (10 mM each)                                  0.2 mM each 
nested HPV16-primer (5 µM)                               0.1 µM  
T7-adapter (10 µM)                                              0.1 µM  
1st PCR product                                                5 µl/reaction 
Expand HiFi Enzyme Blend (5 U/µl)               2.5 U/reaction 
 
Cycling condition 
Initial denaturation:         94 °C          for          3 min 
         Denaturation:         94 °C          for         30 sec  
              Annealing:         45 °C          for   30 sec (1st PCR) 
                                        60 °C          for   30 sec (2nd PCR) 
              Extension:         68 °C          for         4 min  
      Final extension:         68 °C          for         7 min   
                  Cooling:           8 °C                hold 
35 cycles 
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4.19  PCR clean-up 
PCR clean-up was performed using the QIAquick PCR purification kit (Qiagen, Hilden) 
according to the user manual. PCR products were mixed with five volumes of buffer PB and 
transferred into the QIAquick spin column. To bind DNA, the tube was centrifuged at 13000 
rpm for 1 min at RT. The flow-through was discarded and the column was placed back into 
the collection tube. DNA was washed once with 750 µl of buffer PE and centrifuged again. 
After the removal of flow-through, the column was placed back and centrifuged for another 1 
min to discard the residual ethanol. The column was transferred into a new 1.5 ml tube, and 
30 µl of buffer EB (10 mM Tris-HCl, pH 8.5) was carefully pipetted onto the center of the silica 
membrane. For a more efficient recovery, the elution was incubated for 1 min, followed by 
centrifugation for an additional minute. The eluted PCR products were stored at –20°C.  
 
4.20  Gel extraction of DNA fragments 
DNA fragments were extracted from agarose gel with the QIAquick gel extraction kit (Qiagen, 
Hilden) according to the user manual. Under UV light, the DNA band of interest was excised 
from the agarose gel with a scalpel. The gel slice up to 400 mg was exactly weighed and then 
covered with 3 volumes of buffer QG. The reaction was incubated at 50°C for 10 min, and 
mixed by vortexing vigorously every 2–3 min until the gel was completely dissolved. One gel 
volume of isopropanol was added and then mixed thoroughly. The sample with maximal 
volume of 800 µl was loaded into a QIAquick spin column and centrifuged at 13000 rpm for 1 
min at RT to bind DNA onto the silica membrane. The flow-through was discarded, and the 
column was placed back to the same collection tube. The washing step and DNA elution 
procedure remains the same as described in Section 4.19. DNA eluate was stored at –20°C.  
 
4.21  PCR cloning 
Two commercial systems, TOPO TA cloning kit (Invitrogen, Karlsruhe) and StrataClone PCR 
cloning kit (Strategene, La Jolla, U.S.A), were used according to the user manuals. Both 
systems benefit from the DNA re-joining activity of DNA topoisomerase I, which is covalently 
bound to cloning vectors and assists in ligation between vector and insert DNA. Here, the 
StrataClone PCR cloning protocol is briefly described.  
After pipetting the following components together: 3 µl of StrataClone cloning buffer, 2 µl of 
PCR product, and 1 µl of StrataClone vector mix, the reaction mixture was incubated at RT 
for 30 min. Following ligation, the reaction was placed on ice and up to 2 µl of the mixture was 
added to a vial of StrataClone SoloPack competent bacteria. The transformation reaction was 
mixed gently and incubated on ice for 30 min. The transformed bacteria were heat-shocked at 
42°C for 45 sec. The reaction was immediately chilled on ice and incubated for 2 min. To 
recover the bacteria, 250 µl of SOC medium pre-warmed to 42°C was added and incubated 
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at 37°C for 1 h, with horizontal agitation at 180 rpm. During this time, two selective LB-agar 
plates were warmed to 37 °C and 40 µl of 2% (w/v) X-gal was spread evenly on each plate for 
blue-white screening. Finally, two different volumes of the recovered transformation mixture 
were plated onto the screening plates, and then incubated overnight at 37°C. Next day, white 
or light-blue but not dark-blue colonies were picked out for plasmid analysis. 
 
4.22  Mini-preparation of bacterial plasmid DNA 
The colony of choice was picked from the agar plate and inoculated into 4 ml LB-medium 
containing appropriate antibiotics. After shaking overnight at 180 rpm, 37°C, the bacterial 
culture was harvested. About 1.5 ml of culture was transferred into a 2 ml tube, centrifuged at 
13000 rpm for 1 min to collect the bacterial pellet. The supernatant was discarded, only 
leaving a small volume at the bottom. The pellet together with the residual supernatant was 
resuspended by vortexing. To lyse bacteria and release plasmids, 300 µl of TENS buffer (1% 
TE, pH 8.0; 0.1 M NaOH; 0.5% SDS, w/v) was added and incubated for 5 min with horizontal 
agitations. To neutralize the alkali lysis buffer and favor the subsequent precipitation, 150 µl 
of 3 M sodium acetate (pH 5.2) was added, and mixed thoroughly by inverting the tube for 
several times. The reaction mixture was centrifuged at 13000 rpm for 2 min, and the 
supernatant was moved immediately into a 1.5 ml tube filled with 900 µl of ethanol absolute (–
20°C) for DNA precipitation. Mixed well by inverting the tube, the precipitated plasmid DNA 
was spun down at 10000 rpm for 10 min at 4°C. The plasmid pellet was washed with 1 ml of 
70% ethanol and centrifuging again for 5 min to remove the residual salt. The pellet was air-
dried for 30 min to 1 h, and then resuspended with 50 µl of storage buffer (1% TE, pH 8.0; 20 
µg/ml RNase A). The plasmid preparation was stored at 4°C. 
 
4.23  Plasmid DNA sequencing 
After mini-preparation and restriction analysis, plasmid DNA containing inserts with the 
expected sizes were sent to Andreas Hunziker at the DKFZ Genomics and Proteomics Core 
Facility for Sanger DNA sequencing. 
 
4.24  Total RNA isolation from cultured mammalian cells 
RNA isolation was performed using the TRIzol reagent (Invitrogen, Karlsruhe) according to 
the manufacturer’s instruction. Cells were washed twice with ice-cold PBS. For the 75-cm2 
flask, 7.5 ml of TRIzol reagent containing phenol and guanidine isothiocyanate was applied. 
As a chaotropic agent, guanidine isothiocyanate lyses cells and protects RNA from RNase by 
denaturing all protein. The flask was agitated gently at RT for 5 min to completely dissociate 
the nucleoprotein complexes. The lysate was moved into a 15 ml Falcon tube, and 1.5 ml (1/5 
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of TRIzol volume) of chloroform was added for phase separation. The tube was closed firmly, 
shaken intensively by hand for 15 sec, and incubated at RT for 3 min. Centrifuged at 3000 
rpm for 15 min at 4°C, the upper aqueous phase containing RNA was separated from the 
lower phenol-chloroform phase and the interphase both comprising protein and DNA. The 
aqueous phase was transferred into a new tube and mixed with 4 ml of ice-cold isopropanol 
for RNA precipitation. The reaction was incubated at RT for 10 min, and centrifuged at 4000 
rpm for 10 min at 4°C. The RNA pellet was washed with 7.5 ml of 70% ethanol and 
centrifuged again for 5 min. Ethanol was decanted and the pellet was air-dried at RT for 30 
min. Finally, RNA was resuspended in 100 µl of RNase-free water and incubated at 60°C for 
10 min to dissolve completely. The RNA preparation was stored at –80°C.  
The concentration was measured by pipetting 1.5 µl of RNA sample directly on NanoDrop 
spectrophotometer. For quality control, 2 µl of sample was mixed well with 18 µl of RNA-
loading buffer, heated at 65 °C for 15 min to disrupt RNA secondary structure, and loaded 
onto a 1% agarose gel. The 1% MOPS buffer was used for RNA gel electrophoresis. 
 
4.25  Poly-A+ RNA enrichment 
Poly-A+ RNA was extracted from total RNA with Dynabeads Oligo (dT)25 (Invitrogen, 
Karlsruhe) according to the user manual. Before loading samples, 200 µl of magnetic beads 
suspension was pipetted into a 1.5 ml RNase-free tube and placed into a magnet. Incubated 
at RT for 30 sec, the beads pellet was resuspended in 100 µl of 2! binding buffer (20 mM 
Tris-HCl, pH 7.5; 1 M LiCl; 2 mM EDTA). Incubated again in magnet for 30 sec, the 
supernatant was discarded, the tube was transferred into a normal rack and 100 µl of 2! 
binding buffer was added. Up to 75 µg of total-RNA was diluted with DEPC-treated water to 
100 µl, and heated at 65°C for 3 min. The denatured RNA was transferred immediately into 
the beads solution. The reaction was incubated at RT for 5 min to allow the binding. The tube 
was placed back to the magnet and incubated for 30 sec. The pellet was washed twice with 
200 µl of 1! wash buffer (10 mM Tris-HCl, pH 7.5; 150 mM LiCl; 1 mM EDTA). Following the 
washing, beads were dissolved with 10 µl of 1! elution buffer (2 mM EDTA), incubated at 
65°C for 2 min and separated by magnet. The eluted mRNA was transferred into a new 
RNase-free tube and stored at –20°C. 
 
4.26  Reverse transcription PCR 
In reverse transcription PCR (RT-PCR), template RNA is first converted into cDNA by reverse 
transcription, followed by the amplification of cDNA using convenient PCR with gene-specific 
primer pairs. For the synthesis of full-length first-strand cDNA, Superscript III reverse 
transcriptase (Invitrogen, Karlsruhe) was used according to the user manual. The following 
components were pipetted into a 1.5 ml RNase-free tube, plus DEPC-treated water to 14 µl 
!"#$%&"'()"*+)!$#,-+())).52)
total and mixed thoroughly: 5 µg of total RNA or 500 ng of poly-A+ RNA, 1 µl of anchored 
oligo-d(T)23 primer (50 µM) and 1 µl of dNTP-mix (10 mM each). The anchored oligo-dT 
primer (5’-TTTTTTTTTTTTTTTTTTTTTTTV-3’; V=A, C or G) binds to the poly-A tail of mRNA, 
whereas for those transcripts without this feature, random hexamer instead is usually applied 
for priming. The mixture was heated at 65°C for 5 min, chilled on ice and spun down briefly. 
To start the reverse transcription, 4 µl of 5! First-Strand buffer, 1 µl of 0.1 M DTT and 1 µl of 
Superscript III reverse transcriptase (200 U/µl) was added, mixed well and incubated at 50°C 
for one hour. Finally, the reaction was heated at 70°C for 15 min to inactivate the reverse 
transcriptase. The cDNA/RNA hybrids can be directly used as template for the subsequent 
PCR. To improve PCR sensitivity, it is possible to remove the RNA strand either with RNase 
H or alkali treatment as shown below. Following the reverse transcription, 2 µl of 2.5 M NaOH 
was added, mixed by vortexing and spun down briefly. The reaction was incubated at 37 °C 
for 15 min to digest RNA and ceased by neutralization with 10 µl of 2 M HEPES buffer, mixed 
well and spun down. The first-strand cDNA solution was stored at – 20°C. For a typical PCR, 
3 µl of cDNA product was applied as template without any prior purification.   
 
4.27  Rapid amplification of cDNA ends 
The rapid amplification of cDNA ends (RACE) assay is applied to obtain the full-length cDNA 
sequences of specific mRNA molecules, whose partial sequences are previously known. The 
SMART RACE cDNA amplification kit (Becton Dickinson, Heidelberg) was used according to 
the user manual. The first step is to synthesize RACE-ready first-strand cDNA, which is split 
into two separate reactions for 5’-RACE and 3’-RACE. A 5 µl of mixture included with 1 µg of 
total-RNA, 1 µl of 5’-CDS primer and 1 µl of SMART II-A oligo was combined in a 0.5 ml PCR 
tube for the preparation of 5’-RACE-ready cDNA. Likewise, another 5-µl mixture containing 1 
µg of total-RNA and 1 µl of 3’-CDS primer-A was prepared for 3’-RACE-ready cDNA. The 
tubes were incubated at 70°C for 2 min, and chilled immediately on ice. Centrifuged briefly, 
the following materials were added into both tubes: 2 µl of 5! First-Strand buffer, 1 µl of DTT 
(20 mM), 1 µl of dNTP-mix (10 mM each) and 1 µl of MMLV Reverse Transcriptase. The 
reactions (10 µl each) were incubated at 42°C for 1.5 hr in a thermal cycler. Finally, the cDNA 
was diluted with 100 µl of 1! TE buffer, followed by incubation at 72°C for 7 min to inactivate 
the residual reverse transcriptase. After reverse transcription, cDNA was subjected to RACE 
assay by using the Advantage 2 PCR Kit (Becton Dickinson, Heidelberg). For a 50-µl PCR 
reaction, the following components were mixed into a PCR tube for the 5’- or 3’-RACE 
analysis of a specific gene transcript: 34.5 µl of DNase-free water, 5 µl of 10! Advantage 2 
PCR buffer, 1 µl of dNTP-mix (10 mM each), 2.5 µl of 5’- or 3’-RACE-ready cDNA, 5 µl of 10! 
UPM, 1 µl of GSP-forward (for 3’-RACE; 10 µM) or GSP-reverse (for 5’-RACE; 10 µM), and 1 
µl of 50! Advantage 2 polymerase mix. The tube was placed into a thermal cycler, and the 
PCR condition is described as below:  
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Initial denaturation:         94 °C     for      3 min 
         Denaturation:         94 °C     for    30 sec  
              Annealing:         68 °C     for    30 sec 
              Extension:         72 °C     for     3 min  
      Final extension:         72 °C     for    10 min   
                  Cooling:           4 °C         hold           
Subsequently, the RACE PCR products were cloned into pSC-A vector and sequenced with 
the Sanger method. The overlapping sequences resulting from the 5’- and 3’-RACE were 
assembled together to reach the full-length cDNA. Finally, the assumed full-length cDNA was 
verified by using both GSP-forward and reverse in one PCR reaction.    
 
4.28  Nucleic acid transfer from agarose gel onto membrane 
For the detection of specific nucleic acid molecules, DNA or RNA samples separated by gel 
electrophoresis are immobilized onto a solid support such as nylon membrane, quantitatively 
and also maintaining the same position as in the gel, through the vertically downward 
capillary transfer. 
 
4.28.1  DNA transfer by alkaline capillary blotting (Southern blot) 
Immediately after gel photographing, bands of DNA ladder were marked with a scalpel. Briefly 
rinsed in deionized water, the gel was immersed in 0.25 M HCl, and agitated for 10 min to 
partially depurinate DNA. BPB as pH indicator switches color from purple (base form) to 
yellow (acid form). The depurination step is essential for efficient transfer of longer fragments 
(>4 kb) like genomic DNA, and can be omitted for shorter DNA. After depurination, the gel 
was rinsed shortly in water, submerged in denaturation buffer (0.4 M NaOH), and shaken for 
2% 15 min to denature DNA (BPB turns back to purple). Meanwhile, a piece of positively-
charged Hybond-N+ nylon membrane larger than the gel was prepared, wet in water, and 
equilibrated together with two sheets of filter paper in denaturation buffer for 10 min. The 
apparatus for capillary transfer was assembled as follows (bottom-up): 
• a stack of absorbent paper towels 
• two sheets of filter paper (dry) 
• two sheets of filter paper (saturated in denaturation buffer) 
• Hybond-N+ nylon membrane 
• agarose gel 
The assembly was surrounded with plastic wrap and a small weight was placed on the top. 
The transfer is completed in 3-5 h. During the blotting, DNA was driven from the gel onto the 
35 cycles 
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porous nylon membrane by capillary action, bound to the positively-charged groups and 
fixated by the alkaline solvent finally. 
After blotting, the position of DNA ladder was marked for later size determination. The 
membrane was agitated gently in the neutralization buffer (3 M NaCl; 0.3 M sodium citrate; 
0.5 M Tris-HCl, pH = 7.0) for 10 min, and dried thoroughly on filter paper.   
 
4.28.2  RNA transfer by alkaline capillary blotting (Northern blot) 
After electrophoresis and photographing, the position of the 28S and 18S rRNA were marked. 
The gel was rinsed briefly in DEPC-treated water, and soaked in five gel volumes of transfer 
buffer (10 mM NaOH; 3 M NaCl) for 20 min to partially hydrolyze RNA. A piece of Hybond-N+ 
nylon membrane was wet in DEPC-treated water, and incubated in transfer buffer together 
with two sheets of filter paper for 10 min. The apparatus assembly for Northern blot 
resembles the one used in Southern blot (see Section 4.28.1). The time for RNA transfer is 
limited to about one hour, to avoid the over-hydrolyzation caused by alkaline buffer. After 
blotting, the membrane was marked, incubated in 6% SSC for 5 min, and dried on filter paper.   
 
4.29  Radioactive labeling of DNA probes 
The labeling reaction was performed with the Rediprime II DNA labeling kit (GE Healthcare, 
München) according to the user manual. The dsDNA template (minimal length of 200–300 
bp) to be labeled was diluted to 25 ng in 45 µl with DNase-free water, and incubated at 95°C 
for 5 min. The denatured DNA was chilled on ice for 5 min, centrifuged briefly, and transferred 
into a vial of Rediprime II reaction mixture. Five microliter (50 µCi) of ["-32P]dCTP was added 
and mixed thoroughly. The labeling reaction was done at 37°C for 30 min, and terminated by 
20 µl of stop solution (2% TNE; 0.1% BPB, w/v; 0.5% blue dextran, w/v).  
During the labeling, a MicroSpin G-25 column (GE healthcare, München) was prepared for 
the clean-up by gel filtration chromatography according to the user manual. First, the resin 
materials in the spin-column were suspended by vortexing vigorously. The cap was loosened 
'-turn, and the bottom closure was removed. The column was placed into a collection tube, 
and centrifuged at 3000 rpm for 1 min. After the flow-through was discarded, 200 µl of 1% 
TNE buffer (1% TE, pH 8.0; 10 mM EDTA, pH 8.0; 100 mM NaCl; 0.2% SDS) was added and 
centrifuged again for equilibrium. The labeling reaction was mixed with 75 µl of 1% TNE 
buffer, transferred to the center of the column, and centrifuged at 3000 rpm for exactly 1 min. 
Larger DNA fragments pass through the column faster, whereas small molecules like 
impurities retard and in the gel matrix. The DNA eluate was either directly used for 
hybridization after a denaturation with 0.2 M NaOH (final conc.) for 10 min, or stored at 4°C 
for a short period. 
 
!"#$%&"'()"*+)!$#,-+())).6/)
4.30  Nucleic acid hybridization 
To detect the specific nucleic acid sequence, denatured DNA probes were allowed to 
hybridize with DNA or RNA sample blotted on membrane. The binding specificity was 
ensured by a high-stringent hybridization temperature at 68°C. The blot was spread in a 
hybridization bottle smoothly and wet in water briefly. To equilibrate the membrane and 
reduce the hybridization background, the bottle was filled with appropriate volumes (5 ml for 
small and 10 ml for large bottles) of pre-hybridization buffer, and rotated at 68 °C for at least 
one hour. The buffer was replaced by pre-warmed hybridization buffer, and the amount of 
DNA probe required was calculated according to the volume of hybridization buffer. 
Generally, the radioactivity corresponding to 14 ng of DNA input was supplied for 10 ml of 
hybridization buffer. Hybridization was performed overnight at 68°C. Next day, the 
hybridization mixture was collected for reuse. The membrane was agitated gently in wash 
buffer (2! SSC; 0.1% SDS, w/v) at 68°C for 3% 30 min to remove the unspecific binding. 
Finally, the membrane was dried very briefly and packed with plastic wrap. 
Because the DNA probe is present in an excessive amount compared to the complementary 
sequences fixed on the membrane, the radioactive probe can be re-used within the half-life of 
the 32P-isotope (14 days). For this purpose, the hybridization mixture was denatured by 
heating in boiling water for 10 min, and immediately applied for the new hybridization.  
Pre- and Hybridization buffer: 
50 mM sodium phosphate buffer, pH 6.4  
1% (w/v) SDS  
1% Denhardt’s solution  
5% SSC  
0.1 mg/ml tRNA  
50% Denhardt’s solution:   
1% (w/v) Ficoll 400  
1% (w/v) polyvinylpyrrolidone 
1% (w/v) BSA 
 
 
 
4.31  Hybridization signal capture by autoradiography  
Due to the high-energy !-radiation emitted by 32P-isotope, the hybridization signal can be 
captured by exposing an autoradiography film to the blot. For detecting low-abundant 
molecules, an intensifying screen was used to magnify the signal response linearly.  
The blot was placed into the cassette in conjunction with intensifying screen, and a piece of 
MR-film (GE Healthcare, München) was inserted in between. The apparatus was closed 
firmly and kept in –80°C freezer. The duration of exposure depends on the abundance of 
DNA to be detected. In general, it takes hours for a robust band of PCR products or plasmid 
DNA, but days even for genomic Southern blots even with intensifying screen. Finally, the film 
was developed by the automatic Curix 60 film processor. 
The Southern-blot can be used for re-hybridization, but the probe obtained from the last 
hybridization has to be stripped out. For this reason, a boiling solution of 0.1% (w/v) SDS was 
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poured onto the blot, agitated till the temperature down to RT. The blot was then rinsed briefly 
with 2! SSC and dried on filter paper.  
 
4.32  Protein extraction from cultured mammalian cells 
Cells were washed twice with ice-cold PBS. For a 10-cm dish, 1 ml of PBS was added and 
spread throughout the plate. Using a plastic scraper, cells were removed from the bottom and 
then collected into a 2 ml tube. Centrifuged at 2500 rpm for 5 min at 4°C, the cell pellet was 
resuspended in 1 ml of PBS and transferred into a new tube. Centrifuged again, the pellet 
was dissolved with 100 µl of lysis buffer. The lysis was accomplished by incubation on ice for 
30 min. Finally, the cell lysate was centrifuged at 12000 rpm for 5 min at 4°C. The resulting 
supernatant was transferred into a 1.5 ml tube, mixed thoroughly and stored at –70°C. 
RIPA buffer 
50 mM Tris-HCl, pH 7.4 
150 mM NaCl 
1 mM EDTA 
1% (v/v) NP40 
0.5% (w/v) Na-deoxycholate 
0.1% (w/v) SDS 
Lysis buffer 
RIPA buffer 
add the following just before use 
1 mM PMSF 
Complete protease inhibitor, EDTA-free 
(dissolve one tablet in 2 ml water, and 
supply 40 µl per ml RIPA) 
 
 
4.33  Protein concentration determination – Bradford assay 
The Bradford assay is able to measure the protein concentration of complex sample 
solutions. It is based on the observation that Coomassie Brilliant Blue G-250 changes its 
absorbance maximum from 470 nm to 595 nm by binding to protein. The intensity of the 
absorbance shift is quantitatively related to the protein concentration. As relative standard, a 
dilution series with 2, 4, 6, 8, 10, 12, 14 µg of BSA was prepared with water to a volume of 
800 µl each and mixed well. For samples to be tested, appropriate volumes (1–3 µl) of cell 
lysate were applied and diluted with water to 800 µl. After that, 200 µl of Coomassie dye was 
pipetted into disposable plastic cuvettes. The protein dilutions and water reference were 
transferred into the cuvettes and mixed thoroughly. The reaction was allowed to stay at RT for 
10 min, and measured at 595 nm with the Ultrospec 3000 Pro spectrophotometer. The 
absorbance versus BSA amount was calculated to generate a linear regression standard 
curve and thereby the protein concentration of samples was determined. 
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4.34  Protein detection by Western blot 
4.34.1  Denaturing SDS-polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) is a standard method to separate 
polypeptides based on the molecular weight. As an anionic detergent, SDS denatures 
polypeptide chains and provides them with a net negative charging proportional to their 
length. The separation system is a one-dimensional, vertical and discontinuous gel with 
stacking and resolving sections. For a small number of samples, two mini-gels (1-mm thick; 
8%10-cm size) were prepared with the Bio-Rad Mini-PROTEAN II according to the 
manufacturer’s instruction. First, the gel-casting apparatus was assembled, and the following 
reagents for the resolving gel of desired polyacrylamide concentration were added in a 50 ml 
Falcon tube:  
                                                               10%                          12.5% 
H2O                                                       4.05 ml                      3.15 ml 
Resolving buffer                                     2.5 ml                        2.5 ml  
(1.5 M Tris-HCl, pH 8.8) 
Rotiphorese Gel 30                                3.3 ml                        4.2 ml 
10% (w/v) SDS                                      100 µl                        100µl 
TEMED                                                    5 µl                            5 µl 
10% (w/v) APS, prepared daily               50 µl                          50 µl 
 
Immediately after addition of TEMED and ammonium persulfate (APS), contents were mixed 
well and poured quickly. The solution was overlaid with isopropanol and incubated at RT for 
30 min to allow the polymerization of acrylamide monomers. The isopropanol was decanted 
and another mixture for the 5% stacking gel was prepared containing 3.45 ml of H2O, 620 µl 
of stacking buffer (0.5 M Tris-HCl, pH 6.8), 830 µl of Rotiphorese Gel 30, 50 µl of 10% SDS, 6 
µl of TEMED and 60 µl of 10% APS. The stacking gel solution was poured on top of the 
resolving gel and incubated for 20 min. The complete gel was placed in the electrophoresis 
chamber and filled with 1% running buffer. Before loading, cell lysate containing 30 µg of 
protein was combined with 4 µl of 5% sample buffer plus RIPA-buffer to 20 µl. By heating at 
99°C for 10 min, disulfide bonds were broken by !-mercaptoethanol and protein was 
denatured by SDS. Samples were cooled on ice, spun down briefly and loaded onto the gel. 
Five microliters of pre-stained protein marker was applied directly without boiling. Proteins 
were separated by electrophoresis at 200 V for 45 min at RT.  
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4.34.2  Western blot 
Protein can be transferred from the gel onto a supporting surface such as PVDF membrane. 
After SDS-PAGE, the stacking gel was cut off and the resolving gel was immersed in blotting 
buffer for 20–30 min with gentle agitation. A piece of Immobilon-P PVDF membrane was 
activated by methanol for 2–3 min, immediately rinsed with water and then equilibrated in 
blotting buffer. The gel was transferred by the wet-blotting procedure with the Mini Trans-Blot 
set. The blotting apparatus was assembled as below: 
• light side of gel-holder cassette (near anode) 
• a piece of fiber pad (pre-soaked in blotting buffer) 
• a sheet of filter paper (pre-soaked) 
• PVDF membrane 
• protein gel 
• a sheet of filter paper (pre-soaked) 
• a piece of fiber pad 
• dark side of gel-holder cassette (near cathode) 
The cassette was closed firmly and placed in the buffer tank and then filled with ice-cold 
blotting buffer. A stir bar was put into the chamber to keep the buffer substances equally 
distributed during the whole procedure. The transfer was achieved by running at 400 mA, 100 
Volt, for one hour at 4°C.  
 
4.34.3  Immunodetection 
The blot was immersed in ice-cold TBST (1% TBS; 0.1% Tween 20, v/v) with 5% (w/v) milk, 
and agitated at RT for one hour to block unspecific targets. The primary antibody from mouse 
or rabbit recognizing specific human protein was diluted in TBST with 5% milk to the optimal 
working concentration. After blocking, the blot was rinsed briefly in TBST and incubated with 
the antibody dilution either at RT for 1–2 h or overnight at 4°C. The blot was washed with 
TBST for 5 % 5 min at RT. The secondary antibody conjugated with horseradish peroxidase 
(HRP) and directed against the primary one was diluted and incubated with the blot for one 
hour at RT, followed by 5 % 5 min washing. Finally, the specific binding between protein and 
antibody was quantitatively converted to light signal mediated by the enhanced 
chemiluminescence (ECL) detection system. The same volume (1.5 µl) of solution A (luminol 
and enhancer) and solution B (hydrogen peroxide) was mixed and allowed to equilibrate at 
RT for 5 min. The mixture was applied to cover the blot completely and incubated for 2 min. 
The excess fluid was drained off and the blot was packed with transparent wrap. A piece of 
Biomax Light film (GE Healthcare, München) was exposed to the blot for detecting the protein 
bands. 
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After the data interpretation, the primary and secondary antibodies were stripped out of the 
blot by shaking at 50°C for 30 min in the stripping buffer. The membrane was washed with 
TBST at RT for 2% 10 min, and blocked again in TBST with 5% milk. Subsequently, primary 
antibody against human GAPDH protein as internal control was used for the normalization of 
protein amount among different samples. 
 
4.35  ASP16 strategy for HPV16 DNA integration analysis 
4.35.1  GenomePlex whole genome amplification  
Whole genome amplification (WGA) was performed using the GenomePlex WGA 2 kit 
(Sigma-Aldrich, München) according to the manufacturer’s instruction. To reach a 
representative and unbiased WGA, at least 10 ng of genomic DNA is required as starting 
material. For clinical samples the DNA template can be increased to 25–100 ng, dependent 
on the degree of DNA degradation. The template was diluted with DNase-free water to a 
volume of exactly 10 µl, and mixed well with 1 µl of 10! fragmentation buffer in a 0.5 ml PCR 
tube. To fragment genomic DNA efficiently but not excessively, the reaction was incubated at 
95°C for exactly 4 min. The tube was immediately cooled on ice for minutes and spun down 
briefly. Two microliter of 1! library preparation buffer plus 1 µl of library stabilization solution 
was added and incubated at 95°C for 2 min. The reaction was chilled on ice and centrifuged 
briefly. After adding 1 µl of library preparation enzyme, the reaction contents totally 15 µl were 
mixed and placed in a thermal cycler. The OmniPlex library generation was accomplished by 
stepped isothermal reactions as follows: 
                           Step 1:     16 °C     for    20 min 
                           Step 2:     24 °C     for    20 min 
                           Step 3:     37 °C     for    20 min 
                           Step 4:     75 °C     for     5 min 
                           Step 5:      4 °C         hold    
To amplify the OmniPlex library, reagents including 7.5 µl of 10! amplification master mix, 
47.5 µl of water and 5 µl of WGA DNA polymerase were added and mixed thoroughly. To 
reduce the experimental bias, the amplification reaction was performed with a limited cycle 
number in a thermal cycler according to the following condition:  
         Initial denaturation:     95 °C     for     3 min 
                  Denaturation:     94 °C     for    15 sec 
      Annealing/Extension:     65 °C     for     5 min 
                           Cooling:      4 °C        hold 
14 cycles 
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After cycling, 3–5 µl from the 75 µl final products were loaded into a 1.5% agarose gel to 
check the WGA performance. Normally, a successful amplification yields 3–7 µg of DNA. The 
amplified DNA fragments were stored at –20°C and were stable for months. The WGA 
products were directly used as DNA template for PCR without any prior clean-up.   
 
4.35.2  HPV16 DNA enrichment from GenomePlex libraries 
4.35.2.1  Linear amplification by primer extension 
Sequences and combinations of HPV16 primers are shown in Section 4.12.5, 2.11 and 2.12. 
All biotin-labeled HPV16 primers used for linear amplification were individually diluted with 1! 
TE buffer to a concentration of 10 µM. Dilutions of the eight primers used in one reaction were 
blended into one mixture, with a final concentration of 0.1 µM for each primer. For linear 
amplification of HPV16 DNA, the Paq5000 DNA polymerase (Stratagene, La Jolla, U.S.A) 
was applied according to the user manual. The following components were mixed in a 0.5 ml 
PCR tube: 39 µl of DNase-free water, 5 µl of 10! Paq5000 reaction buffer, 1 µl of dNTP-mix 
(10 mM each), 2 µl of mixed biotin-primer (0.1 µM each), 2.5 µl of GenomePlex WGA 
products (HPV16-positive) and 0.5 µl of Paq5000 DNA polymerase (5 units/µl). The tube was 
placed into a thermal cycler, and the targeted regions of HPV16 DNA were linearly amplified 
through primer extension under the cycling condition as shown below. The extent of 
amplification was about 45 fold, generating biotinylated single-stranded DNA molecules. 
             Initial denaturation:         95 °C     for     3 min 
                      Denaturation:         95 °C     for    30 sec  
                           Annealing:         58 °C     for    75 sec 
                           Extension:         72 °C     for    30 sec (1 kb)   
                               Cooling:          4 °C         hold              
 
4.35.2.2  Biotin-streptavidin selection 
Single-stranded DNA carrying a biotin at the 5’ end can be extracted from the background of 
whole genomic DNA via the specific and strong association between biotin and streptavidin. 
The BioMag streptavidin beads (Polysciences, Heidelberg) were used for HPV16 DNA 
selection according to the user manual. A 75-µl suspension of BioMag streptavidin beads  
(1 mg/ml) was pipetted into a 1.5 ml tube. The tube was placed in a magnet and incubated for 
1 min, to allow the separation of magnetic particles from the storage buffer. The supernatant 
was discarded, and the tube was removed from the magnet. The beads were washed with 
100 µl of 2! binding buffer and incubated in the magnet for 1 min. After the removal of 
supernatant, particles were resuspended in 50 µl of 2! binding buffer and combined with 50 
µl of linear-amplified ssDNA products. The mixture was incubated on a normal rack for 15–30 
min at room temperature, and the contents were mixed carefully by tapping the tube 
45 cycles 
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intermittently to keep beads in suspension. The tube was returned to the magnet and 
incubated for 1 min. The supernatant was removed, and particles were washed twice with 
150 µl of wash buffer and three times with 150 µl of 1% TE buffer. In each wash step, the tube 
was removed from the magnetic field, mixed with buffer solutions, and incubated on the 
separator for 1 min. Finally, the reaction was dissolved in 30 µl of 1% TE buffer and stored at 
4°C for a short period. 
2! binding buffer  
40 mM Tris-HCl, pH 7.8  
2 M NaCl,  
2 mM EDTA,  
0.1% (v/v) Tween 20  
Wash buffer:   
20 mM Tris-HCl, pH 7.8  
1 M NaCl  
1 mM EDTA, 
0.05% (v/v) Tween 20 
 
4.35.2.3  Multiplex PCR 
The selected HPV16-positive single-stranded DNA was amplified and converted to double-
stranded DNA by multiplex PCR. In addition, the Roche-A (RA) and Roche-B (RB) 
sequencing primers needed for the later pyrosequencing were incorporated. Primer 
sequences and combinations are shown in Section 4.12.5, 2.11 and 2.12. The RA-HPV16 
nested primers were individually diluted with 1! TE buffer to a 10-µM stock solution. A 10! 
mixture was prepared by combining the eight RA-HPV16 primers used in one PCR reaction at 
a final concentration of 1 µM each. Multiplex PCR was performed using the Qiagen multiplex 
PCR kit (Qiagen, Hilden) according to the user manual. The following reagents were mixed in 
a 0.5 ml PCR tube and placed into a thermal cycler, including 25 µl of 2! Qiagen multiplex 
PCR master mix, 5 µl of 10! RA-HPV16 primer mixture (1 µM each), 2 µl of RB-GPUA primer 
(10 µM), 13 µl of DNase-free water and 5 µl of DNA template from the selection step. The 
reaction was accomplished with the condition as below: 
          Initial denaturation:         95 °C   for    15 min 
                   Denaturation:         94 °C   for    30 sec 
                        Annealing:         58 °C   for    75 sec 
                        Extension:         72 °C   for     1 min (1 kb) 
                Final extension:         72 °C   for    10 min 
                            Cooling:           4 °C      hold 
After PCR, the tube was placed in the magnet and incubated for 1 min. Finally, the 
supernatant containing multiplex PCR product was collected and purified with QIAquick PCR 
purification kit as described in Section 4.19. The concentration was determined by NanoDrop 
spectrophotometer. One hundred nanogram of purified DNA from each reaction was 
examined on a 1.5% agarose gel, and further analyzed by Southern hybridization with the 
HPV16-complete DNA probe.   
35 cycles 
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4.35.3  Massively parallel pyrosequencing  
The HPV16-positive PCR products from multiple DNA samples were mixed together in equal 
amounts (100 ng of each purified multiplex-PCR reaction). The DNA mixture was checked by 
NanoDrop spectrophotometer for quantitation and quality control. DNA was sent to the DKFZ 
Genomics and Proteomics Core Facility for massively parallel pyrosequencing with the 
Genome Sequencer FLX system (Roche, Mannheim), which gives rise to hundreds of 
thousand sequence reads (up to 250 nt) in one sequencing run. Each individual sequence 
read represents only one single-molecule DNA template. Because the unique 4-nt barcode 
designated to each sample had been incorporated into the RB-GPUA fusion primer, DNA 
mixture was sequenced using the Roche-B sequencing primer. By doing this, all sequence 
reads carry the barcode important for later sequence sorting, even if some of them are not 
fully sequenced. 
 
4.35.4  Sequence analysis with bioinformatics tools 
The pyrosequence reads were analyzed with a computer program written in Perl language by 
my colleague Sasithorn Chotewutmontri as part of her PhD thesis. Details about the 
procedure of sequence analysis are explained in Section 2.11.  
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Appendix 1: viral-cellular junction sequences identified in cell lines 
 
The 3’ junction sequence of SiHa 
This junction was determined by restriction-site PCR (see Section 2.1.1). The viral sequence 
part is shown in red, from HPV16 position 1588 to 3133. The blue sequence indicates the 
cellular part from position 74087558 to 74087156 of chromosome 13 (NC_000013.10). 
GGACTTACACCCAGTATAGCTGACAGTATAAAAACACTATTACAACAATATTGTTTATATTTACACATT
CAAAGTTTAGCATGTTCATGGGGAATGGTTGTGTTACTATTAGTAAGATATAAATGTGGAAAAAATAGA
GAAACAATTGAAAAATTGCTGTCTAAACTATTATGTGTGTCTCCAATGTGTATGATGATAGAGCCTCCA
AAATTGCGTAGTACAGCAGCAGCATTATATTGGTATAAAACAGGTATATCAAATATTAGTGAAGTGTAT
GGAGACACGCCAGAATGGATACAAAGACAAACAGTATTACAACATAGTTTTAATGATTGTACATTTGAA
TTATCACAGATGGTACAATGGGCCTACGATAATGACATAGTAGACGATAGTGAAATTGCATATAAATAT
GCACAATTGGCAGACACTAATAGTAATGCAAGTGCCTTTCTAAAAAGTAATTCACAGGCAAAAATTGTA
AAGGATTGTGCAACAATGTGTAGACATTATAAACGAGCAGAAAAAAAACAAATGAGTATGAGTCAATGG
ATAAAATATAGATGTGATAGGGTAGATGATGGAGGTGATTGGAAGCAAATTGTTATGTTTTTAAGGTAT
CAAGGTGTAGAGTTTATGTCATTTTTAACTGCATTAAAAAGATTTTTGCAAGGCATACCTAAAAAAAAT
TGCATATTACTATATGGTGCAGCTAACACAGGTAAATCATTATTTGGTATGAGTTTAATGAAATTTCTG
CAAGGGTCTGTAATATGTTTTGTAAATTCTAAAAGCCATTTTTGGTTACAACCATTAGCAGATGCCAAA
ATAGGTATGTTAGATGATGCTACAGTGCCCTGTTGGAACTACATAGATGACAATTTAAGAAATGCATTG
GATGGAAATTTAGTTTCTATGGATGTAAAGCATAGACCATTGGTACAACTAAAATGCCCTCCATTATTA
ATTACATCTAACATTAATGCTGGTACAGATTCTAGGTGGCCTTATTTACATAATAGATTGGTGGTGTTT
ACATTTCCTAATGAGTTTCCATTTGACGAAAACGGAAATCCAGTGTATGAGCTTAATGATAAGAACTGG
AAATCCTTTTTCTCAAGGACGTGGTCCAGATTAAGTTTGCACGAGGACGAGGACAAGGAAAACGATGGA
GACTCTTTGCCAACGTTTAAATGTGTGTCAGGACAAAATACTAACACATTATGAAAATGATAGTACAGA
CCTACGTGACCATATAGACTATTGGAAACACATGCGCCTAGAATGTGCTATTTATTACAAGGCCAGAGA
AATGGGATTTAAACATATTAACCACCAGGTGGTGCCAACACTGGCTGTATCAAAGAATAAAGCATTACA
AGCAATTGAACTGCAACTAACGTTAGAAACAATATATAACTCACAATATAGTAATGAAAAGTGGACATT
ACAAGACGTTAGCCTTGAAGTGTATTTAACTGCACCAACAGGATGTATAAAAAAACATGGATATACAGT
GGAAGTGCAGTTTGATGGAGACATATGCTGCTCAGCTTAGCTGATTAACCCTGGACAGATAAGACTGGA
GCCTATTGGGCATTGTCACAATGTCTAAAGATGACTGTTAGGAACCTGCTTCTGTGACTAGTGGTGGGG
ATAAGGGAATCCCAATGAAGGACACCTCAGATAACCCAGTATGTCTACTATACTTATATATCTAAATTC
TCATTGTAATTCCACCGGATTCACACTTATCACAGCTATGGAATATTTTATGAATTAGGTTGTTCTAGT
GAGTTCTTCGGAAGCCTGGAAATATAGTCCCCAGTTTGAGGATGCCACGTCTTGTGGCCTCAGTCATGG
CAGTAAGGCACAGTTGAGGTAGCTTGGGCTCTGCAACTGGAAAATAAGGGGTTGAAAGTTCTGGTAACT
TTTCATAGTGGGGGCTC 
 
The 3’ junction sequence of MRI-H186 
This junction was determined by restriction-site PCR (see Section 2.1.2). The viral sequence 
part is shown in red, from HPV16 position 1588 to 2754. The blue sequence indicates the 
cellular part from position 128815788 to 128816380 of chromosome 8 (NC_000008.9). 
GGACTTACACCCAGTATAGCTGACAGTATAAAAACACTATTACAACAATATTGTTTATATTTACACATT
CAAAGTTTAGCATGTTCATGGGGAATGGTTGTGTTACTATTAGTAAGATATAAATGTGGAAAAAATAGA
GAAACAATTGAAAAATTGCTGTCTAAACTATTATGTGTGTCTCCAATGTGTATGATGATAGAGCCTCCA
AAATTGCGTAGTACAGCAGCAGCATTATATTGGTATAAAACAGGTATATCAAATATTAGTGAAGTGTAT
GGAGACACGCCAGAATGGATACAAAGACAAACAGTATTACAACATAGTTTTAATGATTGTACATTTGAA
TTATCACAGATGGTACAATGGGCCTACGATAATGACATAGTAGACGATAGTGAAATTGCATATAAATAT
GCACAATTGGCAGACACTAATAGTAATGCAAGTGCCTTTCTAAAAAGTAATTCACAGGCAAAAATTGTA
AAGGATTGTGCAACAATGTGTAGACATTATAAACGAGCAGAAAAAAAACAAATGAGTATGAGTCAATGG
ATAAAATATAGATGTGATAGGGTAGATGATGGAGGTGATTGGAAGCAAATTGTTATGTTTTTAAGGTAT
CAAGGTGTAGAGTTTATGTCATTTTTAACTGCATTAAAAAGATTTTTGCAAGGCATACCTAAAAAAAAT
TGCATATTACTATATGGTGCAGCTAACACAGGTAAATCATTATTTGGTATGAGTTTAATGAAATTTCTG
CAAGGGTCTGTAATATGTTTTGTAAATTCTAAAAGCCATTTTTGGTTACAACCATTAGCAGATGCCAAA
ATAGGTATGTTAGATGATGCTACAGTGCCCTGTTGGAACTACATAGATGACAATTTAAGAAATGCATTG
GATGGAAATTTAGTTTCTATGGATGTAAAGCATAGACCATTGGTACAACTAAAATGCCCTCCATTATTA
ATTACATCTAACATTAATGCTGGTACAGATTCTAGGTGGCCTTATTTACATAATAGATTGGTGGTGTTT
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ACATTTCCTAATGAGTTTCCATTTGACGAAAACGGAAATCCAGTGTATGAGCTTAATGATAAGAACTGG
AAATCCTTTTTCTCAAGGACGTGGTCCAGATTAAGTTTGCACGAGGACGAGGACAAGGAAAACCCATCT
TGAACAGCGTACATGCTATACACGCACCCCTTTCCCCCGAATTGTTTTCTCTTTTGGAGGTGGTGGAGG
GAGAGAAAAGTTTACTTAAAATGCCTTTGGGTGAGGGACCAAGGATGAGAAGAATGTTTTTTGTTTTTC
ATGCCGTGGAATAACACAAAATAAAAAATCCCGAGGGAATATACATTATATATTAAATATAGATCATTT
CAGGGAGCAAACAAATCATGTGTGGGGCTGGGCAACTAGCTAAGTCGAAGCGTAAATAAAATGTGAATA
CACGTTTGCGGGTTACATACAGTGCACTTTCACTAGTATTCAGAAAAAATTGTGAGTCAGTGAACTAGG
AAATTAATGCCTGGAAGGCAGCCAAATTTTAATTAGCTCAAGACTCCCCCCCCCCCAAAAAAAGGCACG
GAAGTAATACTCCTCTCCTCTTCTTTGATCAGAATCGATGCATTTTTTGTGCATGACCGCATTTCCAAT
AATAAAAGGGGAAAGAGGACCTGGAAAGGAATTAAACGTCCGGTTTGTCCGGGGAGGAAAGAGTTAACG
GTTTTTTTCACAAGGGTCTCTGCTGACTCCCCCGG 
 
The 5’ junction sequence of MRI-H186 
This junction was determined by restriction-site PCR (see Section 2.1.2). The blue sequence 
indicates the cellular part from position 128814789 to 128815779 of chromosome 8 
(NC_000008.9). The viral sequence part is shown in red, from HPV16 position 4871 to 5885.  
 
GATCGCTTTAACCGAGGAGTTTGAGACCAGCCTGGGCAACATGACCAGACTGCCTCTCTACAAAAAGTT
TAAAAAATTAACCGGGTGTGGTGGTGCACTGCACTCCCAGCTACTGGGCTGGGGTATCAGGCTGAGGTA
GGAGGTTTGCTTTGAGCCCGGGGGGATCGAGGCTGCAGTGAGCTTTGATTGTGCCACTGCACTCCAGCC
TGGGTGACAGAAGGAGACCCTGTCTCAAAAATAATAAGAATAATAATTAATAATAATAGGCCAAACCAA
ATACCCATCACCTTCTGCTGTGCCTCCCCTTTCCCCAATAAATCCAGTGTCTTGCTTTCAAATTTTGTG
GTTAAAAAAGATGATGAGTTTCTAAGACGTGGGGGCTAAAGCTTGTTTGGCCGTTTTAGGGTTTGTTGG
AATTTTTTTTTCGTCTATGTACTTGTGAATTATTTCACGTTTGCCATTACCGGTTCTCCATAGGGTGAT
GTTCATTAGCAGTGGTGATAGGTTAATTTTCACCATCTCTTATGCGGTTGAATAGTCACCTCTGAACCA
CTTTTTCCTCCAGTAACTCCTCTTTCTTCGGACCTTCTGCAGCCAACCTGAAAGAATAACAAGGAGGTG
GCTGGAAACTTGTTTTAAGGAACCGCCTGTCCTTCCCCCGCTGGAAACCTTGCACCTCGGACGCTCCTG
CTCCTGCCCCCACCTGACCCCCGCCCTCGTTGACATCCAGGCGCGATGATCTCTGCTGCCAGTAGAGGG
CACACTTACTTTACTTTCGCAAACCTGAACGCGGGTGCTGCCCAGAGAGGGGGCGGAGGGAAAGACGCT
TTGCAGCAAAATCCAGCATAGCGATTGGTTGCTCCCCGCGTTTGCGGCAAAGGCCTGGAGGCAGGAGTA
ATTTGCAATCCTTAAAGCTGAATTGTGCAGTGCATCGGATTTGGAAGCTACTATATTCACTTAACACTT
GAACGCTGAGCTGCAAACTCAACGGGTAGCACACCCATACCAGGGTCTCGCCCAGTGGCACGCCTAGGA
TTATATAGTCGCACAACACAACAGGTTAAAGTTGTAGACCCTGCTTTTGTAACCACTCCCACTAAACTT
ATTACATATGATAATCCTGCATATGAAGGTATAGATGTGGATAATACATTATATTTTTCTAGTAATGAT
AATAGTATTAATATAGCTCCAGATCCTGACTTTTTGGATATAGTTGCTTTACATAGGCCAGCATTAACC
TCTAGGCGTACTGGCATTAGGTACAGTAGAATTGGTAATAAACAAACACTACGTACTCGTAGTGGAAAA
TCTATAGGTGCTAAGGTACATTATTATTATGATTTAAGTACTATTGATCCTGCAGAAGAAATAGAATTA
CAAACTATAACACCTTCTACATATACTACCACTTCACATGCAGCCTCACCTACTTCTATTAATAATGGA
TTATATGATATTTATGCAGATGACTTTATTACAGATACTTCTACAACCCCGGTACCATCTGTACCCTCT
ACATCTTTATCAGGTTATATTCCTGCAAATACAACAATTCCTTTTGGTGGTGCATACAATATTCCTTTA
GTATCAGGTCCTGATATACCCATTAATATAACTGACCAAGCTCCTTCATTAATTCCTATAGTTCCAGGG
TCTCCACAATATACAATTATTGCTGATGCAGGTGACTTTTATTTACATCCTAGTTATTACATGTTACGA
AAACGACGTAAACGTTTACCATATTTTTTTTCAGATGTCTCTTTGGCTGCCTAGTGAGGCCACTGTCTA
CTTGCCTCCTGTCCCAGTATCTAAGGTTGTAAGCACGGATGAATATGTTGCACGCACAAACATATATTA
TCATGCAGGAACATCCAGACTACTTGCAGTTGGACATCCCTATTTTCCTATTAAAAAACCTAACAATAA
CAAAATATTAGTTCCTAAAGTATCAGGATTACAATACAGGGTATTTAGAATACATTTACCTGACCCCAA
TAAGT 
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The 3’ junction sequence of MRI-H196 
This junction was determined by restriction-site PCR (see Section 2.1.2). The viral sequence 
part is shown in red, from HPV16 position 2387 to 3858. The blue sequence indicates the 
cellular part from position 47967861 to 47968023 of chromosome 11 (NC_000011.9). The 
sequence in black (TTAC) does not match with both the HPV16 and cellular sequences.  
 
TTTGGTTACAACCATTAGCAGATGCCAAAATAGGTATGTTAGATGATGCTACAGTGCCCTGTTGGAACT
ACATAGATGACAATTTAAGAAATGCATTGGATGGAAATTTAGTTTCTATGGATGTAAAGCATAGACCAT
TGGTACAACTAAAATGCCCTCCATTATTAATTACATCTAACATTAATGCTGGTACAGATTCTAGGTGGC
CTTATTTACATAATAGATTGGTGGTGTTTACATTTCCTAATGAGTTTCCATTTGACGAAAACGGAAATC
CAGTGTATGAGCTTAATGATAAGAACTGGAAATCCTTTTTCTCAAGGACGTGGTCCAGATTAAGTTTGC
ACGAGGACGAGGACAAGGAAAACGATGGAGACTCTTTGCCAACGTTTAAATGTGTGTCAGGACAAAATA
CTAACACATTATGAAAATGATAGTACAGACCTACGTGACCATATAGACTATTGGAAACACATGCGCCTA
GAATGTGCTATTTATTACAAGGCCAGAGAAATGGGATTTAAACATATTAACCACCAGGTGGTGCCAACA
CTGGCTGTATCAAAGAATAAAGCATTACAAGCAATTGAACTGCAACTAACGTTAGAAACAATATATAAC
TCACAATATAGTAATGAAAAGTGGACATTACAAGACGTTAGCCTTGAAGTGTATTTAACTGCACCAACA
GGATGTATAAAAAAACATGGATATACAGTGGAAGTGCAGTTTGATGGAGACATATGCAATACAATGCAT
TATACAAACTGGACACATATATATATTTGTGAAGAAGCATCAGTAACTGTGGTAGAGGGTCAAGTTGAC
TATTATGGTTTATATTATGTTCATGAAGGAATACGAACATATTTTGTGCAGTTTAAAGATGATGCAGAA
AAATATAGTAAAAATAAAGTATGGGAAGTTCATGCGGGTGGTCAGGTAATATTATGTCCTACATCTGTG
TTTAGCAGCAACGAAGTATCCTCTCCTGAAATTATTAGGCAGCACTTGGCCAACCACCCCGCCGCGACC
CATACCAAAGCCGTCGCCTTGGGCACCGAAGAAACACAGACGACTATCCAGCGACCAAGATCAGAGCCA
GACACCGGAAACCCCTGCCACACCACTAAGTTGTTGCACAGAGACTCAGTGGACAGTGCTCCAATCCTC
ACTGCATTTAACAGCTCACACAAAGGACGGATTAACTGTAATAGTAACACTACACCCATAGTACATTTA
AAAGGTGATGCTAATACTTTAAAATGTTTAAGATATAGATTTAAAAAGCATTGTACATTGTATACTGCA
GTGTCGTCTACATGGCATTGGACAGGACATAATGTAAAACATAAAAGTGCAATTGTTACACTTACATAT
GATAGTGAATGGCAACGTGACCAATTTTTGTCTCAAGTTAAAATACCAAAAACTATTACAGTGTCTACT
GGATTTATGTCTATATGACAAATTTACCCATTGTAGGCTTCACTGGGAAGATTAATATTTAGTAAATAC
CTGAATTAGGTGCGAGAGCTGGCCATGTGGCTGTCTGAGGCAAAAGCATTCTAAGCATAGAAAACAACA
AATGTGGCGGCTAGGCGCGGTGGCTCACACCTGCAGCCCAGAACTTTGGGAG 
 
 
The 5’ junction sequence of MRI-H196 
This junction was determined by restriction-site PCR but not completely sequenced (see 
Section 2.1.2). Therefore, it is shown in discontinuous sequence parts. The blue sequence 
indicates the cellular part from position 46953161 to 46953669 of chromosome 11 
(NC_000011.9). The viral sequence part is shown in red, from HPV16 position 5321 to 6653.  
 
GAGGGAAACAAATTCATTTAACAGACGTTTATTGTATAACTGATTTCTGCAGGCACTGCACATGGTCCC
AGAAATTTAAAGATGAATGAAGACTGTCTCTGCCCTCATGGAACTCACAATCTAGTAGGAAGAATTTTT
TAAAAAGACATAAATGGTTATAAAAGTGCATACTAGCTGGGCGCGGTGGCTCACGCCTGTAATCCCAGC
ACTTTAGGAGGCTGAGGCGGGTGGATCACCTGAGGTCAGGAGTTCGAGAGCAGCCTGACCAAAATGGAG
AAACCCCGTCTCTACTAAAAATACAAAATCAGCCAGGTGCAGTGCGCATGCCTGTAATCCCAGCTACTT
GGGAGGCTGAGGCAGGAAAATCTCTTGAACCCGGGAGGTGGAGGTTGCAGTGAGCCGAGATCACGCCAC
TGCAGTCCAGCCTGGGTGAAAGAGCGAGTCTCTGTCTCAAAAAAACAAAACAAAACAAAACAAAACAAA
ACAAAACAAAACTGCATAGTCTAGGA 
ATAATGGATTATATGATATTTATGCAGATGACTTTATTACAGATACTTCTACAACCCCGGTACCATCTG
TACCCTCTACATCTTTATCAGGTTATATTCCTGCAAATACAACAATTCCTTTTGGTGGTGCATACAATA
TTCCTTTAGTATCAGGTCCTGATATACCCATTAATATAACTGACCAAGCTCCTTCATTAATTCCTATAG
TTCCAGGGTCTCCACAATATACAATTATTGCTGATGCAGGTGACTTTTATTTACATCCTAGTTATTACA
TGTTACGAAAACGACGTAAACGTTTACCATATTTTTTTTCAGATGTCTCTTTGGCTGCCTAGTGAGGCC
ACTGTCTACTTGCCTCCTGTCCCAGTATCTAAGGTTGTAAGCACGGATGAATATGTTGCACGCACAAAC
ATATATTATCATGCAGGAACATCCAGACTACTTGCAGTTGGACATCCCTATTTTCCTATTAAAAAACCT
AACAATAACAAAATATTAGTTCCTAAAGTATCAGGATTACAATACAGGGTATTTAGAATACATTTACCT
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GACCCCAATAAGTTTGGTTTTCCTGACACCTCATTTTATAATCCAGATACACAGCGGCTGGTTTGGGCC
TGTGTAGGTGTTGAGGTAGGTCGTGGTCAGCCATTAGGTGTGGGCATTAGTGGCCATCCTTTATTAAAT
AAATTGGATGACACAGAAAATGCTAGTGCTTATGCAGCAAATGCAGGTGTGGATAATAGAGAATGTATA
TCTATGGATTACAAACAAACACAATTGTGTTTAATTGGTTGCAAACCACCTATAGGGGAACACTGGGGC
AAAGGATCCCCATGTACCAATGTTGCAGTAAATCCAGGTGATTGTCCACCATTAGAGTTAATAAACACA
GTTATTCAGGATGGTGATATGGTTGATACTGGCTTTGGTGCTATGGACTTTACTACATTACAGGCTAAC
AAAAGTGAAGTTCCACTGGATATTTGTACATCTATTTGCAAATATCCAGATTATATTAAAATGGTGTCA
GAACCATATGGCGACAGCTTATTTTTTTATTTACGAAGGGAACAAATGTTTGTTAGACATTTATTTAAT
AGGGCTGGTACTGTTGGTGAAAATGTACCAGACGATTTATACATTAAAGGCTCTGGGTCTACTGCAAAT
TTAGCCAGTTCAAATTATTTTCCTACACCTAGTGGTTCTATGGTTACCTCTGATGCCCAAATATTCAAT
AAACCTTATTGGTTACAACGAGCACAGGGCCACAATAATGGCATTTGTTGGGGTAACCAACTATTTGTT
ACTGTTGTTGATACTACACGCA 
 
 
The 3’ junction sequence of integration variant B in MRI-H186 
This junction was determined by DIPS-PCR (see Section 2.8.2). The viral sequence part is 
shown in red, from HPV16 position 911 to 1223. The blue sequence indicates the cellular part 
from position 128744999 to 128745226 of chromosome 8 (NC_000008.9). The sequence in 
black (32 nt) does not match with both the HPV16 and cellular sequences.  
 
ATGGATGGTTTTATGTAGAGGCTGTAGTGGAAAAAAAAACAGGGGATGCTATATCAGATGACGAGAACG
AAAATGACAGTGATACAGGTGAAGATTTGGTAGATTTTATAGTAAATGATAATGATTATTTAACACAGG
CAGAAACAGAGACAGCACATGCGTTGTTTACTGCACAGGAAGCAAAACAACATAGAGATGCAGTACAGG
TTCTAAAACGAAAGTATTTGGGTAGTCCACTTAGTGATATTAGTGGATGTGTAGACAATAATATTAGTC
CTAGATTAAAAGCTATATGTATAGAAAAACAAAGTAGAACCATCAGGGCTCTTACAGTTGTTAAAAGTG
ATGTGTCACTTTTAAACAATGGATATTTTGAATTCCAGAGAAAATGGTGTTAGGTAAAGAGTGACATTT
TATTATAAATTTCCTCCAATGTCATCTCATTTACTTTTAAATTGAACTTAGGTGTGTTTGAACTTGTCC
CTGAACTCTTAGTCACTCAAAACACAAACACACAGTTTGTAAAGAAAGTTTGCCTCCTGTGAGACCCAC
AAGGCAGAGGGATTTGATGGGT 
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Appendix 2: myc-HPV16 hybrid mRNA and MycHPV16E2 fusion protein 
 
cDNA sequence of myc-HPV16 hybrid mRNA 
The sequence with a length of 1607 nt is shown below, starting from the first nucleotide of c-
myc exon1 to the early poly-A site of HPV16 (AATAAA, pos. 4215 – 4220). Details about the 
hybrid mRNA are explained in Section 2.5.  
 
ACCCCCGAGCTGTGCTGCTCGCGGCCGCCACCGCCGGGCCCCGGCCGTCCCTGGCTCCCCTCCTGCCTC
GAGAAGGGCAGGGCTTCTCAGAGGCTTGGCGGGAAAAAGAACGGAGGGAGGGATCGCGCTGAGTATAAA
AGCCGGTTTTCGGGGCTTTATCTAACTCGCTGTAGTAATTCCAGCGAGAGGCAGAGGGAGCGAGCGGGC
GGCCGGCTAGGGTGGAAGAGCCGGGCGAGCAGAGCTGCGCTGCGGGCGTCCTGGGAAGGGAGATCCGGA
GCGAATAGGGGGCTTCGCCTCTGGCCCAGCCCTCCCGCTGATCCCCCAGCCAGCGGTCCGCAACCCTTG
CCGCATCCACGAAACTTTGCCCATAGCAGCGGGCGGGCACTTTGCACTGGAACTTACAACACCCGAGCA
AGGACGCGACTCTCCCGACGCGGGGAGGCTATTCTGCCCATTTGGGGACACTTCCCCGCCGCTGCCAGG
ACCCGCTTCTCTGAAAGGCTCTCCTTGCAGCTGCTTAGACGCTGGATTTTTTTCGGGTAGTGGAAAACC
AGCAGCCTCCCGCGACGATGCCCCTCAACGTTAGCTTCACCAACAGGAACTATGACCTCGACTACGACT
CGGTGCAGCCGTATTTCTACTGCGACGAGGAGGAGAACTTCTACCAGCAGCAGCAGCAGAGCGAGCTGC
AGCCCCCGGCGCCCAGCGAGGATATCTGGAAGAAATTCGAGCTGCTGCCCACCCCGCCAAGCAGCAACG
AAGTATCCTCTCCTGAAATTATTAGGCAGCACTTGGCCAACCACCCCGCCGCGACCCATACCAAAGCCG
TCGCCTTGGGCACCGAAGAAACACAGACGACTATCCAGCGACCAAGATCAGAGCCAGACACCGGAAACC
CCTGCCACACCACTAAGTTGTTGCACAGAGACTCAGTGGACAGTGCTCCAATCCTCACTGCATTTAACA
GCGCACACAAAGGACGGATTAACTGTAATAGTAACACTACACCCATAGTACATTTAAAAGGTGATGCTA
ATACTTTAAAATGTTTAAGATATAGATTTAAAAAGCATTGTACATTGTATACTGCAGTGTCGTCTACAT
GGCATTGGACAGGACATAATGTAAAACATAAAAGTGCAATTGTTACACTTACATATGATAGTGAATGGC
AACGTGACCAATTTTTGTCTCAAGTTAAAATACCAAAAACTATTACAGTGTCTACTGGATTTATGTCTA
TATGACAAATCTTGATACTGCATCCACAACATTACTGGCGTGCTTTTTGCTTTGCTTTTGTGTGCTTTT
GTGTGTCTGCCTATTAATACGTCCGCTGCTTTTGTCTGTGTCTACATACACATCATTAATAATATTGGT
ATTACTATTGTGGATAACAGCAGCCTCTGCGTTTAGGTGTTTTATTGTATATATTATATTTGTTTATAT
ACCATTATTTTTAATACATACACATGCACGCTTTTTAATTACATAATTACATAATGTAATTGTTACATA
TAATTGTTGTATACCATAACTTACTATTTTTTCTTTTTTATTTTCATATATAATTTTTTTTTGTGTTTG
TTTGTTTGTTTTTTAATAAA 
 
 
MycHPV16E2 fusion protein sequence 
The 225 amino acids sequence of MycHPV16E2 fusion protein is shown below. Details about 
this protein are explained in Section 2.7.1.  
 
MPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQQQSELQPPAPSEDIWKKFELLPTPPSSNEVSSPE
IIRQHLANHPAATHTKAVALGTEETQTTIQRPRSEPDTGNPCHTTKLLHRDSVDSAPILTAFNSAHKGR
INCNSNTTPIVHLKGDANTLKCLRYRFKKHCTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWQRDQFL
SQVKIPKTITVSTGFMSI 
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Appendix 3: HPV16 genome reference sequence (see Section 4.11.2) 
ACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAACCGGTTAGTATAA
AAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCCACAGGAGCGACCCAGAAAGTT
ACCACAGTTATGCACAGAGCTGCAAACAACTATACATGATATAATATTAGAATGTGTGTACTGCAAGCA
ACAGTTACTGCGACGTGAGGTATATGACTTTGCTTTTCGGGATTTATGCATAGTATATAGAGATGGGAA
TCCATATGCTGTATGTGATAAATGTTTAAAGTTTTATTCTAAAATTAGTGAGTATAGACATTATTGTTA
TAGTTTGTATGGAACAACATTAGAACAGCAATACAACAAACCGTTGTGTGATTTGTTAATTAGGTGTAT
TAACTGTCAAAAGCCACTGTGTCCTGAAGAAAAGCAAAGACATCTGGACAAAAAGCAAAGATTCCATAA
TATAAGGGGTCGGTGGACCGGTCGATGTATGTCTTGTTGCAGATCATCAAGAACACGTAGAGAAACCCA
GCTGTAATCATGCATGGAGATACACCTACATTGCATGAATATATGTTAGATTTGCAACCAGAGACAACT
GATCTCTACTGTTATGAGCAATTAAATGACAGCTCAGAGGAGGAGGATGAAATAGATGGTCCAGCTGGA
CAAGCAGAACCGGACAGAGCCCATTACAATATTGTAACCTTTTGTTGCAAGTGTGACTCTACGCTTCGG
TTGTGCGTACAAAGCACACACGTAGACATTCGTACTTTGGAAGACCTGTTAATGGGCACACTAGGAATT
GTGTGCCCCATCTGTTCTCAGAAACCATAATCTACCATGGCTGATCCTGCAGGTACCAATGGGGAAGAG
GGTACGGGATGTAATGGATGGTTTTATGTAGAGGCTGTAGTGGAAAAAAAAACAGGGGATGCTATATCA
GATGACGAGAACGAAAATGACAGTGATACAGGTGAAGATTTGGTAGATTTTATAGTAAATGATAATGAT
TATTTAACACAGGCAGAAACAGAGACAGCACATGCGTTGTTTACTGCACAGGAAGCAAAACAACATAGA
GATGCAGTACAGGTTCTAAAACGAAAGTATTTGGGTAGTCCACTTAGTGATATTAGTGGATGTGTAGAC
AATAATATTAGTCCTAGATTAAAAGCTATATGTATAGAAAAACAAAGTAGAGCTGCAAAAAGGAGATTA
TTTGAAAGCGAAGACAGCGGGTATGGCAATACTGAAGTGGAAACTCAGCAGATGTTACAGGTAGAAGGG
CGCCATGAGACTGAAACACCATGTAGTCAGTATAGTGGTGGAAGTGGGGGTGGTTGCAGTCAGTACAGT
AGTGGAAGTGGGGGAGAGGGTGTTAGTGAAAGACACACTATATGCCAAACACCACTTACAAATATTTTA
AATGTACTAAAAACTAGTAATGCAAAGGCAGCAATGTTAGCAAAATTTAAAGAGTTATACGGGGTGAGT
TTTTCAGAATTAGTAAGACCATTTAAAAGTAATAAATCAACGTGTTGCGATTGGTGTATTGCTGCATTT
GGACTTACACCCAGTATAGCTGACAGTATAAAAACACTATTACAACAATATTGTTTATATTTACACATT
CAAAGTTTAGCATGTTCATGGGGAATGGTTGTGTTACTATTAGTAAGATATAAATGTGGAAAAAATAGA
GAAACAATTGAAAAATTGCTGTCTAAACTATTATGTGTGTCTCCAATGTGTATGATGATAGAGCCTCCA
AAATTGCGTAGTACAGCAGCAGCATTATATTGGTATAAAACAGGTATATCAAATATTAGTGAAGTGTAT
GGAGACACGCCAGAATGGATACAAAGACAAACAGTATTACAACATAGTTTTAATGATTGTACATTTGAA
TTATCACAGATGGTACAATGGGCCTACGATAATGACATAGTAGACGATAGTGAAATTGCATATAAATAT
GCACAATTGGCAGACACTAATAGTAATGCAAGTGCCTTTCTAAAAAGTAATTCACAGGCAAAAATTGTA
AAGGATTGTGCAACAATGTGTAGACATTATAAACGAGCAGAAAAAAAACAAATGAGTATGAGTCAATGG
ATAAAATATAGATGTGATAGGGTAGATGATGGAGGTGATTGGAAGCAAATTGTTATGTTTTTAAGGTAT
CAAGGTGTAGAGTTTATGTCATTTTTAACTGCATTAAAAAGATTTTTGCAAGGCATACCTAAAAAAAAT
TGCATATTACTATATGGTGCAGCTAACACAGGTAAATCATTATTTGGTATGAGTTTAATGAAATTTCTG
CAAGGGTCTGTAATATGTTTTGTAAATTCTAAAAGCCATTTTTGGTTACAACCATTAGCAGATGCCAAA
ATAGGTATGTTAGATGATGCTACAGTGCCCTGTTGGAACTACATAGATGACAATTTAAGAAATGCATTG
GATGGAAATTTAGTTTCTATGGATGTAAAGCATAGACCATTGGTACAACTAAAATGCCCTCCATTATTA
ATTACATCTAACATTAATGCTGGTACAGATTCTAGGTGGCCTTATTTACATAATAGATTGGTGGTGTTT
ACATTTCCTAATGAGTTTCCATTTGACGAAAACGGAAATCCAGTGTATGAGCTTAATGATAAGAACTGG
AAATCCTTTTTCTCAAGGACGTGGTCCAGATTAAGTTTGCACGAGGACGAGGACAAGGAAAACGATGGA
GACTCTTTGCCAACGTTTAAATGTGTGTCAGGACAAAATACTAACACATTATGAAAATGATAGTACAGA
CCTACGTGACCATATAGACTATTGGAAACACATGCGCCTAGAATGTGCTATTTATTACAAGGCCAGAGA
AATGGGATTTAAACATATTAACCACCAGGTGGTGCCAACACTGGCTGTATCAAAGAATAAAGCATTACA
AGCAATTGAACTGCAACTAACGTTAGAAACAATATATAACTCACAATATAGTAATGAAAAGTGGACATT
ACAAGACGTTAGCCTTGAAGTGTATTTAACTGCACCAACAGGATGTATAAAAAAACATGGATATACAGT
GGAAGTGCAGTTTGATGGAGACATATGCAATACAATGCATTATACAAACTGGACACATATATATATTTG
TGAAGAAGCATCAGTAACTGTGGTAGAGGGTCAAGTTGACTATTATGGTTTATATTATGTTCATGAAGG
AATACGAACATATTTTGTGCAGTTTAAAGATGATGCAGAAAAATATAGTAAAAATAAAGTATGGGAAGT
TCATGCGGGTGGTCAGGTAATATTATGTCCTACATCTGTGTTTAGCAGCAACGAAGTATCCTCTCCTGA
AATTATTAGGCAGCACTTGGCCAACCACCCCGCCGCGACCCATACCAAAGCCGTCGCCTTGGGCACCGA
AGAAACACAGACGACTATCCAGCGACCAAGATCAGAGCCAGACACCGGAAACCCCTGCCACACCACTAA
GTTGTTGCACAGAGACTCAGTGGACAGTGCTCCAATCCTCACTGCATTTAACAGCTCACACAAAGGACG
GATTAACTGTAATAGTAACACTACACCCATAGTACATTTAAAAGGTGATGCTAATACTTTAAAATGTTT
AAGATATAGATTTAAAAAGCATTGTACATTGTATACTGCAGTGTCGTCTACATGGCATTGGACAGGACA
TAATGTAAAACATAAAAGTGCAATTGTTACACTTACATATGATAGTGAATGGCAACGTGACCAATTTTT
GTCTCAAGTTAAAATACCAAAAACTATTACAGTGTCTACTGGATTTATGTCTATATGACAAATCTTGAT
ACTGCATCCACAACATTACTGGCGTGCTTTTTGCTTTGCTTTTGTGTGCTTTTGTGTGTCTGCCTATTA
ATACGTCCGCTGCTTTTGTCTGTGTCTACATACACATCATTAATAATATTGGTATTACTATTGTGGATA
ACAGCAGCCTCTGCGTTTAGGTGTTTTATTGTATATATTATATTTGTTTATATACCATTATTTTTAATA
CATACACATGCACGCTTTTTAATTACATAATGTATATGTACATAATGTAATTGTTACATATAATTGTTG
TATACCATAACTTACTATTTTTTCTTTTTTATTTTCATATATAATTTTTTTTTTTGTTTGTTTGTTTGT
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TTTTTAATAAACTGTTATTACTTAACAATGCGACACAAACGTTCTGCAAAACGCACAAAACGTGCATCG
GCTACCCAACTTTATAAAACATGCAAACAGGCAGGTACATGTCCACCTGACATTATACCTAAGGTTGAA
GGCAAAACTATTGCTGATCAAATATTACAATATGGAAGTATGGGTGTATTTTTTGGTGGGTTAGGAATT
GGAACAGGGTCGGGTACAGGCGGACGCACTGGGTATATTCCATTGGGAACAAGGCCTCCCACAGCTACA
GATACACTTGCTCCTGTAAGACCCCCTTTAACAGTAGATCCTGTGGGCCCTTCTGATCCTTCTATAGTT
TCTTTAGTGGAAGAAACTAGTTTTATTGATGCTGGTGCACCAACATCTGTACCTTCCATTCCCCCAGAT
GTATCAGGATTTAGTATTACTACTTCAACTGATACCACACCTGCTATATTAGATATTAATAATACTGTT
ACTACTGTTACTACACATAATAATCCCACTTTCACTGACCCATCTGTATTGCAGCCTCCAACACCTGCA
GAAACTGGAGGGCATTTTACACTTTCATCATCCACTATTAGTACACATAATTATGAAGAAATTCCTATG
GATACATTTATTGTTAGCACAAACCCTAACACAGTAACTAGTAGCACACCCATACCAGGGTCTCGCCCA
GTGGCACGCCTAGGATTATATAGTCGCACAACACAACAGGTTAAAGTTGTAGACCCTGCTTTTGTAACC
ACTCCCACTAAACTTATTACATATGATAATCCTGCATATGAAGGTATAGATGTGGATAATACATTATAT
TTTTCTAGTAATGATAATAGTATTAATATAGCTCCAGATCCTGACTTTTTGGATATAGTTGCTTTACAT
AGGCCAGCATTAACCTCTAGGCGTACTGGCATTAGGTACAGTAGAATTGGTAATAAACAAACACTACGT
ACTCGTAGTGGAAAATCTATAGGTGCTAAGGTACATTATTATTATGATTTAAGTACTATTGATCCTGCA
GAAGAAATAGAATTACAAACTATAACACCTTCTACATATACTACCACTTCACATGCAGCCTCACCTACT
TCTATTAATAATGGATTATATGATATTTATGCAGATGACTTTATTACAGATACTTCTACAACCCCGGTA
CCATCTGTACCCTCTACATCTTTATCAGGTTATATTCCTGCAAATACAACAATTCCTTTTGGTGGTGCA
TACAATATTCCTTTAGTATCAGGTCCTGATATACCCATTAATATAACTGACCAAGCTCCTTCATTAATT
CCTATAGTTCCAGGGTCTCCACAATATACAATTATTGCTGATGCAGGTGACTTTTATTTACATCCTAGT
TATTACATGTTACGAAAACGACGTAAACGTTTACCATATTTTTTTTCAGATGTCTCTTTGGCTGCCTAG
TGAGGCCACTGTCTACTTGCCTCCTGTCCCAGTATCTAAGGTTGTAAGCACGGATGAATATGTTGCACG
CACAAACATATATTATCATGCAGGAACATCCAGACTACTTGCAGTTGGACATCCCTATTTTCCTATTAA
AAAACCTAACAATAACAAAATATTAGTTCCTAAAGTATCAGGATTACAATACAGGGTATTTAGAATACA
TTTACCTGACCCCAATAAGTTTGGTTTTCCTGACACCTCATTTTATAATCCAGATACACAGCGGCTGGT
TTGGGCCTGTGTAGGTGTTGAGGTAGGTCGTGGTCAGCCATTAGGTGTGGGCATTAGTGGCCATCCTTT
ATTAAATAAATTGGATGACACAGAAAATGCTAGTGCTTATGCAGCAAATGCAGGTGTGGATAATAGAGA
ATGTATATCTATGGATTACAAACAAACACAATTGTGTTTAATTGGTTGCAAACCACCTATAGGGGAACA
CTGGGGCAAAGGATCCCCATGTACCAATGTTGCAGTAAATCCAGGTGATTGTCCACCATTAGAGTTAAT
AAACACAGTTATTCAGGATGGTGATATGGTTGATACTGGCTTTGGTGCTATGGACTTTACTACATTACA
GGCTAACAAAAGTGAAGTTCCACTGGATATTTGTACATCTATTTGCAAATATCCAGATTATATTAAAAT
GGTGTCAGAACCATATGGCGACAGCTTATTTTTTTATTTACGAAGGGAACAAATGTTTGTTAGACATTT
ATTTAATAGGGCTGGTACTGTTGGTGAAAATGTACCAGACGATTTATACATTAAAGGCTCTGGGTCTAC
TGCAAATTTAGCCAGTTCAAATTATTTTCCTACACCTAGTGGTTCTATGGTTACCTCTGATGCCCAAAT
ATTCAATAAACCTTATTGGTTACAACGAGCACAGGGCCACAATAATGGCATTTGTTGGGGTAACCAACT
ATTTGTTACTGTTGTTGATACTACACGCAGTACAAATATGTCATTATGTGCTGCCATATCTACTTCAGA
AACTACATATAAAAATACTAACTTTAAGGAGTACCTACGACATGGGGAGGAATATGATTTACAGTTTAT
TTTTCAACTGTGCAAAATAACCTTAACTGCAGACGTTATGACATACATACATTCTATGAATTCCACTAT
TTTGGAGGACTGGAATTTTGGTCTACAACCTCCCCCAGGAGGCACACTAGAAGATACTTATAGGTTTGT
AACATCCCAGGCAATTGCTTGTCAAAAACATACACCTCCAGCACCTAAAGAAGATCCCCTTAAAAAATA
CACTTTTTGGGAAGTAAATTTAAAGGAAAAGTTTTCTGCAGACCTAGATCAGTTTCCTTTAGGACGCAA
ATTTTTACTACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCAC
CACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTATGTTGAAT
TAGTGTTGTTTGTTGTGTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATATTAAGTTGTATGTGTG
TTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATGCTTGTGTAACTATTGTGTCATGC
AACATAAATAAACTTATTGTTTCAACACCTACTAATTGTGTTGTGGTTATTCATTGTATATAAACTATA
TTTGCTACATCCTGTTTTTGTTTTATATATACTATATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCA
ACCGAATTCGGTTGCATGCTTTTTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATG
GTTTAAACTTGTACGTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGC
CAACCATTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCATAT
AAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCTTGTTTTAACT
AACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAATGTCACCCTAGTTCATACA
TGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAACTGCACATGGGTGTGTGCAAACCGTTT
TGGGTTACACATTTACAAGCAACTTATATAATAATACTAA 
